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Abstract 
Bariatric surgery offers sustained dramatic weight loss and remission of diabetes, yet the 
mechanisms of these health benefits are not clear. In the present study, I profiled 
circulating and colorectal microRNAome in response to bariatric surgery (Roux-en-Y 
gastric bypass). Indeed, the response of circulating and colorectal microRNA profiles to 
RYGB were striking and selective. Fourteen circulating microRNA and thirteen colorectal 
microRNA exhibited significantly alteration post RYGB. Interestingly, circulating miR-122 
decreased dramatically (56 fold) post RYGB surgery. The expression of hepatic miR-122 
and its metabolic targets were examined both in in vivo RYGB surgical model and in an in 
vitro mechanistic model. Manipulation of microRNA-122 cold induce changes of key 
enzymes involved in energy metabolism, glucose transport, glycolysis, TCA cycle, pentose 
phosphate shunt, fatty acid oxidation and gluconeogenesis, suggesting an overall 
increased energy expenditure status after RYGB. Furthermore, potential mechanisms 
involved in the control of hepatic miR-122 were investigated, with focus on metabolites 
(glucose, and fatty acids), hormones (glucocorticoid) and transcription factors (PPARs). 
Finally, by correlating the circulating microRNAome and metabolome data, we were able 
to generate a comprehensive landscape of the crosstalk between microRNAs and 
metabolic pathways. Follow-up studies will allow a detailed understanding of microRNAs 
responsible for regulating specific metabolic pathways, and conversely identifying 
metabolites capable of regulating the expression and activity of specific microRNAs. 
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1.  Introduction 
1.1 Obesity and bariatric surgery 
1.1.1 Obesity epidemiology 
Obesity is an increasingly important public health issue worldwide. Overweight and obesity 
are defined as abnormal or excessive fat accumulation that may impair health. Body mass 
index (BMI), which is an index of weight-to-height that is commonly used to classify 
overweight and obesity in adults, is defined as a person's weight in kilograms divided by 
the square of their height in meters (kg/m2). World Health Organisation (WHO) defines that 
a BMI greater than or equal to 25 is overweight, whereas a BMI greater than or equal to 30 
is obesity. According to WHO statistics, the prevalence of obesity has nearly doubled since 
1980. In 2008, more than 1.4 billion adults were overweight. Of these over 200 million men 
and nearly 300 million women were obese (WHO 2008). In the UK, according to the NHS, 
nearly a quarter of adults in England were obese in 2008. Just under a third of women 
(32%) were overweight and 42% of men were overweight (Statistics on obesity, physical 
activity and diet: England, 2010). It was estimated that by 2040, 60% of men and 50% of 
women could be clinically obese (Preston ^ et al. 2014). Obesity and its co-morbidities, 
such as type 2 diabetes mellitus (T2DM), sleep apnea, hypertension and hyperlipidaemia, 
are responsible for a huge health and economic burden worldwide (Yach et al. 2006). 
Multiple factors have been shown to contribute to obesity, such as poor diet, sedentary 
lifestyle, environmental factors, genetics and disturbed energy balance (Aronne 2002). 
Treatments for obesity include dietary therapy, exercise and behavioral interventions, 
weight loss medications and bariatric surgery. Notably, studies have shown that bariatric 
surgery can provide long term sustained weight loss and place type 2 diabetes in 
remission within days (Buchwald, Avidor, Braunwald & Jensen 2004a). 
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1.1.2 Bariatric surgery 
1.1.2.1 Bariatric surgery types and procedure 
Generally speaking, surgical treatment for morbid obesity falls into three categories: 
restrictive surgery, malabsorptive surgery and combined restrictive/malabsorptive surgery. 
The restrictive surgery includes vertical banded gastroplasty (VGB) and laparoscopic 
adjustable gastric banding (LAGB), which simply restrict the intake of food via decreasing 
the volume of the stomach. The malabsorptive surgery is able to reduce the nutrient 
absorption via altered bile flow. One example of a malabsorptive procedure is bilio-
pancreatic diversion (BPD), which diverts bile into the terminal segment of the ileum so 
that bile and food are only mixed in the final segment of the small bowel. Combined 
restrictive and malabsorptive gastric bypass (Roux-en-Y-Gastric bypass, RYGB) surgery, 
involving both the restriction of the stomach and the bypass of the small bowel, is 
considered the most effective and the gold standard of bariatric surgery techniques. It can 
induce more rapid and substantial weight loss than the restrictive surgery. It is also the 
most commonly performed bariatric surgery accounting for 40% of the over 344,000 
metabolic operations worldwide in 2008 (Buchwald & Oien 2009). RYGB can lead to a 
68%-83% rapid weight loss during the first 12 months to 2 years (Buchwald, Avidor, 
Braunwald & Jensen 2004a). Furthermore, it is believed that RYGB not only makes people 
“lighter”, but also makes them “healthier”. The majority of patients with diabetes, 
hyperlipidemia, hypertension and obstructive sleep apnea that underwent bariatric surgery 
experienced complete resolution or significant improvement of their health status 
(Buchwald, Avidor, Braunwald & Jensen 2004a).  
During the RYGB procedure, a surgical stapler is used to create a small vertical gastric 
pouch (Figure 1.1). This 30-50mL small pouch is completely separated from the remnant 
stomach. The small pouch is anatomised to the jejunum (upper alimentary limb), whereas 
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the excluded biliary pancreatic limb is anastomosed to the lower alimentary (Roux) limb. 
After RYGB surgery, the food bypasses about 95% of stomach tissue, the entire 
duodenum and part of the jejunum. Hence, foods are mainly mixed with bile in the distal 
jejunum (alimentary limb) and absorption is facilitated through the remaining portion of the 
small bowel. 
 
Figure 1-1 The principle of Roux-en-Y-Gastric bypass surgery  
(left, normal anatomical gastrointestinal system; right, RYGB surgery) 
 
1.1.2.2 Outcomes of bariatric surgery 
Sustained weight loss 
In a meta-analysis of the effectiveness of surgical treatment of obesity (Maggard et al. 
2005), the author systematically assessed 147 studies, 89 of which contributed to the 
weight loss analysis. In 32 studies comparing RYGB procedures with randomized control, 
and involving 2,937 patients, average weight loss outcomes for RYGB averaged 43.46kg 
at 12 months. In 36 months after surgery, 21 studies and 1281 pooled patients showed an 
average 41.46kg weight loss. Another meta-analysis extracted 22,094 patients’ weight loss 
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information from 136 studies. Similarly, they found 43.48kg absolute weight loss, which 
accounts for 34.93% of initial weight (Maggard et al. 2005). The Swedish Obese Subjects 
(SOS) study post-operatively follows bariatric surgery patients and matched medically 
treated controls (Sjostrom et al. 2004). At 8 years post-operative, the average weight loss 
was 20kg among 251 surgically treated patients, whereas the average weight did not 
change in the medically treated patient cohort. Clearly, effective weight loss was achieved 
in morbidly obese patients undergoing bariatric surgery and unlike behavior intervention 
and exercise in the medically treat cohort, bariatric surgery induced weight loss is 
sustainable in the long term.  
Resolution of diabetes 
Besides the sustainable long term weight loss, it has been consistently reported that 
bariatric surgery can induce long-term remission of type 2 diabetes mellitus (T2DM). An 
analysis of 136 studies that included a total of 22,094 patients who underwent bariatric 
surgery showed that 84% of bariatric surgery patients showed resolution of T2DM 
(Maggard et al. 2005). The SOS project showed that bariatric surgery patients have a 
lower incidence of developing diabetes and higher diabetes recovery rate at both 2 years 
(77%) and 10 years (73%) (Sjostrom et al. 2004). Furthermore, two studies, which 
included patients with T2DM or impaired glucose tolerance showed normalised 
glycosylated hemoglobin (HbA1c) levels in 89% and 82% of patients after RYGB without 
any anti-diabetic medication (Pories et al. 1995; Schauer et al. 2004). Additionally, in a 
pilot study that examined the effects of gastric bypass surgery in T2DM patients with 
BMI>35 and T2DM patients with BMI<35, the four year follow-up results show that 90% of 
patients with BMI<35 and 98% of patients with BMI>35 exhibited normalised glycaemia 
(Rubino et al. 2010).  
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1.2 Mechanisms of bariatric surgery mediated effects 
Different types of bariatric surgery may have different weight loss and anti-diabetic effect. 
Restrictive procedures control diabetes exclusively through weight-loss induced 
improvements in peripheral insulin. On the contrary, malabsorptive procedures such as 
RYGB can ameliorate glycemic control in T2DM within days or weeks after surgery, long 
before the drastic weight loss (Kashyap et al. 2010). Evidence suggests that malabsorptive 
bariatric surgery related diabetes resolution is more than just decreased body weight and 
changed food intake. Multiple hypotheses have been proposed to explain the early effect 
of RYGB surgery on diabetes. Over the past decade, there has been an exponential 
increase in the analysis of the altered metabolic mechanisms after RYGB surgery, which 
mainly falls into the following areas (Figure 1.2): 1) altered intestinal and hepatic glucose 
metabolism, 2) increased gut hormone secretion, 3) shifted gut microbiota, 4) remodelled 
muscle promoter methylation, 5) changed brain effects, 6) changed bile flow and bile acids 
composition. Here, I will focus on previous studies in both human and animal models and 
discuss the above-mentioned mechanisms individually. 
 
Figure 1-2 Schematic representation of the potential mechanisms that underlie weight loss and glycaemic 
control after bariatric surgery.  
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1.2.1 Altered intestinal glucose metabolism 
In the past, the gastrointestinal (GI) tract was not often considered in T2DM research. 
Attention was normally given to the liver, muscle, brown and white adipose tissue and 
pancreas, which are the essential organs involved in glucose homeostasis control. Here, 
I’ll provide two examples of why bariatric surgery draws attention to the GI tract in treating 
T2DM and how the GI tract and the liver work together to improve glucose metabolism 
post RYGB.  
In 2008, Troy et al. first provided evidence that the beneficial effects of bariatric surgery 
involves increased intestinal gluconeogenesis and stimulation of hepatoportal glucose 
sensor (Troy et al. 2008). Due to the inability to perform RYGB in mice, their study was 
based on a RYGB mimic model enterogastro anastomosis (EGA, malabsorptive 
procedure) and a gastric lap-band model (GLB, restrictive procedure). By comparison to 
these two models, a better understanding of the two procedures could be achieved 
independently of body weight loss. They found that the EGA procedure specifically 
induced a strong inhibition of food intake and quickly improves glucose homeostasis. 
However, the effects were not observed in GLB pair-fed mice. The key observation was 
that EGA specifically resulted in induction of both Glucose 6-phosphatase (Glc6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK) in the distal jejunum and ileum. Glc6Pase 
and PEPCK are two of the most important enzymes involved in liver gluconeogenesis, 
which are also expressed in small intestine. Glc6Pase and PEPCK also proved to be two 
key triggers for the release of glucose by the small intestine. Indeed, glucose tracer 
dilution studies showed that this increase in Glc6Pase and PEPCK could translate into a 
significant glucose release by the small intestine in the post-absorptive situation. 
Furthermore, hepatoportal vein glucose sensing requires the presence of glucose 
transporter 2 (GLUT2), since the increased endogenous intestinal gluconeogenesis effects 
after EGA were abolished in GLUT2 knockout mice (Troy et al. 2008).  
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It should be noted that although EGA is an intervention that is similar to RYGB, it does not 
completely model RYGB procedure, because there is no intestinal segment that 
represents the Roux limb. Moreover, contradictory results were shown in two recent 
reports in both obese diabetic animals and human, in which they did not find the increased 
intestinal gluconeogenesis post RYGB (Hayes et al. 2011; Wolff et al. 2009).   
In 2013, Saeidi et al. demonstrated that intestinal glucose metabolism is reprogrammed 
after RYGB and this reprogramming is triggered by exposure of the Roux limb to 
undigested nutrients (Saeidi et al. 2013). It was reported that the Roux limb of RYGB 
surgical rat exhibits up-regulated glucose transporter 1 (GLUT1), an enhanced basolateral 
glucose uptake and an augmented aerobic glycolysis (Saeidi et al. 2013). All these effects 
were suggested to meet the increased bioenergetic demand in the Roux limb. The above-
mentioned effect means that the intestine exhibits the highest rate of glucose uptake and 
becomes a major tissue for glucose disposal post RYGB. Moreover, the increased 
intestinal glucose uptake showed a positive correlation with glycemic control post RYGB. 
To find the reason why the intestine exhibited glucose metabolism reprogramming, the 
author developed a rat model in which a loop of jejunum is transected and transposed 
between the oesophagus and the stomach. A similar effect was observed in this 
transposed jejunum. Hence, the authors argue that undigested nutrients are a major 
reason for the post RYGB Rous limb glucose reprogramming (Saeidi et al. 2013).  
I.2.2 Altered hormone secretion 
Altered gut hormones are the most widely studied area in metabolic surgery.  In the past, 
the hindgut and foregut hypotheses were proposed to explain the beneficial metabolic 
effects of bariatric surgery (Cummings et al. 2013).  
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Hindgut theory suggests that diabetes resolution results from more rapid delivery of 
nutrients to the distal intestine, which could induce the L cells to release hormones such as 
glucagon-like peptide-1 (GLP-1) and peptide Y (PYY). Both GLP-1 and PYY exhibit 
anorectic actions and are implicated in mediating the weight loss effect after bariatric 
surgery. GLP-1 is produced in response to a meal, which could stimulate insulin release in 
response to nutrient ingestion, increase insulin biosynthesis and inhibit glucagon secretion 
(Baggio & Drucker 2007). Furthermore, GLP-1 could decrease food intake through its 
effect on the hypothalamus and brainstem (Baggio & Drucker 2007). Similarly, PYY is also 
a peptide hormone synthesised by the intestinal L- cells in the distal GI tract in response to 
food ingestion. PYY was reported to increase energy expenditure and postpone stomach 
emptying (Baggio & Drucker 2007). The majority of previous studies have shown an 
increase in GLP-1 and PYY levels post RYGB surgery (Vincent & Le Roux 2008; Borg et 
al. 2006). Furthermore, to rule out weight loss as the contributor of increased GLP-1, a 
comparison between RYGB and body weight matched controls proved that GLP-1 only 
increased in RYGB and not in diet induced weight loss controls (Laferrère et al. 2008).  
Also, by using oxctreotide to block PYY release, post RYGB patients could 
correspondently increase food intake (Le Roux et al. 2006). In all, the above evidence 
suggests that both GLP-1 and PPY play an important role in post-RYGB metabolic 
benefits.  
The foregut theory suggests that exclusion of proximal small intestine could reduce or 
suppress the secretion of anti-incretin hormones, which could improve blood glucose 
control. However, support for this theory has been gradually eroded since 1) by assessing 
the impact of ileal transposition (IT, no foregut anatomical structure) and duodenal-jejunal 
exclusion (DJE, with foregut anatomical structure), a comparable weight loss, 
improvement in glucose tolerance and increase in GLP-1 was found (Kindel et al. 2009). 
Furthermore, by administration of GLP1 receptor antagonist, the improved glucose 
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tolerance in DJE subjects could be abolished (Kindel et al. 2009). Hence, gut hormones 
secreted via distal L-cells are the major factors contributing to improved glucose 
metabolism post RYGB.  
Besides the above-mentioned gut hormones, ghrelin, which is a unique orexigenic 
hormone secreted from the stomach, was also widely examined post RYGB surgery. 
Ghrelin is a peptide produced by the X/A‐like endocrine cells in the fundus of the stomach 
during fasting (Date et al. 2000). Ghrelin expression has been proven to induce body 
weight and regulate glucose and energy metabolism (Klok et al. 2007). Previous research 
reported a reduction in circulating ghrelin post-RYGB. The author believed that the empty 
stomach and bypassed duodenum could generate a continuous stimulatory signal, which 
could in turn inhibit gherlin secretion via “override inhibition” (Cummings et al. 2002). On 
the contrary, other studies reported ghrelin either to be increased or unaltered (Barazzoni 
et al. 2013). This discrepancy may be due to the inconsistency of measurements between 
labs and ghrelin expression changing with weight loss and the potential fluctuation before 
establishing the homeostasis point post RYGB.  
1.2.3 Shifted gut microbiota 
Recent studies have shown that gut microbiota play an important role in obesity by 
increasing the host’s energy harvesting efficiency. The gut microbiota has been reported to 
be different between lean and obese individuals (Turnbaugh et al. 2006) (Turnbaugh et al. 
2008) (Ley et al. 2005). A shift of gut microbiota colonisation has been observed in 
multiple studies of bariatric surgery (Li et al. 2011a; Paziuk et al. 2013a; H. Zhang et al. 
2009a) and conserved among human, rat and mice. Consistently, a rapid and sustained 
increase in the γ-proteobacteria (Escherichia) and Verrucomicrobia (Akkermansia) and a 
significant decrease in Firmicutes was noted (Liou et al. 2013b). These changes may be 
elicited by the changed dietary composition, altered intestinal luminal pH and influenced 
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bile flow. One remaining question is whether the shifted microbiota is the cause or result of 
post-RYGB metabolism benefits, such as facilitated weight loss. An elegant study involving 
transfer of the gut bacteria from RYGB mice to unoperated germ-free mice has been 
reported. Liou et al. found that these faecal transplanted animals exhibited weight loss and 
decreased fat mass (Liou, Paziuk, Jesus-Mario Luevano, Machineni, Turnbaugh & Kaplan 
2013b). It suggested that change in gut microbiota might lead to, rather than be the 
consequence of, weight loss after RYGB. However, colonising RYGB microbiota in 
recipient mice for 2 weeks only elicited about 5% weight loss compared to 30-40% in 2 
week post RYGB surgery in rats. It suggested that shifted microbiota is not the sole reason 
of facilitated weight loss post RYGB. Nevertheless, faecal transplant still provides a novel 
and promising method of obesity treatment in the near future. 
1.2.4 Remodeled muscle promoter methylation 
Skeletal muscle is widely recognised as the most important organ involved in the 
development of insulin resistance in T2DM. Epigenetic factors, such as DNA methylation, 
appear to play a vital role in controlling environmentally induced transcriptional response, 
which could further regulate metabolism. In 2009, Barres et al. found that peroxisome 
proliferator-activated receptorγ (PPARγ) coactivator-1 α (PGC-1α) is hypermethylated and 
PGC-1α mRNA is decreased in T2DM patients, concomitant with reduced mitochondrial 
content in type 2 diabetic patients (Barrès et al. 2009).  Following this study, in 2013, 
Barres et al. (Barrès et al. 2013) showed that the metabolic benefits post-RYGB may be 
caused via epigenetic regulation, such as promoter methylation. The author found that 
post-RYGB there was an increase in PGC-1α mRNA expression and a decrease in PDK4 
mRNA expression in skeletal muscle. Furthermore, these mRNA alterations are strongly 
inversely correlated with their promoter methylation levels (Barrès et al. 2013). Hence, 
changes in DNA methylation and metabolic gene transcription may contribute to the post-
RYGB metabolism and insulin regulation.  
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1.2.5 Changed brain effects 
More and more attention has been drawn to brain mediated mechanisms in regulating 
energy metabolism. For RYGB surgery, three aspects of brain related/mediated effects 
have been described, 1) reduced appetite and changed food preference, 2) influenced 
hypothalamic signalling and 3) changed vagal mediated effects.  
1.2.5.1 Reduced appetite and changed food preference 
Conventional low calorie diet treatment for obesity showed an 80%-90% failure rate 
(Ayyad & Andersen 2000). The reason may be due to the robust compensatory 
mechanism, whereby low calorie diet leads to an increase in hunger, a decrease in satiety 
and a decrease in energy expenditure after initial weight loss. Unlike natural weight loss, 
patients undergoing RYGB surgery, on the other hand, reported reduced hunger, a faster 
satiation during meals and exhibit an increased energy expenditure (Roux et al. 2006) 
(Dixon et al. 2005). In addition to appetite, it has been increasingly recognised that RYGB 
may alter food intake through shifted taste preference. For example, patients showed a 
preference for high-fat diet over low fat diet before surgery, but this reversed after RYGB 
surgery (Thirlby et al. 2006). Additionally, many post RYGB patients experienced nausea, 
vomiting and abdominal pain after intake of fat and milk products, such as ice cream 
(Kenler et al. 1990). Furthermore, animal experiments also clearly demonstrated that post 
RYGB rats showed a decreased acceptance for a high-fat diet compared to the sham 
operated rat, and the effect could be increased with time post surgery (Zheng et al. 2009). 
In all, both the reduced appetite and shifted food preference towards healthy food may 
contribute to the restricted calorie intake post RYGB surgery.  
1.2.5.2 Influenced hypothalamic signaling  
In the brain, many anatomical regions are recognised to play roles in metabolism 
homeostasis. However, the hypothalamus is a particularly crucial region in sensing and 
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integrating signals from the periphery and effecting physiological changes in order to 
maintain energy homeostasis (Schwartz 2006). The hypothalamic arcuate nucleus 
contains two populations of neurons with opposing effects, specifically the orexigenic 
AgRP/NPY neurons and anorexigenic POMC neurons (Hahn et al. 1998). It was shown 
that leptin inhibits AgRP/NPY neurons and excites POMC neurons (Cone 2005). 
Furthermore, the effect of serotonin (5-hydroxytryptamine, 5-HT) is also mediated by the 
POMC expressed 5-hydroxytryptamine 2C receptors (Y. Xu et al. 2008). Both leptin and 
5HT have been reported to be altered post RYGB surgery, possibly stimulating the 
hypothalamus POMC neuron while inhibiting the AgRP/NPY neuron to achieve the 
reduced appetite effects. AgRP/NPY neuron can synthesise neuropeptide Y and γ-
aminobutyric acid (GABA). Interestingly, GABA expression was shown to be increased in 
post-RYGB faecal samples and the increased expression was believed to be derived from 
microbial processing of putrescine (J. V. Li et al. 2011a). There are no studies 
investigating whether the gut microbiota generated GABA contribute to brain GABA levels.  
Additionally, there is an established cross-talk between the hypothalamus and peripheral 
organs in controlling glucose homeostasis. For example, glucose sensing POMC neurone 
has been reported to control systemic blood glucose. High-fat diet induced obese mice 
exhibited an impaired uncoupling protein 2 mediated glucose sensing in POMC neuron 
(Parton et al. 2007). Furthermore, Osundiji et al showed that hypothalamic glucose 
sensors may also play an important role in controlling insulin secretion from the pancreas 
(Osundiji et al. 2012).  
1.2.5.3 Vagal mediated effects. 
The vagus is an important signaling relay system which sends signals between the gut and 
the brain. The vagal nerve has been proven to play a key role in the regulation of food 
intake, body weight control and release of gastrointestinal hormones, such as gastrin and 
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secretin. The vagal mediated effect post RYGB is still controversial. One study showed 
that vagal dissection during gastric bypass surgery could contribute to the early weight 
loss effect (Yong Wang & Liu 2009). However, another study showed that the preservation 
of vagal nerves during surgery was associated with greater and more sustained weight 
loss post RYGB (Seyfried et al. 2011). In all, the vagal mediated effects post RYGB 
surgery are still unclear and further studies should be carried out using vagatomy surgery.  
1.2.6 Changed bile flow and bile acids composition 
Bile acids are derived from hepatic cholesterol and oxysterols. Bile acids are known to 
regulate lipid and glucose metabolism via nuclear receptor farnesoid X receptor (FXR) and 
a G-protein family receptor TGR-5 (Fiorucci et al. 2010). Furthermore, bile acids could 
stimulate GLP-1 secretion through TGR5 activation in mice (Katsuma et al. 2005). Multiple 
studies have shown that circulating bile acid levels are more than 2 times higher post 
RYGB surgery compared to non-surgical controls (Simonen et al. 2012; Kohli et al. 2013). 
This increase could be mediated by an increased activity of hepatic CYP27A1, indicating a 
favoured acidic bile acid synthesis pathway. However, the most interesting finding of 
RYGB elicited bile acid alteration is not the increased total bile acid, but the decreased 
taurine-conjugated bile acids (Simonen et al. 2012).  It was showed that decreased 
taurine-conjugated bile acid after RYGB rather than increased serum total bile acids is 
highly correlated with the decreased respiratory quotient (RQ, stands for energy 
expenditure) (Simonen et al. 2012). Furthermore, increased lipid oxidation and decreased 
glucose oxidation after RYGB was only observed in those individuals who had a decrease 
in the levels of taurine-conjugated bile acids (Simonen et al. 2012). There is still an 
absence of detailed information  following this intriguing observation. Nevertheless, the 
role of bile acid provides another alternative mechanism of weight loss and glycaemic 
control post RYGB surgery.  
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1.3 MicroRNA 
MicroRNAs (microRNAs) are 18-25 nucleotides long non-coding RNAs that can silence or 
repress potentially thousands of genes at the post transcriptional level (L. He & Hannon 
2004). The first microRNA (lin-4) was discovered in 1993 in C elegans (R. C. Lee et al. 
1993). Seven years later, the second highly conserved microRNA let-7 was discovered 
(Reinhart et al. 2000). Since then many new microRNAs have been identified. There were 
1028 human microRNA sequences annotated on September 2010. Four years later, there 
are currently 1872 known homo sapien microRNAs according to miRBase 
(http://www.mirbase.org). MicroRNAs are estimated to regulate the expression of more 
than 60% of protein-coding genes (Friedman et al. 2009). MicroRNAs are not only involved 
in multiple biological processes, but also play important roles in various diseases. 
1.3.1 MicroRNA biogenesis 
The biogenesis of microRNA takes place through multiple-steps, which include RNAse 
enzymes Drosha and Dicer, and ultimately results in the production of mature 22 
nucleotide microRNA. MicroRNA biogenesis is initiated by RNA polymerase (pol) II or RNA 
pol III, which can help to form hairpin-shaped primary microRNA transcripts (pri-
microRNA). Pri-microRNA is then cleaved by the nuclear RNase III enzyme (Drosha) and 
DGCR8 (Pasha) to release the 70 nt precursor of microRNA (pre-microRNA) (Han et al. 
2004). After nuclear processing, pre-microRNAs are exported to the cytoplasm by 
Exportin-5  (XPO-5) in complex with Ran-GTP (Bohnsack et al. 2004). Cytoplasmic pre-
microRNAs are then processed and multi-protein RNA induced-silencing complex (RISC) 
is assembled mediated by the RISC loading complex (RLC), which is a multi-protein 
complex composed of cytoplasmic RNase III (Dicer), double stranded Tar RNA binding 
protein (TRBP), protein activator of PKR (PACT) and core component Argonaute-2 (Ago2) 
(Tomari et al. 2004; MacRae et al. 2008). The loop of the pre-microRNA is cleaved by 
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Dicer to produce an approximately 22 nucleotide double stranded microRNA duplex. 
Finally, one strand of the dicer duplex is bound by Argonaute to form an miRNA-induced 
silencing complex (miRISC), which targets mRNAs for regulation. The other strand, which 
is often called the star strand (miRNA*), is degraded. (Fig.1.3) 
Traditionally, it was believed that microRNA repress protein production via decreasing 
translational efficiency or facilitating mRNA degradation by de-adenylation. However, a 
recent study using ribosome profiling shows that the lowered mRNA levels account for the 
majority (84%) of decreased target protein production (H. Guo et al. 2010). Interestingly, 
microRNA inhibits its target’s expression first by translation repression, followed by mRNA 
degradation.  
	  
 Figure 1-3 The biogenesis of microRNA 
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1.3.2 microRNA and metabolism 
Diabetes is a worldwide chronic disease defined as a metabolic disorder of multiple 
aetiologies. It is characterised by hyperglycaemia with disturbances of carbohydrate, fat 
and protein metabolism resulting from defects in insulin secretion, insulin action, or both 
(Alberti & Zimmet 1998). MicroRNA plays an important role in insulin production, secretion 
and pancreatic development. Recent data have also shown that microRNAs have a 
different expression pattern in hyperglycaemic status (Heneghan et al. 2010).  
1.3.2.1 MicroRNAs in regulating glucose metabolism 
The first insulin production and secretion related microRNA, miR-375, was reported in 
2004, and is a pancreatic islet-specific microRNA (Poy et al. 2004). The over-expression of 
miR-375 suppressed glucose-induced insulin secretion, and conversely, inhibition of 
endogenous miR-375 enhanced insulin secretion (Poy et al. 2004). EI Quaamari A et al. 
have shown that miR-375 is involved in regulation of insulin gene expression thorough 3'-
phosphoinositide-dependent protein kinase-1 (PDK1). PDK1 has a central role in the 
regulation of cell growth and organ development, and the ablation of PDK1 in beta-cells 
could induce diabetes after a reduction in beta-cell mass (Rintelen et al. 2001; Hashimoto 
et al. 2006). MiR-375 directly targets PDK1 and reduces its protein expression resulting in 
decreased glucose-stimulatory action on insulin gene expression and DNA synthesis. Poy 
and colleagues also provide evidence that miR-375 is essential for glucose homeostasis, 
pancreatic alpha and beta cell turnover and adaptive beta-cell expansion in response to 
increasing insulin demand in insulin resistance (Poy et al. 2009).  Moreover, by knocking 
out miR-375, mice suffered hyperglycaemia and glucose intolerance, which is associated 
with impaired gluconeogenesis (Poy et al. 2009). In summary, miR-375 plays a key role in 
regulating glucose metabolism not only via regulating insulin secretion, but also by 
regulating  pancreatic cell development.  
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There is also some evidence that other microRNAs are also involved in regulating insulin 
secretion and islet development. Plaisance et al. have shown that over-expression of miR-
9 in insulin-secreting cells could cause a reduction in exocytosis elicited by glucose 
(Plaisance et al. 2006)13, and Lovis et al. showed that miR-124a and miR-96 modulate the 
expression of proteins involved in insulin exocytosis and affect the insulin secretion of the 
beta-cell line MIN6B1 (Lovis, et al. 2008a). Additionally, Foxa2 has been described as a 
main regulator of pancreatic development and is also involved in glucose metabolism and 
insulin secretion and miR-124a plays a key role in pancreatic development through the 
regulation of Foxa2 expression (Baroukh et al. 2007).  
More recently, several studies have monitored the microRNA expression changes 
between normoglycaemic and hyperglycaemic exposure or diabetes both in vitro and in 
vivo. MiR-30d (X. Tang et al. 2009), miR-125a (Herrera et al. 2009), miR-133a (Fred et al. 
2010) and miR-126 (Zampetaki et al. 2010) all showed differences in levels of expression 
between normal and abnormal glucose levels, which indicates that they may be involved in 
insulin gene expression or diabetes progress.  
1.3.2.2 microRNA in regulating lipid metabolism 
Lipids don’t only act as energy stores, but are also an important class of signalling 
molecule. MiR-33 and miR-122 are two of the most well-studied lipid homeostasis related 
microRNAs.  
For miR-33, an interesting miR-33-SREBP (sterol regulatory element binding proteins) 
regulatory circuit has been established (Rayner et al. 2010). SREBP is an important class 
of transcriptional factor that controls the expression of numerous genes involved in fatty 
acid and cholesterol metabolism and the production of phospholipids and triglycerides 
(Horton et al. 2002). The conservative miR-33a is embedded in the intron of SREBP-2 on 
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chromosome 22, whereas the miR-33b is located in the intron of SREBP-1 on 
chromosome 17. The intron microRNAs are normally co-expressed with the host genes, 
hence the co-expression pattern of SREBP and miR-33 has been found in multiple tissue 
types, including liver, brain, heart, muscle, spleen, kidney and lung (Najafi-Shoushtari et al. 
2010; Rayner et al. 2010). The activation of SREBP-1 induces the expression of genes 
involved in fatty acid, phospholipid and triglyceride synthesis, whereas SREBP-2 activates 
genes that control cholesterol synthesis and uptake (Ye & DeBose-Boyd 2011). 
Interestingly, miR-33a and miR-33b could inhibit fatty acid degradation and cholesterol flux 
through their targets adenosine triphosphate–binding cassette transporter A1 (ABCA1) 
and carnitine palmitoyltransferase 1A (CPT1A) (Najafi-Shoushtari et al. 2010; Rayner et al. 
2010). This suggests that miR-33 and its host gene SREBP could coordinate with each 
other to achieve, and more efficiently control, lipid and cholesterol homeostasis.  
MiR-122 is another well-studied hepatic microRNA regulating lipid metabolism. The 
discovery of miR-122 dates back to 2002 (Lagos-Quintana et al. 2002) and  has been 
identified as the most abundant microRNA in the liver, and accounts for around 70% of all 
hepatic microRNA (Chang et al. 2004). Multiple studies have revealed the important roles 
of miR-122 in regulating lipid metabolism. By inhibiting miR-122 using antisense locked 
nucleic acid, decreased plasma cholesterol and triglyceride levels are observed, which is 
associated with increased fatty acid oxidation and changed cholesterol biosynthesis (Esau 
et al. 2006). On the contrary, adenoviral overexpression of miR-122 leads to increased 
cholesterol biosynthesis (Krutzfeldt et al. 2005).   
Besides the aforementioned miR-33 and miR-122, other microRNAs have also been 
related to lipid metabolism. For example, miR-14 and miR-278 have been shown to 
regulate fat metabolism in Drosophila melanogaster (Telernan & Cohen 2006; P. Xu et al. 
2003). By knocking out miR-14 in vivo, flies showed increased levels of triglycerides and 
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diacylglycerol (P. Xu et al. 2003). In addition, miR-14-null flies had significantly increased 
lipid droplet accumulation in adipose tissue. MiR-278 mutants showed elevated insulin 
production and a lean phenotype via a reduction in whole body fat levels (Telernan & 
Cohen 2006). Previous studies have also shown that miR-103 and miR-107 (Wilfred et al. 
2007), the miR-143 clusters (Esau et al. 2004) and the miR-17-92 clusters (Qiang Wang et 
al. 2008) are all involved in regulating fatty acid metabolism.  
1.3.2.3 microRNA in metabolic syndrome 
Metabolic syndrome is defined as a combination of medical disorders which could increase 
the risk of developing cardiovascular diseases and diabetes (Alberti et al. 2006). According 
to the National Cholesterol Education Program’s Adult Treatment Panel III report (ATP III), 
there are 6 components of metabolic syndrome: abdominal obesity, atherogenic 
dyslipidemia, raised blood pressure, insulin resistance and glucose intolerance, a pro 
inflammatory state, and a prothrombotic state (the abnormal tendency of developing blood 
clots) (Grundy et al. 2004). MicroRNA have been implicated as key regulators of metabolic 
homeostasis. It is not surprising that under an abnormal metabolic environment, such as 
obesity and diabetes, the expression of microRNAs is altered. The result of this change 
could either be beneficial, in that it helps to maintain normal metabolic homeostasis, or 
detrimental, facilitating the abnormal metabolic process.  
Numerous studies have addressed the microRNA dysregulation in diabetes and obesity 
using various animal models and in patients. For example, in non-obese diabetic (NOD) 
mice, the miR-29 family, miR-21, and miR-34a showed up-regulation in pancreatic islet 
cells (Roggli et al. 2010). In leptin receptor-deficient (db/db) mice, miR-34a and miR-146, 
expressed in pancreatic islet cells, were up-regulated (Lovis, Roggli, et al. 2008b). In leptin 
deficient obese (ob/ob) mice and diet induced obesity (DIO) mice, miR-143 and miR-802 
are increased in the liver (Jordan et al. 2011; Kornfeld et al. 2013), while miR-103 and 
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miR-107 is altered in the white adipose tissue (Wilfred et al. 2007). Inconsistent results 
have been published for miR-375; Bolmeson et al. showed miR-375 merely changed in 
human diabetic subjects’ islet cells (Bolmeson et al. 2011), whereas Zhao et al. reported 
that miR-375 is up-regulated in the islets of T2DM (Zhao et al. 2010).  
Recent studies also suggest that extracellular circulating microRNA could be considered 
as biomarkers of diabetes and obesity. By using a cohort of 80 patients, a group of 
microRNAs were found to be correlated with T2DM, including decreased miR-20b, miR-21, 
miR-24, miR-15a, miR-126, miR-191, miR-197, miR-223, miR-320, and miR-486 
expression and elevated miR-28-3p expression (Zampetaki et al. 2010). Kong et al. 
reported that 7 microRNAs could be linked with diabetes including miR-9, miR-29a, miR-
30d, miR-34a, miR-124a, miR-146a and miR-375 (Kong et al. 2011). A more recent study 
profiled circulating microRNAs in 32 men after surgery-induced weight loss and in 6 
morbidly obese patients and identified a microRNA signature of obesity (Ortega et al. 
2013). The result was cross-validated in 80 men and 22 surgery-induced weight loss 
patients. It was suggested that morbidly obese patients showed a marked increase of miR-
140-5p, miR-142-3p, miR-222 and decreased levels of miR-532-5p, miR-125b, miR-130b, 
miR-221, miR-15a, miR-423-5p and miR-520-3p. Bariatric surgery-induced weight loss 
leads to a significant decrease in miR-140-5p, miR-122, miR-193-5p and miR-16-1 and up-
regulation of miR-221 and miR-199-3p (Ortega et al. 2013).  
1.3.3 Circulating microRNAs 
Blood containing RNA has long been considered as a promising biomarker for disease 
diagnosis. The phenomenon that circulating RNA can stably survive in RNase-rich plasma 
dated back to 2004 (El-Hefnawy et al. 2004). The important features and functions of 
circulating microRNA are summarised and presented below.  
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1.3.3.1 Circulating microRNAs stability 
Circulating microRNAs have been consistently reported to remain stable in serum, which 
contains high levels of ribonuclease enzymes, which degrade RNA. However, microRNA 
combined proteins or packaged particles may function to protect circulating microRNAs 
from being digested by RNase. Moreover, circulating RNA has been shown to withstand 
high temperatures, extreme pH levels, multiple freeze-thaw cycles, prolonged incubation at 
room temperature (24 hours) (Tewari et al., 2008) and even 10 years storage (Zhu et al., 
2009).  
1.3.3.2 Detecting circulating microRNA 
Since circulating microRNAs are present at much lower concentration than other tissues, 
detecting and analysing them is a real challenge. There are several technologies available 
for circulating microRNA profiling, such as deep sequencing, microRNA microarray and 
quantitative real-time PCR (qRT-PCR). The most widely used is qRT-PCR, which has a 
high specificity and sensitivity; for example a previous study has shown that 220 
microRNAs can be detected in a single cell (Tang et al., 2006). Technology development 
makes the detection of low level circulating RNA possible. Nonetheless, conflicting data 
have been published due to differences in blood collection and serum separation 
protocols, the use of various microRNA profiling methods and a lack of a universally 
accepted method of normalisation. In solid tissue samples, microRNA expression is 
always normalised with internal consistently expressed reference RNAs, for example 18S, 
5S ribosome RNA and small nuclear RNAs. For circulating microRNA, the expression 
stability of the above mentioned reference RNAs needs to be examined before using them 
to normalise the data. Synthetic C elegans microRNAs, cel-miR-39, cel-miR-54 and cel-
miR-238, have been used as internal standards and have proved to be an alternative 
useful normalisation tool (Mitchell et al. 2008). Different normalisation methods need to be 
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examined and compared before drawing any conclusion related to circulating microRNA 
expression level. 
1.3.3.3 Circulating microRNAs secretion and function 
Based on recent findings, there are at least four ways that microRNAs can be combined 
with protein or packaged and transported into the bloodstream. MicroRNAs can be 
packaged into exosomes or microparticles and secreted into circulating blood. Both 
exosomes and microparticles are membrane-bound small particles with different sizes. 
Exosomes originate from endosome-derived intracellular multivesicular bodies, with range 
from 30 to 100 nm, whereas microparticles, also called microvesicles, are larger (100-1500 
nm) and are shed directly from the cell membrane (Ratajczak et al., 2006). Both exosome 
and microparticles have been reported as physiological carriers of microRNA (Zhang et al., 
2010, Hunter et al., 2008). Likewise, cellular microRNA can be exported in conjunction 
with high density lipoprotein (HDL) (Vickers et al., 2011) and 96 KDa argonaute protein 2 
(Ago-2) (Turchinovich et al., 2011, Arroyo et al., 2011). Jason D. Arroyo and colleagues 
elegantly demonstrated that at least two forms of circulating microRNA exist in plasma or 
serum, vesicle-associated and non-membrane bound forms. Surprisingly, approximately 
90% of microRNAs in circulation are present in the latter non-membrane bound form 
(Arroyo et al., 2011). Vickers et al. found that plasma-derived high density lipoproteins 
(HDL) contain microRNAs. Furthermore, these HDL can transport endogenous microRNA 
to recipient cells with functional abilities (Vickers et al., 2011). This evidence suggests that 
circulating microRNA may function as communicators between cells, yet little is known 
about how these circulating microRNAs are secreted into the circulation and what 
functional differences there are between the above-mentioned vesicle-associated and non-
membrane bound microRNAs.  
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1.4 Hypothesis 
The aims of this project were 1) to examine whether RYGB surgery influences circulating 
and colorectal microRNA profiles 2) to determine whether the microRNAs are involved with 
the altered metabolic effects post RYGB surgery and 3) to assess the causes of RYGB 
induced microRNA dysregulation. 
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2. Materials and Methods 
2.1 Animal experiment and tissue collection 
2.1.1 Design of the animal study 
The animal experiment was carried out under a UK home office license (PL 70-6669). 
Thirteen male Sprague Dawley (SD) rats were individually housed and kept under a 
12h/12h light/dark cycle at room temperature. All rats were acclimatized and fed on high 
fat diet (Altromin C 1090 - 60 obesity-inducing diet) for 1 week prior to the experiment. 
Animals were randomly divided into two groups: RYGB (n=8) and sham (n=5). The 
antibiotic combination amoxicillin/flucoxacillin was administrated to all rats at a dose of 
12.5 mg each,  pre-surgery.  
The sham procedure was carried out including a 7 mm gastrotomy on the anterior wall of 
the stomach with subsequent closure (interrupted prolene 5-0 sutures) and a 7 mm 
jejunotomy with subsequent closure (running prolene 6-0 suture). For the RYGB 
procedure, the proximal jejunum was divided 15 cm distal to the pylorus to create a 
biliopancreatic limb. After identification of the cecum, the ileum was then followed 
proximally to create a common channel of 25 cm. Here, a 7 mm side-to-side Jejuno-
Jejunostomy (running prolene 7-0 suture) between the biliopancreatic limb and the 
common channel was performed. The gastric pouch and alimentary limb were 
anastomosed end-to-side using a running prolene 7-0 suture. The gastric remnant was 
closed with interrupted prolene 5-0 sutures. The complete bypass procedure lasted 
approximately 60 minutes and the abdominal wall was closed in layers using 4-0 and 5-0 
prolene sutures. Approximately 20 minutes before the anticipated end of general 
anesthesia, all rats were injected with 0.1 ml of 0.3% buprenorphine subcutaneously to 
minimize postoperative discomfort.  Immediately after abdominal closure, all rats were 
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injected subcutaneously with 5 ml of normal saline to compensate for intra-operative fluid 
loss. After 24 hours of wet diet (normal chow soaked in tap water), regular chow was 
offered on postoperative day 2 and throughout the remaining experiment period. 
2.1.2 Tissue collection method 
Tissues, including liver (left lobe), pancreas, spleen, heart, white fat, duodenum 
(biliopancreatic limb if RYBG), jejunum (alimentary if RYBG), ileum (common channel if 
RYBG) and colon were collected 53 days after surgery. Approximately 5ml of the whole 
blood was taken from the heart, 2.5 ml of which was transferred into an EDTA-containing 
tube (BD Bioscience) for Taqman low density assay cards (TLDA) and the remaining to a 
sodium heparin-coated tube (BD Bioscience) for metabonomics analysis. After a gentle 
shake, blood with anti-coagulant reagents was immediately centrifuged at 6000 rpm at 
room temperature for 10 minutes. The plasma samples obtained using the  anticoagulants 
were then transferred into two 1.5ml RNase-free Eppendorf tubes, separately. All samples 
were immediately snap-frozen in liquid nitrogen and stored at -80ºC. 
 
Figure 2-1 Experiment outline for rat with RYGB and sham-operated surgery 
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2.2 Tissue culture 
All cell culture reagents were supplied by Invitrogen (Life Technology), unless otherwise 
stated, and Corning standard tissue culture plated plasticware was used for all cultures. 
2.2.1 Cell resuscitation 
In order to resuscitate a cell line, a vial of frozen cells was removed from liquid nitrogen 
storage. Cells were allowed to reach room temperature for 1-2 minutes, warmed gently in 
a water bath (37ºC) until partially thawed. Approximately 0.5mL pre-warmed media was 
then added into the vial and the mixture was then centrifuged at 1000g for 1minute. The 
DMSO containing freeze media was removed and cells were re-suspended in 1mL 
complete media. Cells were cultured in T25 flasks under standard culture conditions 
(37ºC, 5%CO2 and 95% air). After reaching confluence, cells were transferred into T75 
flasks for routine culturing and experiments.  
2.2.2 Cell passaging 
Cells were routinely maintained in T75 flasks in approximately 15mL complete media. 
Cells were subcultured after reaching approximately 80% confluence. To sub the adherent 
cells, the cell monolayer was first rinsed with sterile phosphate-buffered saline (PBS) and 
then incubated with 0.05% trypsin-EDTA (ethylenediaminetetraacetic acid) until 
suspension. Cells were gentle shaken and pipetted up and down to minimise the 
trypsinisation time. Trypsinisation was terminated by adding an equal volume of complete 
media. The media-trypsin cell mixture was then centrifuged at 1000g for five minutes. The 
supernatant was removed and the pellet re-suspended in fresh media and seeded into 
new flasks at 1:3 to 1:6 dilutions depending on the different cell lines. 
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2.2.3 Cell count 
Cells were manually counted using haemocytometer and  Trypan Blue reagent was used 
to determine cell viability. Trypan Blue dye is taken up by dead cells, due to 
permeabilisation of their cell membrane, allowing differentiation between live and dead 
cells. Generally, an aliquot of the cell suspension (10µL) was added to an equal volume of 
0.4% Trypan Blue (10µL). The cells and Trypan Blue were mixed with a pipette and then 
incubated at room temperature for 1-2 minutes. Approximately 8µL of the mixture was then 
loaded onto a haemocytometer. Non-blue cells (live population) were counted in at least 9 
squares, averaged, and the total number of live cells determined by the equation below. 
Generally cells are diluted 1:1 (vol:vol) with Trypan Blue, thus there is a dilution factor of 2 
in the equation. Furthermore, the number of cells in the Trypan Blue suspension are in an 
area of 1mm x 1mm x 0.1mm (or 0.1mm3), hence to calculate cells/mL need to multiply by 
104 in the equation. 
Cell number = cell count (per square) * 2 *104  
2.2.4 Cell freezing 
In order to preserve the cell line, cells were frozen and stored in liquid nitrogen. To prepare  
stock, cells from early passage were pelleted and resuspended in 95% media and 5% of 
dimethylsulphoxide (DMSO). Cells were then frozen at -80ºC  for 24 hours before finally 
transferred into a liquid nitrogen dewer. 
2.2.5 FAO cell line culture condition 
FAO (rat hepatocarcinoma) were routinely cultured in complete media consisting of phenol 
red-free MEM (minimum essential medium, Invitrogen) supplemented with 10% v/v FBS 
(fetal bovine serum), 1% v/v NEAA (non- essential amino acids), 2mM L-glutamine and 1% 
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Penicillin/Streptomycin (100U/mL, 100µg/mL respectively) to prevent the growth of 
bacteria.  
2.2.6 B13(H) cell line culture condition 
B13 (pancreatic progenitor cell line) were routinely cultured in complete media consisting 
of DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% v/v FBS (fetal 
bovine serum) and 1% Penicillin/Streptomycin (100U/mL, 100µg/mL respectively) to 
prevent the growth of bacteria. After reaching the required number, B13 cells can be 
induced to differentiate by synthetic glucocorticoid dexamethasone (10nM) (Shen et al. 
2000), which was dissolved in ethanol.  
2.2.7 Glucose treatment experiment  
Glucose treatments were carried out in 6 well plates. Cells (5 X 105 / well) were seeded 
with 2.5mL normal FAO complete media (MEM, 10%FBS, 1% Pen/Strep, 2mM L-
glutamine and 1%NEAA) at two days before treatment. FAO cells were given 24 hours 
(37ºC, 5% CO2) to attach to the plastic substrate in the normal media. After which, the 
media was aspirated, cells were carefully washed with warm PBS and an equivalent 
volume (2.5mL) of experimental media (glucose-free MEM without serum and antibiotics) 
added. After 24 hours incubation, media was aspirated and cells were replenished with 
2.4mL fresh experimental media. In the meantime, α-D-Glucose (Sigma-Aldrich, 180.16 
g/mol) was dissolved in experimental media to 625mM, 375mM and 125mM and sterilised 
using a 0.2µM filter (Millipore). Glucose solution (100µL) was added into each 6 well plate 
with an equal amount of media added as controls. Hence the final glucose treatment 
concentrations in each well were 25mM, 15mM and 5mM. All experiments were done with 
at least three biological replicates and FAO cells were harvested after 2 hour and 8 hour 
incubation at 37ºC, 5% CO2. All cells were washed with cold PBS before harvesting with 
1mL Trizol.  
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2.2.8 Dexamethasone treatment 
Dexamethasone treatments were carried out in 6 well plates. Similar to the glucose 
treatment experiment, FAO cells (5 X 105 / well) were seeded with 2.5mL complete FAO 
culture media (phenol red-free MEM, 10% v/v FBS (foetal bovine serum), 1% v/v NEAA, 
2mM L-glutamine and 1% Penicillin/Streptomycin) two days before treatment. Old media 
was removed and a serum-free media was added into cells 24 hours later. On treatment 
day, old media was replaced with fresh serum free media and ethanol dissolved 
dexamethasone (treatment concentration 10nM) was added. Dexamethasone stock 
solution was 1mM. A serial dilution was applied with 1:100 (v:v) and then 1:1000 (v:v) 
which made the final treatment concentration 10nM in cell culture media. Two sets of 
experiments were carried out. For 24 hour treatment, 3 biological replicates were used and 
cells were maintained in same dexamethasone contained media for the whole 24 hours. 
For 96 hour treatment experiment, 6 biological replicates were used and the experimental 
dexamethasone containing media was replaced with fresh at 48 hours. All cells were 
incubated at 37ºC, 5% CO2 and cells were washed with cold PBS before harvesting with 
1mL Trizol.  
2.2.9 PPARα (fenofibrate) and PPARγ (rosiglitazone) treatment 
PPARα and PPARγ agonist treatment experiments were carried out in B13H cell line. 
Generally, B13 cells were seeded into 6 well plate in 2.5mL normal B13 media (DMEM, 
10%FBS and 1% Pen/Strep) with 5X105 cells in each well. Treatment with dexamethasone 
(10nM, dissolved in ethanol, prepared and preserved in glass, used within 1 month) was 
applied for two weeks to allow pancreas to liver transdifferentiation. Cells were replenished 
with fresh B13 media and dexamethasone every 2 days. At day 15, all B13 media with 
dexamethasone was removed and the transdifferentiated hepatocyte-like B13H cells were 
washed with 1mL warm PBS. Then, 2.5mL experimental media (DMEM, no FBS, Pen/step 
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and no dexamethasone) was added to each well. Fenofibrate (306.84g/mol, Abcam) was 
dissolved in ethanol to final concentrations of 10mM, 30mM and 50mM (0.0180g 
fenofibrate in 1mL ethanol). Rosiglitazone (357.43g/mol, Abcam) was dissolved in DMSO 
to final concentrations of 10mM, 30mM and 50mM (0.0179g rosiglitazone in 1mL DMSO). 
To treat the B13H cells, 2.5µL fenofibrate/ rosiglitazone solution was added into each well, 
which made the final fenofibrat/ rosigalitazone treatment concentrations 10µM, 20µM and 
50µM. For fenofibrate control wells, 2.5µL ethanol vehicle was added, while 2.5µL DMSO 
vehicle was added for rosiglitazone control wells. All treatments were done with 3 
biological replicates. The treated cells were harvested after 24h incubation in 37ºC, 5% 
CO2. All cells were washed with cold PBS before harvesting with 1mL Trizol.  
2.2.10 Fatty acid (arachidonic acid) treatment 
2.2.10.1 Arachidonic acid treatment for 1 hour 
Arachidonic acid treatment experiment was carried out in B13H cell line. As before, 5X105 
B13 cells were seeded into wells of 6 well plates in 2.5 mL normal B13 media (DMEM, 
10%FBS and 1% Pen/Strep). Treatment with dexamethasone (10nM, dissolved in ethanol, 
prepared and preserved in  glass , used within 1 month) were applied for two weeks to 
allow pancreas to liver transdifferentiation. Cells were replenished with fresh B13 media 
and dexamethasone every 2 days. At day 15, B13 media with dexamethasone was 
removed and the transdifferentiated hepatocyte-like B13H cells were washed with 1mL 
warm PBS. Then, 2.5mL experimental media (DMEM, no FBS, no Pen/step and no 
dexamethasone) were added to each well. Arachidonic acid (purchased from Sigma-
Aldrich, liquid, 250mg/mL = 780mM) was diluted to 300mM (1:2.6 dilution), 100mM (1:7.8 
dilution) and 30mM (1:26 dilution) in ethanol. To treat the B13H cells, 2.5µL arachidonic 
acid solution was added into each well, which made the final arachidonic acid treatment 
concentrations 30µM, 100µM and 300µM. For control wells, 2.5µL ethanol vehicle was 
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added. All treatments were done with at least 3 biological replicates. The treated cells 
were harvested after 1 hour incubation in 37ºC, 5% CO2. All cells were washed with cold 
PBS before harvesting with 1mL Trizol.  
2.2.10.2 Arachidonic acid treatment for 10 minutes, 1 hour, 4 hour and 10 hour 
Arachidonic acid treatment experiment was carried out in B13H cell line. B13 cells 
(2.5X105) were seeded into 12 well plate in 1mL normal B13 media (DMEM, 10%FBS and 
1% Pen/Strep). Treatment with dexamethasone (10nM, dissolved in ethanol, prepared and 
preserved in glass, used within 1 month) was applied for two weeks to allow pancreas to 
liver transdifferentiation. Cells were replenished with fresh B13 media and dexamethasone 
every 2 days. At day 15, all B13 media with dexamethasone was removed and the 
transdifferentiated hepatocyte-like B13H cells were washed with 0.5 mL warm PBS. Then, 
1mL experimental media (DMEM, no FBS, Pen/step and dexamethasone) was added to 
each well. Arachidonic acid (purchased from Sigma-Aldrich, liquid, 250mg/mL = 780mM) 
was diluted to 150mM (1:5.2 dilution), 100mM (1:7.8 dilution) and 50mM (1:15.6 dilution) in 
ethanol. To treat the B13H cells, 1µL arachidonic acid solution was added into each well, 
which made the final arachidonic acid treatment concentrations 50µM, 100µM and 150µM. 
For control wells, 1µL ethanol vehicle was added. All treatments were done with at least 3 
biological replicates in each time points. The treated cells were harvested after 10 minutes, 
1 hour, 4 hour and 10 hour incubation in 37ºC, 5% CO2. All cells were carefully washed 
with cold PBS before harvesting with 0.5mL Trizol.  
2.2.11 microRNA inhibitor/mimic transfection 
MiRDIAN miR-122 mimic (C-320349-05-0005) and scrambled microRNA negative mimic 
control (CN-001000-01-05) were purchased from Thermo Scientific. Pancreatic derived 
B13 cells were plated 1x105 in 24 well plates and dexamethasone  (10nM) was used to 
transdifferentiate the cells into hepatocytes for 2 weeks as described before (Marek et al. 
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2003). Dexmethasone was removed 24 hours before transfection. Before transfection, all 
cells were changed into the serum/antibiotics-free OPTI-MEM media (Invitrogen). Cells 
were transfected using Lipofectamine 2000 (Invitrogen) for 96 hours. Transfection complex 
was prepared according to manufacture’s description. MiR-122 mimic and scramble 
control were dissolved with siRNA buffer to the concentration of 20µM. To treat the cells 
with 20nM, mimics and control were further diluted in Opti-MEM (invitrogen) (1:100). 
Lipofectamine was diluted 6:100 (v:v, lipo:opti-MEM). Both reagents were incubated 5 
minutes at room temperature and then mixed together with gentle pipetting. Mixtures were 
incubated at room temperature for exactly 20 minutes. Finally, the complete 100µl mixture 
was added to assigned 24 well plate wells with cells and  400µL opti-MEM. Cells were 
harvested 96 hours later with PBS wash before harvesting. 
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2.3 RNA isolation and quantification 
2.3.1 Circulating RNA extraction and optimisation 
Isolation of plasma total RNA was performed using the mirVANA PARIS isolation kit 
(Ambion, Applied Biosystems Inc.) following the manufacturer’s instructions with minor 
modifications. Plasma total RNA extraction method was optimised by comparing mirVANA 
microRNA isolation kit, TRIzol reagent (Invitrogen) and mirVANA PARIS kit (Ambion, 
Applied Biosystems Inc.). MirVANA PARIS kit was found to be the best-performing and all 
plasma samples in this study were examined using this method.  
Working as an extraction normalizer, synthetic Caenorhabditis elegans cel-mir-39 (cel-
miR-39) was added to the mixture of plasma and denature buffer. In order to analyse the 
protein denaturation time, the plasma sample was divided into three and incubated with 2 
X denature buffer for 0 minute, 5 minutes and 20 minutes with multiple concentrations of 
cel-miR-39s (25fmol, 50fmol, 250fmol and 500fmol). The result suggested 5 minutes 
incubation time with 250fmol spike-in cel-miR-39 was optimal. All of the plasma samples 
were then extracted using the conditions described above.  
As shown in Figure 2.2 below, plasma (100µL) was diluted with 100 µL cell disruption 
buffer (provided by miRVANA PARIS kit) and then an equal volume of 2 X denature 
solution (miRVANA PARIS kit ) was added. The dilution of plasma is crucial for achieving 
successful RNA isolation since plasma contains a large amount of protein which could not 
be completely separated if inappropriately diluted. Synthetic Caenorhabditis elegans cel-
mir-39 was added to the mixture of diluted plasma and denature solution. By adding equal 
amount (400µL) of acid phenol:chloroform solution, RNA was separated as supernatant. 
The RNA was then purified using filter cartridge containing a glass-fiber filter which 
immobilizes the RNA by washing with solution I and II as per manufacturer’s instruction. 
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Finally, RNAs were eluted by 100 µL 95ºC DNase, RNase-free water. All of the samples 
were stored at -80ºC until use.  
 
 
2.3.2 Tissue/ cell total RNA extraction 
Total tissue and cells containing RNA was extracted from the liver/ colon tissue and cell 
culture collection using Trizol (Invitrogen) following the manufacturer’s instructions. RNA 
Zap (Ambion) was used to clean surfaces to remove potential RNases. To minimise RNA 
degradation, frozen liver/colon were cut frozen and transferred into Trizol immediately. 
Approximately 50mg tissue sample and one T75 flask of cells were extracted using 1ml of 
Trizol. Following homogenisation at room temperature, the insoluble material was removed 
by centrifugation at 12000g for 10 minutes. Chloroform (200µL, Sigma) was then added to 
each sample and the samples were shaken vigorously for 15 seconds and  centrifuged at 
4ºC at 12000g for 15 minutes to achieve phase separation. The top aqueous phase which 
contains RNA was then transferred into a new EP tube. Total RNA, which includes 
ribosomal RNA, mRNA, transfer RNA, microRNA etc., was then precipitated with 0.5mL 
isopropanol at room temperature for 10 minutes. Samples were centrifuged at 12000rpm 
for 10 minutes to pellet the RNA. The RNA pellet was then washed with 75% ethanol 1-2 
Figure 2-2 Plasma total RNA extraction procedure 
The plasma isolated from rats was diluted with cell disruption buffer (supplied with the miRVANA PARIS kit) and spiked 
with synthetic cel-miR-39. The plasma/disruption buffer mixture was then mixed with acid phenol:chloroform and RNA 
was purified with filter cartridge and eluted using 100µl water.  
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times, air-dried, and dissolved in RNA-free water. The solution containing pure RNA was 
aliquoted, and stored at -80ºC. 
2.3.3 Tissue RNA quality control (Agilent bioanalyzer) 
In order to assess the purity and integrity of the RNA samples, Agilent Bioanalyser and 
Eukaryote total RNA Nano kit were used to determine the RNA integrity number (RIN) 
which indicates the extent of RNA degradation and purity. Generally, a RIN score bigger 
than 8 is considered as good quality RNA,  which could be further processed with deep 
sequencing/ microRNA array/ TLDA experiments. The Agilent bioanalyser produces an 
electropherogram and gel-like image which allows users to visualise RNA degradation. A 
typical Agilent bioanalyser report is shown below (Figure 2.3). 
The Bioanalyser protocol was followed as per the manufacturer’s protocol and conducted 
at the Genomics Laboratory in the Medical Research Council Center at Hammersmith 
Hospital. 
   52 
 
 
Figure 2-3 Example of Agilent bioanalyzer result 
The X axis has units of seconds (s) whilst the Y axis is fluorescence units (FU). Sample 1-11 (rat liver and colon total 
RNAs) `+have RIN greater than 8. For sample 12 (rat total plasma RNA), the RIN cannot be detected. The two major 
peaks in sample 1-11 are the ribosome RNA 18s and 28s, respectively. In sample 12, due to the existence of RNase, 
there is no ribosome RNA detected. 
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2.3.4 Tissue RNA quantification (Nanodrop) 
To measure the RNA concentration, a Nanodrop, micro-volume ultraviolet-visible 
spectrophotometer (Thermo Scientific, Germany), was used. Nanodrop measures the 
absorbance spectrum from 220nm to 350nm using 1-3 µL of the sample. RNA has 
maximum absorbance at 260nm and pure RNA has a 260:280 ratio of 2.0-2.1. Hence low 
260:280 and 260:230 absorbance ratios indicate the presence of impurities in the samples. 
Generally, RNA could be defined as good quality with a 260:280 and 260:230 absorbance 
ratio ranging from 1.8 to 2.0. A low 260:230 ratio may be the result of residual phenol and 
guanine and further purification step should be added to increase the ratio. 
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2.4 PCR 
2.4.1 Taqman the low density array card (TLDA) 
In order to increase the small quantity of cDNA, the RT products were preamplified. A fixed 
amount of 2.5 µL RT product was combined with 12.5 µL Taqman PreAmp Master Mix 
(2×) and 2.5 µL Megaplex™ PreAmp Primers (10×) to generate a final 25 µL 
preamplification PCR mix. Preamplification was carried out by following the manufacture’s 
instruction. The 10µL preamplification PCR product was diluted with 30µL 0.1XTE pH 8.0. 
The diluted preamplification PCR product was stored at -20ºC until required.  
Diluted preamplification product (9µL) was combined with 450 µL Taqman universal PCR 
Master Mix (no AmpErase UNG, 2X) and 441µL RNase/DNase free water. QPCR reaction 
mix (100 µL) was loaded into each port of the TaqMan MicroRNA Array. The array card 
was centrifuged and then mechanically sealed with Applied Biosystems 7900HT upgrade 
kit. qRT-PCR reaction was carried out using an Applied Biosystems 7900HT thermocycler 
according to the manufacture’s recommended conditions. 
2.4.2 Taqman single microRNA/ mRNA qPCR 
In order to detect individual microRNAs, Taqman microRNA assay was used. A fixed 
volume of 5µL of RNA solution from 100µL elute was used as input into each reverse 
transcription reaction. Since 100µL plasma was extracted and finally eluted with 100 µL 
RNase/DNase free water, 5 µL of RNA solution represents the RNA corresponding to 5 µL 
of plasma. For tissue/ cell extracted RNA samples, RNA were diluted to 2ng/µl. The RNA 
was reverse transcribed by Taqman microRNA reverse transcription (RT) kit and Taqman 
microRNA stem loop primers (Applied biosystems).  Generally, a master RT master mix 
was made using 100mM dNTP, Multiscribe TM Reverse transcriptase, 10X Transcription 
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buffer, RNase inhibitor and DNase-RNase free water. The master mix differed between 
mRNA and microRNA. The master mix components are listed below (Table 2.1). 
 
 mRNA RT mix (µL) microRNA RT mix (µL) 
10Xbuffer 2 0.75 
dNTP 0.8 0.075 
RT-primer 2 1.5 
Reverse transcriptase 1 0.5 
RNase inhibitor 1 0.08 
Water 3.2 2.08 
cDNA/ reverse transcribed RNA 10 2.5 
Total reaction volume 20 7 
	  
RT product (2.4 µL) was then combined with 17.25 µL TaqMan® Fast Universal PCR 
Master Mix II (2×), no UNG, 1.725 µL TaqMan® Small RNA Assay (20×)/ Taqman mRNA 
Assay (20X) and 13.23 µL water to generate final 34.4 µL volume. Each qPCR plate well 
was loaded with 10µL mixture and all experiments were done in triplicate using an Applied 
Biosystem 7500HT fast system.  
2.4.3 Semi-quantitative PCR 
Traditional semi-quantitative PCR was performed for detecting PPAR downstream genes. 
A two step RT-PCR reaction was applied here. Both the reverse transcription step and 
PCR amplification step were carried out using a MJ Research Peltier PTC-200 
thermocycler.  
 
Table 2-1 Mix of Taqman qPCR for mRNA and microRNA 
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mRNA was reverse-transcribed (RT) into cDNA using MMLV reverse transcriptase 
(SuperScript II Reverse Transcriptase, Invitrogen). For a 25.5µL reaction, a total amount of 
14µL RNA (500ng) was mixed with random hexamers, heated at 65ºC for 5 minutes and 
then placed on ice. RT master mix was then prepared with 1µL dNTP (10mM), 5µL first 
strand buffer, 2µL Dithiothreitol (DTT, to stabilise the enzyme) and 0.5µL MMLV 
superscript II. The mixture was gently mixed and run on the thermal cycler with program 
shown below (Table 2.2).  
 
Temperature Time 
25ºC 10 minutes 
42ºC 90 minutes 
70ºC 15 minutes 
 
In the PCR amplification step, a total amount of 18µL PCR master mix was made 
containing 0.5µL Tfi polymerase (Invitrogen), 4µL PCR reaction buffer, 1.2µL MgCl2 
(50mM), 0.4µL dNTp (10mM), 0.5µL PCR primer (both reverse strand and forward strand) 
and 11µL DNase-RNase free water. The solution was then mixed with 2µL cDNA and PCR 
reaction was then performed in the thermal cycler. An initial denaturation step was applied 
at 94ºC for 2 minutes. Thirty  cycles of PCR were then performed with denaturing at 94ºC 
for 30 seconds, annealing (with different temperature for different genes) for 30 seconds, 
and elongation for one minute. After the completion of the designated number of cycles the 
protocol was completed by 5 minutes of extension at 72ºC. 
Different genes require specific annealing and elongation time. The primers and PCR 
program of tested genes are listed below (Table 2.3). All primers were synthesised by 
Table 2-2 Reverse transcript PCR program for mRNA expression 
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Sigma-Aldrich. 
 
Gene Forward primer 
sequence 
Reverse primer 
sequence 
Annealing 
temperature 
Product size 
Beta-actin cctctatgccaacacagt agccaccaatccacacag 55ºC 125bp 
ACO attcggtgttgtaagtgc ttggtgggtgggtgttga 55ºC 417bp 
CYP4A1 caggccattgggaacttgaa ggtccaggtgatcccaggtaa 57ºC 448bp 
FABP gcgatgggtctgcctgag cacggactttatgcctttgaa 57ºC 243bp 
 
Finally, PCR products were examined using electrophoresis through 2% agarose gels. 
Gels were made by adding agarose powder to 1xTBE buffer, made up from 10x TAE stock 
(Sigma-Aldrich), and heating it in a microwave oven to dissolve. Ethidium bromide (1µL in 
50mL TBE agarose mixture) was added to the gels to allow visualisation of PCR products. 
Gels were then allowed to set in a tank for 30 minutes. For a 20 well gel, a total amount of 
1.5µL PCR product was mixed with 7.5µL loading dye. Electrophoresis was setup at 100V 
for 30-60 minutes and PCR products were visualised by exposure to UV light using 
BioRad transilluminator. All PCR product quantification was performed using the Kodak 
Imaging Station 4000MM.  
Table 2-3 Primer, Tm and product size of β-actin, ACO, Cyp4a1 and Fabp 
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2.5 Illumina deep sequencing 
MicroRNA library was prepared using Illumina TruSeq Small RNA sample preparation kit 
(Illumina) following the official preparation guide. Briefly, 1µg of total RNA was used for 
library construction. Firstly, both 3’ and 5’ adaptors were attached to the ends of the small 
RNAs and then the template was constructed by RT reaction and PCR amplification with a 
specific primer to tag each sample. The PCR amplification program is shown below (Table 
2.4). To enrich and purify the construct, PCR product was fractionated using 
polyacrylamide gene electrophoresis and the bands between 145 to 160 bp were cut for 
further purification. All cDNA construct was assessed using Agilent bioanalyzer with 
Agilent High sensitive DNA kit (Agilent Technologies).  
 
Temperature Time Cycle 
98ºC 30 seconds 1 
98ºC 10 seconds 
11 60ºC 30 seconds 
72ºC 15 seconds 
72ºC 10 minutes 1 
4ºC ∞ 1 
 
MicroRNA-seq constructs were then run on the Illumina HiSeq machine at Genomics Lab, 
Hammersmith Campus, Imperial College London. The raw data was processed to 
demultiplex (separate the treatment by index) using CASAVA 1.8.2. Cutadapt 1.2.1 was 
then applied to trim the 3’ adaptors and filter the sequence by size which left the sequence 
between 15 to 25 bp. FastQX (Babraham Institute) was then used to assess the quality 
control of the reads and Extract and Count Tool was applied to condense the reads into a 
text file only containing the nucleotide sequence and the number of times it occurred. All 
Table 2-4 PCR program for small RNA enrichment 
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text files were then analysed using miRanalyzer V0.2 
(http://bioinfo5.ugr.es/miRanalyzer/miRanalyzer.php) which was used to generate a list of 
differential expressed microRNAs and all potential novel non-coding RNAs.  
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2.6 Protein extraction and quantification 
2.6.1 Tissue protein extraction us RIPA buffer 
Whole liver extract was prepared using RIPA buffer (SIGMA-Aldrich). Approximately 50mg 
of liver tissue was homogenized with 500 µL RIPA buffer containing 1% protease inhibitor 
cocktail (SIGMA-Aldrich). Samples were centrifuged at 12,000 rpm for 5 minutes. The 
aqueous phase protein was collected and immediately frozen at 80ºC.  
2.6.2 BCA assay for protein quantification 
Protein concentrations were determined using the bicinchoninic assay (BCA, Thermo 
Scientific). Briefly, protein samples and pre-diluted standard proteins were measured 
simultaneously. Twenty five µL of a protein sample was placed into a well of a 96 well 
plate with 200µL working solution (containing 100µL A and 100µL B solution). Protein 
samples/standards were mixed with working solution gently and then incubated at 37ºC for 
30 minutes. Protein concentration was then determined by measuring the absorbance at 
560nM on a FluoStar micro plate reader. Protein concentrations were determined through 
a standard curve. The protein samples used in this study were extracted from two batches. 
Both sets of BCA standard curve are shown below (Figure 2.4).  
 
Figure 2-4 BCA 
standard curve.  
The x axis is the 
protein 
concentration, and 
the y axis is the 
absorbance at 
560nm.  
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2.7 Immunoblot 
Briefly, 20 µg of protein was separated by 10% SDS-PAGE gel. The protein was then 
electro-transferred onto wet nitrocellulose membrane. The nonspecific binding sites were 
blocked for 1 hour and incubated with primary & secondary antibodies. Membranes were 
washed and visualised by chemiluminescent regent (Merck Millipore) with BioRad imaging 
system. 
2.7.1 Protein sample preparation 
Protein samples were diluted to 20µl (20µg) with water. All protein samples, 
chemiluninescent ladder (5µl, Cell signalling) and Novex Sharp Pre-Stained Protein 
Standards (5µL, Invitrogen) were mixed with loading buffer prepared on day of use (66mM 
Tris pH6.8, 26%w/v glycerol, 2.1%w/v SDS, 0.01%w/v bromophenol blue and 5%v/v β-
mercaptoethanol) and heated to 95°C for 5 minutes to allow denaturation. Following 
denaturation, all samples and ladders were centrifuged at 10000 rpm for 5 minutes and 
the supernatants were loaded on to a SDS polyacrylamide gel. 
2.7.2 SDS-PAGE gel eletrophorse 
All samples and ladders were electrophoresed at 60v in stacking gel composed of 5%w/v 
acrylamide, clean water, 0.07%w/v fresh ammonium persulphate and 1x SDS stacking gel 
buffer composed of 0.125M Tris pH6.8 and 0.1%w/v SDS until all samples were properly 
lined up. A voltage of 100v was then applied to allow sufficient separation in resolving gel 
(10%w/v acrylamide, water, 0.07%w/v fresh ammonium persulphate and 1x SDS resolving 
gel buffer composed of 0.6M Tris pH8.8 and 0.16%w/v SDS). 2.7.3 Protein transfer 
          62 
Briefly, a transfer sandwich was made with two sponges, two filter cards and a 
nitrocellulose membrane. Wet transfer (with transferring buffer) was used in all 
experiments. Transfer was performed in 1x transfer buffer at 150V, 400mA for 75 mins. An 
ice block was inserted into the tank in order to maintain a cool transferring temperature. 
The result of protein transfer was confirmed with ponceau red staining (0.1% Ponceau S 
w/v in 5% v/v acetic acid, Sigma Aldrich). Ponceau red was washed with PBS-T (1x 
phosphate buffered saline and 0.1%v/v Tween-20) three times after visualisation.  
2.7.4 Blocking and antibody incubation 
All blots were incubated with blocking buffer (PBS-T plus 5%w/v semi- skimmed milk 
powder) for 1 hour at room temperature. Blots were then incubated with primary antibodies 
(dilutions are shown below, table 2.5) overnight at 4ºC. Blots were then washed with PBS-
T 3 times and incubated with secondary horseradish peroxidise (HRP) conjugated 
antibody (dilutions are shown below, table 2.5) for 1 hour at room temperature. All blots 
were washed with PBS-T 3 times and stained with 5mL Lunminata Forte Western HRP 
Substrate (Millipore). All blots were visualised and quantified with Kodak IS4000MM 
station. 
The following primary antibodies were used with all dilution listed below (Table 2.5): citrate 
synthase (Abcam, ab129095), uncoupling protein 2 (Abcam, ab67241), AMP-activated 
protein kinase beta1 (Abcam, ab32112), Phospho-AMPKβ1 (Ser108) Antibody (4181, New 
England Biolabs) and anti-β actin antibody (Sigma-Aldrich). Secondary anti-mouse and 
anti-rabbit antibodies were all purchased from Abcam.  
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Antibodies Dilution of primary 
antibody 
Secondary antibody Dilution of 
secondary antibody 
CS 1:1000 anti-rabbit 1:10000 
UCP2 1:500 anti-mouse 1:2500 
AMPKβ1 1:1000 anti-rabbit 1:1000 
phospho-AMPKβ1 1:1000 anti-rabbit 1:1000 
β-actin 1:1000 anti-mouse 1:10000 
 
Table 2-5 Immunoblot antibody dilution ratio 
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3. Effect of Roux-en-Y gastric bypass surgery on rat 
microRNAome 
3.1 Introduction 
Obesity and its co-morbidities including cardiovascular disease and type 2 diabetes have 
become one of the biggest socioeconomic problems worldwide. Currently, bariatric surgery 
is the most effective treatment strategy for morbidly obese patients. The “gold standard” 
Roux-en-Y gastric bypass (RYGB) is the most widely used procedure (Maggard et al. 
2005). Surprisingly, RYGB surgery not only provides sustained long-term weight loss, but 
also resolves type 2 diabetes within days after surgery (Buchwald, Avidor, Braunwald, 
Jensen, et al. 2004b). These intriguing post-surgery effects have led to a rising number of 
research studies, which mainly focused on the alteration of gut hormones, postoperative 
metabolism and the shift of gut microbial composition. However, the fundamental 
molecular mechanisms, which could explain these changes, have not yet been completely 
clarified.  
As described in the introduction chapter, microRNAs have begun to emerge as key 
metabolic regulators. MicroRNAs are controlled by metabolic stimuli, such as food borne 
nutrients or hormones (Dumortier et al. 2013). At the same time, microRNAs control 
metabolic processes by regulating their targets. This bidirectional crosstalk has led to an 
interesting hypothesis that microRNA behavior is a link between metabolic stimuli and the 
host energy homeostasis. For patients undergoing RYGB surgery, it is likely energy 
homeostasis is altered by the drastic anatomical changes and that a novel metabolic 
balance could be subsequently established. The molecules, which are involved in these 
processes, may also contribute to the various post surgery benefits. Here, plasma and 
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colonic tissue were used to investigate the impact of RYGB surgery on circulating and 
local microRNAome, respectively.  
In this chapter, the global circulating and colonic microRNA expression from RYGB- and 
SHAM-operated healthy male Sprague Dawley (SD) rats was profiled at 8 weeks post 
surgery, using microRNA Taqman low density array card (TLDA) and Illumina deep 
sequencing platform, respectively. 
3.2 Methods  
1. Roux-en-Y gastric bypass surgery is described in 2.1.1 
2. Tissue samples collection is described in 2.1.2 
3. Tissue total RNA extraction is described in 2.3.2 
4. Tissue RNA quantification and quality assessment is described in 2.3.3 
5. Taqman low density array card preparation is described 2.4.1 
6. Taqman single microRNA assay is described 2.4.2 
7. Illumina deep sequencing procedure is described 2.5 
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3.3 Result with discussion 
3.3.1 Clinical effects of RYGB surgery on rats 
Data relevant to the effects in post RYGB surgery rats are presented in Figure 3.1. The 
daily body weight and gut hormone level of all animals were determined by Dr. Florian 
Seyfried and are presented here to profile the overall post surgery changes. The RYGB 
surgery induced a reduction of 22.0% of pre-surgical body weight (BW) in SD rats (n=8) 
over 52 days (pre-surgery BW=467.9±12.9g, post-surgery BW=377.75±33.9g), whereas 
sham animals (n=5) maintained an average of body weight of 573.2 g. Similar to previously 
reported observations by others (Roux et al. 2006), we also observed altered plasma 
concentrations of gut hormones, e.g., GLP-1 and PYY were significantly elevated following 
RYGB surgery (GLP-1RYGB=71.5±11.7 pmol/L, GLP-1SHAM=10.5±3.3 pmol/L, p<0.001; 
PYYRYGB=26.2±5.6 pmol/L, PYYSHAM=10.4±4.8 pmol/L, p<0.001).   
Body weight curves 
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Figure 3-1 Body weight and 
gut hormone of RYGB and 
SHAM operated rats 
(A) Daily body weight and 
circulating gut hormones 
expression 
The body weights were 
measured daily and data 
presented as body weight 
alteration ± SD compared to day 
0 (surgical day). (RYGB n=8 and 
SHAM n=5) 
(B) Gut hormones (GLP-1 and 
PYY)   
Data are expressed as mean 
with SEM. **and*** stands for 
p<0.01 and p<0.0001 of RYGB 
vs SHAM operated, using a 
student t test.  
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3.3.2 Circulating microRNA profiles after RYGB surgery 
3.3.2.1 Circulating microRNA isolation, spike-in optimisation and profiling method 
selection 
Plasma total RNA extraction method was optimised by comparing the mirVANA microRNA 
isolation kit (Ambion, Applied Biosystems Inc.), TRIzol reagent (Invitrogen) and mirVANA 
PARIS kit (Ambion, Applied Biosystems Inc.). MirVANA PARIS kit was found to be the 
most robust extraction approach and was selected for examination of all plasma samples 
in the current study. As previous studies suggested (Mitchell et al. 2008), synthetic 
Caenorhabditis elegans cel-mir-39 (5 fmol/µl cel-miR-39) was added to the solution of the 
plasma and denature solution mixture (100µl plasma diluted with 100µl cell disruption 
buffer and 200µl denature solution), as an internal standard. In order to find the optimal 
protein denaturation time, the pooled plasma sample was divided into three aliquots and 
incubated with 2 X denature buffer for 0 minute, 5 minutes and 20 minutes with multiple 
concentration of cel-miR-39 (e.g., 25 fmol, 50 fmol, 250 fmol and 500 fmol). The 
quantitative PCR results suggested 5-minutes incubation time with 250 fmol spike-in cel-
miR-39 was optimal. Hence, all of the plasma samples were extracted as described above.  
Since microRNAs are present at much lower concentrations in plasma compared with that 
in other tissues, detecting and analyzing them are a real challenge. There are several 
technologies available for circulating microRNA profiling, such as deep sequencing, 
microRNA microarray and quantitative real-time PCR (qRT-PCR). llumina microRNA deep 
sequencing and Agilent microRNA microarray methods require good quality total RNA 
(Agilent Bioanalyzer RNA integrity number higher than 8) and a minimum RNA loading 
amount of 200 ng/µl (5µl) and 150ng/µl (5µl), respectively. However, the Bioanalyzer 
quality indicator (RNA integrity number, RIN) uses ribosomal RNA as internal control and 
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the lack of ribosomal RNA in plasma means that successful RIN determination is not 
possible. Thus, total circulating RNAs cannot achieve the required quantity and quality 
metrics. In fact, typical concentrations of plasma RNAs are only around 2.5 ng/mL plasma 
(RYKOVA et al. 2006). Therefore, it is technically difficult to profile circulating microRNAs 
by microarray or deep sequencing methods unless the volume of the plasma sample being 
examined is greater than 50mL. The most widely used circulating microRNA profiling tool 
is qRT-PCR which has the highest specificity and sensitivity. A previous study showed that 
qRT-PCR is sensitive enough to detect as little as 8 copies of a target RNA in the sample 
and 220 microRNAs can be detected even in a single cell (F. Tang et al. 2006).  Hence, I 
used TLDA card, which is essentially parallel qRT-PCR for all detectable expressed 
microRNAs in rats, to profile the microRNAome of 4 post RYGB and 4 sham-operated SD 
rats.  
Firstly, to assess the efficiency of plasma total RNA extraction and evaluate the quality 
and quantity of RNA samples, constitutively expressed miR-16 was examined using single 
Taqman microRNA RT-qPCR. As shown in Table 3.1, all 8 samples (4 RYGB and 
4SHAM) exhibited measureable and consistent amounts of circulating miR-16 levels (Ct 
value of 23 approximates 10,000 copies of microRNA). Four biological replicated were 
profiled here, while all the results were confirmed with 13 rats. This data indicates a 
successful extraction of plasma RNAs and relatively similar extraction efficiency.  
 
 RYGB operated rat SHAM operated rat 
Circulating miR-16 Ct 23.25 23.5 23.24 23.11 23.49 23.65 23.25 23.2 
MiR-16 was detected by Taqman microRNA RT-qPCR (Probe No. 000391). Technical triplicates were loaded in qPCR 
plates. Negative control was set with qPCR master mix without reverse transcribed microRNA. All amplification curves 
were adjusted using auto-baseline correction and fix threshold of 0.2. Data presented here is the raw cycle of threshold 
(Ct) value. 
Table 3-1 Quality control miR-16 expression pre-test in all TLDA tested samples 
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3.3.2.2 Pre-processing the raw data of microRNA low density array card 
Taqman Array Rodent Card is able to detect 373 microRNAs expressed in the rat base 
Sanger miRBase V15 (The current miRBase records 728 mature Rattus norvegicus 
microRNAs). Each complete assay contains two sets of cards (Card A and B). Card A 
detects well-characterized microRNAs, which tend to be functionally defined or highly 
expressed, while Card B detects most of the recently discovered, less functionally defined 
and narrowly or low expressed microRNAs. The raw data from microRNA TLDA card was 
first processed by Applied Biosystems commercial software SDS V2.4. Cycle threshold 
(Ct) value was calculated by SDS V2.4 with an automatic baseline correction and fixed 
threshold of 0.2. The optimised plots of ∆Rn vs cycle of all microRNAs are presented 
below (Figure 3.2).  
 
 
Figure 3-2 ∆Rn vs Cycle plot for Taqman ® Array Rodent Card (A+B)   
With automatic baseline correction, fixed threshold of 0.2 (Rn is the fluorescence of the reporter dye divided by the 
fluorescence of a passive reference dye and ∆Rn is Rn minus the baseline 
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Mammalian U6 non-coding RNA was set by TLDA as a quality control and both A and B 
cards contain 4 wells to evaluate U6 expression. As seen in Table 3.2, the raw U6 Ct 
values for each of the samples were relatively consistent and stable across all cards, with 
no obvious outliers.  
 
Mamm U6 Ct 
Value 
Card A (4 replicates) Card B (4 replicates) 
RYGB 1 24.46 24.51 24.72 25.13 25.07 24.95 25.08 25.05 
RYGB 2 24.56 24.39 25.23 25.89 25.68 25.78 25.79 25.43 
RYGB 3 25.37 24.86 25.06 24.96 25.37 25.30 25.69 25.47 
RYGB 4 23.62 23.12 23.16 23.47 23.35 23.00 23.18 23.35 
SHAM 1 25.27 25.29 25.00 25.28 24.71 25.42 25.50 25.45 
SHAM 2 25.33 25.31 25.34 24.93 26.41 26.69 26.56 26.74 
SHAM 3 26.59 26.72 26.59 26.43 27.09 27.23 27.28 27.03 
SHAM 4 26.23 25.98 26.04 25.88 27.03 27.10 26.57 26.73 
Raw U6 Ct values were extracted using Invitrogen TLDA software SDS V2.4. All amplification curves were adjusted 
using auto-baseline correction and fix threshold of 0.2. Data presented here is the raw cycle  threshold (Ct) value. 
 
Boxplots were then constructed based on all microRNA adjusted Ct values with all 8 
samples using automatic baseline correction and a fixed threshold of 0.2. The minimum 
and maximum number of all data within the box included the first quartile (the middle 
number between the smallest number and the median of the data) and third quartile (the 
middle value between the median and the highest value of the data). Overall, the raw data 
exhibited a comparable distribution crossing all samples.  
Table 3-2 TLDA Quality control U6 expression 
          71 
 
 
3.3.2.3 Normalization method comparison 
There are two sources of variation in microRNA expression analysis, biological variation 
and technical variation. The aim of normalization is to reduce the technical variation to 
better show biological difference. A Ct value of 35 means there is one copy of the target 
microRNA in a sample. According to the manufacture’s recommendation, a Ct value of 32 
(8 copies of target) is used as a threshold and microRNA Ct value less than 32 is defined 
as expressed. Only expressed microRNA targets (Ct<32) were included in analysis. 
Although there are a few studies published on plasma/serum circulating microRNAs, there 
is still no consensus on the most appropriate method of normalization. Thus, we tested 
four widely used normalization methods including C.elegans spike-in, global, U6 and 
multiple endogenous microRNAs normalization (Y. Zhang et al. 2010; X. Chen et al. 
2008).   
Figure 3-3 Boxplot of adjusted Ct values with all TLDA tested samples 
Plot displays the 25th percentile (left end of box), 75th percentile (right end of box), and median (line in the middle of 
box). Whiskers contain the1.5 interquartile.  
 
Ct 
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In order to select appropriate endogenous microRNAs for normalization, the stability of 
potential endogenous microRNA normalizers were first checked. The U6 small nuclear 
RNA (Mamm-U6) is the most frequently used reference gene. There are four detection 
wells in both A and B Taqman microRNA rodent cards and average expression are 
presented as Mamm-U6-01 and Mamm-U6-02. Both were included as normalizer 
candidates. MiR-16 has been widely used as plasma/serum reference gene and was 
identified as consistently expressed in previous research (Resnick et al. 2009). MiR-223 
and miR-1937b were found to be well expressed and relatively consistent in our data 
across all eight rats. Thus, these five microRNAs were selected as normalizers. The Ct 
value for these five microRNAs ranged from 19.99 to 26.84 and the average Ct values 
were 20.91, 21.80, 23.85, 24.89 and 25.56 for mmu-miR-1937b, mmu-miR-16, mmu-miR-
223, Mamm-U6-02 and Mamm-U6-01, respectively (Figure 3.4). The expression levels of 
these five endogenous microRNA shared a similar pattern and were consistent across all 
of our samples.  
 
 
Figure 3-4 Raw Ct value of 5 endogenously expressed normalizer microRNAs 
Plot displays the non-normalized raw Ct values of 5 endogenous microRNA normalizer candidates. Ct 
values were calculated using auto-baseline correction and fixed threshold of 0.2. 
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The coefficient of variance (CV) of normalized RQ (fold change) for each expressed 
individual microRNA was then calculated. Calculation details are presented below (Figure 
3.5). All four methods were analyzed and the cumulative distribution of RQ CV with four 
normalization method and un-normalized data were ranked and plotted to select the best 
one.  
 
 
Figure 3-5 The cumulative distribution calculation method of the coefficient of variance (CV) of normalized 
RQ (fold change) 
Four different normalizers were calculated first based on four different normalization methods. All raw Ct values were 
normalized by the normalizers and non-normalized Ct was used for comparison. Normalized Cts were anti-log2 
transformed to acquire relative microRNA expression value. Fold changes (RQ) of RYGB/SHAM were then 
calculated for all microRNAs. The coefficient of variance (CV) values were finally ranked and plotted in order to 
visualize the result. 
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RQ CV of the data was compared using the different normalization methods (Figure 3.6). 
Normalization using global and U6 clearly result in decreased CV values, but normalizing 
with the 5 endogenous microRNAs significantly reduced the overall CV values. The widely 
used spiked-in cel-miR-39 normalization method, on the other hand, led to a more variable 
data set than the non-normalized one. It may be due to the fact that synthesis of single 
strand cel-miR-39 RNA is not as stable as plasma microRNAs, which are bound with AGO 
protein. Although multiple optimization experiments were carried out to choose optimal 
spike-in amounts and time points, cel-miR-39 could still be partially degraded, which led to 
the large variance of the normalized data. Hence, the 5 endogenous microRNAs 
normalization was determined as the optimal method and, therefore, selected for all 
downstream analysis. 
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Figure 3-6 Cumulative distribution with four normalization method of microRNA RQ (fold change) verses 
coefficient of variation (CV) values 
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3.3.2.4 Overall circulating microRNA profile 
The circulating microRNA profile of the RYGB and SHAM operated rats were analysed 
using the 5 endogenous microRNAs normalization method. MicroRNAs were defined as 
expressed only if it could be detected in three out of four biological replicates which belong 
to the same biological group. As shown in Figure 3.7, 113 microRNAs were present in 
RYGB surgical rats, while 92 microRNAs were detected in SHAM operated ones. Among 
these expressed microRNAs, 88 of them were detected in both RYGB and SHAM 
operated rats, while 25 and 4 of them were only expressed in RYGB and SHAM rats, 
respectively. The list of these detectable microRNAs can be found in Table 3.3.  
 
 
SHAM 
4 
RYGB 
25 
Figure 3-7 Detectable circulating microRNA number in TLDA tested samples 
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only	  in	  RYGB	   Only	  in	  SHAM	   Common	  
hsa-­‐miR-­‐206	   mmu-­‐miR-­‐122	   hsa-­‐miR-­‐140-­‐3p	   mmu-­‐miR-­‐1971	  
hsa-­‐miR-­‐421	   mmu-­‐miR-­‐130a	   hsa-­‐miR-­‐200c	   mmu-­‐miR-­‐19a	  
mmu-­‐miR-­‐1188	   mmu-­‐miR-­‐197	   hsa-­‐miR-­‐214	   mmu-­‐miR-­‐19b	  
mmu-­‐miR-­‐15b	   mmu-­‐miR-­‐222	   hsa-­‐miR-­‐223	   mmu-­‐miR-­‐20a	  
mmu-­‐miR-­‐1928	   	   hsa-­‐miR-­‐30a-­‐3p	   mmu-­‐miR-­‐2134	  
mmu-­‐miR-­‐194	   	   hsa-­‐miR-­‐30e-­‐3p	   mmu-­‐miR-­‐2138	  
mmu-­‐miR-­‐1961	   	   hsa-­‐miR-­‐93*	   mmu-­‐miR-­‐21	  
mmu-­‐miR-­‐203	   	   Mamm	  U6	   mmu-­‐miR-­‐215	  
mmu-­‐miR-­‐2146	   	   mmu-­‐let-­‐7c	   mmu-­‐miR-­‐223	  
mmu-­‐miR-­‐2183	   	   mmu-­‐miR-­‐106a	   mmu-­‐miR-­‐24	  
mmu-­‐miR-­‐218	   	   mmu-­‐miR-­‐106b	   mmu-­‐miR-­‐25	  
mmu-­‐miR-­‐30d	   	   mmu-­‐miR-­‐125b-­‐5p	   mmu-­‐miR-­‐26a	  
mmu-­‐miR-­‐34b-­‐3p	   	   mmu-­‐miR-­‐126-­‐3p	   mmu-­‐miR-­‐26b	  
mmu-­‐miR-­‐34c*	   	   mmu-­‐miR-­‐126-­‐5p	   mmu-­‐miR-­‐27a	  
mmu-­‐miR-­‐363	   	   mmu-­‐miR-­‐1274a	   mmu-­‐miR-­‐27b	  
mmu-­‐miR-­‐434-­‐3p	   	   mmu-­‐miR-­‐1-­‐2	   mmu-­‐miR-­‐29a	  
mmu-­‐miR-­‐463*	   	   mmu-­‐miR-­‐133a	   mmu-­‐miR-­‐29b*	  
mmu-­‐miR-­‐467b	   	   mmu-­‐miR-­‐138	   mmu-­‐miR-­‐29c	  
mmu-­‐miR-­‐532-­‐3p	   	   mmu-­‐miR-­‐139-­‐5p	   mmu-­‐miR-­‐301a	  
mmu-­‐miR-­‐685	   	   mmu-­‐miR-­‐140	   mmu-­‐miR-­‐30a	  
mmu-­‐miR-­‐694	   	   mmu-­‐miR-­‐142-­‐3p	   mmu-­‐miR-­‐30b	  
mmu-­‐miR-­‐712	   	   mmu-­‐miR-­‐1	   mmu-­‐miR-­‐30c	  
mmu-­‐miR-­‐721	   	   mmu-­‐miR-­‐145	   mmu-­‐miR-­‐30e	  
mmu-­‐miR-­‐877*	   	   mmu-­‐miR-­‐146a	   mmu-­‐miR-­‐31	  
rno-­‐miR-­‐190b	   	   mmu-­‐miR-­‐148a	   mmu-­‐miR-­‐320	  
	   	   mmu-­‐miR-­‐150	   mmu-­‐miR-­‐328	  
	   	   mmu-­‐miR-­‐152	   mmu-­‐miR-­‐335-­‐3p	  
	   	   mmu-­‐miR-­‐155	   mmu-­‐miR-­‐342-­‐3p	  
	   	   mmu-­‐miR-­‐16	   mmu-­‐miR-­‐375	  
	   	   mmu-­‐miR-­‐17	   mmu-­‐miR-­‐451	  
	   	   mmu-­‐miR-­‐186	   mmu-­‐miR-­‐463	  
	   	   mmu-­‐miR-­‐188-­‐5p	   mmu-­‐miR-­‐465C	  
	   	   mmu-­‐miR-­‐1894-­‐3p	   mmu-­‐miR-­‐466k	  
	   	   mmu-­‐miR-­‐1896	   mmu-­‐miR-­‐652	  
	   	   mmu-­‐miR-­‐1897-­‐5p	   mmu-­‐miR-­‐673	  
	   	   mmu-­‐miR-­‐1904	   mmu-­‐miR-­‐720	  
	   	   mmu-­‐miR-­‐191	   mmu-­‐miR-­‐744	  
	   	   mmu-­‐miR-­‐192	   mmu-­‐miR-­‐872	  
	   	   mmu-­‐miR-­‐1937b	   mmu-­‐miR-­‐92a	  
	   	   mmu-­‐miR-­‐1937c	   rno-­‐miR-­‐1	  
	   	   mmu-­‐miR-­‐193b	   rno-­‐miR-­‐146B	  
	   	   mmu-­‐miR-­‐1951	   rno-­‐miR-­‐632	  
	   	   mmu-­‐miR-­‐195	   rno-­‐miR-­‐664	  
	   	   mmu-­‐miR-­‐1969	   rno-­‐miR-­‐7*	  
Table 3-3 All detectable circulating microRNAs in RYGB and SHAM operated rats 
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3.3.2.5 Clustering analysis of microRNAs  
We then generated an overall view of microRNA expression profiles using principal 
component analysis (PCA). PCA, an unsupervised method which is a linear 
rearrangement of the original variables, is widely used to analyse massive data sets such 
as gene express data, which contain much larger numbers of variables than observations 
(Yeung & Ruzzo 2001). PCA was performed here to find combinations of microRNAs 
differentiating between RYGB and SHAM operated rats. Figure 3.8 shows the PCA scores 
plot of all microRNA expression including both the expressed and non-expressed ones. 
Clear separation can be seen between RYGB group (red) and SHAM group (blue), which 
indicates alterations in rat circulating microRNAome after RYGB surgery.  
 
Figure 3-8 PCA of normalised microRNA 
expression in 8 TLDA tested samples 
Each symbol represents one biological sample, 
with its colour indicating the group to which it 
belongs to (Blue=SHAM, Red=RYGB) 
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3.3.2.6 Identification of differentially expressed microRNAs 
A two-tailed Student’s t-test was carried out on the normalized circulating microRNA data 
to determine the statistically differentially expressed microRNAs between RYGB and 
SHAM operated group. Fourteen microRNAs were found to be differentially expressed at a 
significance level of 0.05 (Figure 3.9). Eleven of the altered microRNAs were significantly 
down-regulated (e.g. miR-122, miR-93*, miR-872*, miR-7*, miR-146a, miR-342-3p, miR-
150, miR-139-5p, miR-30a-3p, miR-30e and miR-320), whereas 3 microRNAs, namely, 
miR-463*, miR-34c* and miR-1188, were up-regulated in the RYGB group. Compared to 
sham-operated rats, these RYGB-altered microRNAs vary within a range of 1.5 to 6 fold 
change with the exception of miR-122, which exhibited a 56-fold down-regulation in RYGB 
animals. MiR-122 is a liver-enriched microRNA which is highly active in a number of 
metabolic processes, e.g. cholesterol synthesis and fatty acid beta-oxidation (Esau et al. 
2006; Elmen et al. 2008). Due to its dramatic change and important metabolic function, I 
subsequently focused on validation and metabolic function examination of miR-122 after 
bariatric surgery in Chapter 4. 
Besides miR-122, a few other microRNAs, which were found here to be differentially 
expressed, have also exhibited interesting metabolic function, reported in previous studies. 
For instance, the expression of miR-146a was significantly decreased in PBMCs from type 
2 diabetes patients compared to control subjects (Balasubramanyam et al. 2011). 
Additionally, the reduced miR-146a level in PBMC was highly associated with insulin 
resistance, poor glycemic control and the concentration of several circulating pro-
inflammatory cytokines (TNFa and IL6) (Balasubramanyam et al. 2011). MiR-320 is 
another well-studied microRNA, which has been linked with insulin resistance. MiR-320 
can inhibit insulin–PI3-K signalling in adipocytes, resulting in insulin resistance (Ling et al. 
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2009). Moreover, miR-320 targets p85, which plays a critical role in cell growth by 
increasing Akt phosphorylation and thus the level of Glut4 (Ling et al. 2009). The 
decreased miR-320 in our study may also be associated with improved insulin resistance 
post RYGB. Finally, circulating miR-1188 was found to be down-regulated 1.7 fold in newly 
diagnosed diabetic cats, together with 45 fold up-regulation of miR-122 (Fleischhacker, 
Bauersachs, Wehner, Hartmann & Weber 2013b). The up-regulated miR-1188 and 
significant down-regulation of miR-122 in my study is consistent with an anti-diabetic effect 
of RYGB.  
Another interesting finding is that among 11 differentially expressed microRNAs, 7 are 
reverse strand microRNA labeled with “*” or “-3p”. As mentioned in the introduction, 
microRNA synthesis generates equal amounts of microRNA duplexes, but their individual 
strand accumulation is mostly asymmetric at the steady state. The most abundant strand 
is referred as forward strand microRNA (-5p), whereas the less abundant strand is referred 
as passenger strand/ reverse strand (*/3p). An siRNA study revealed that the relative 
thermodynamic stability of the ends of the duplex determines which strand is to be 
selected (Petri et al. 2011). Interestingly, another quantification experiment demonstrated 
that although the presence of microRNA* strand is universal, specific accumulation was 
found with certain microRNA species (Kuchenbauer et al. 2011). Here, the multiple 
reverse strand microRNAs were found to be differentially expressed, highlighting the 
importance of these long ignored microRNAs and also sheds some light on their potential 
metabolic related functions 
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microRNAs Fold change p value 
miR-93* -3.34 0.0008 
miR-463* 5.74 0.0028 
miR-146a -3.63 0.0029 
miR-122 -56.81 0.0095 
miR-34c* 11.19 0.01 
miR-872* -1.84 0.0103 
miR-30a-3p -1.81 0.0153 
miR-150 -1.92 0.0162 
miR-7* -3.42 0.0164 
miR-139-5p -2.17 0.0179 
miR-30e -1.62 0.0219 
miR-320 -3.33 0.0249 
miR-342-3p -3.65 0.0374 
miR-1188 5.39 0.0377 
 
 
Figure 3-9 Differentially expressed circulating microRNA after RYGB 
A. Differentially expressed circulating microRNAs 
Fold change is the microRNA expression ratio between the two experimental conditions: positive/yellow means that 
microRNA is up- regulated at RYGB compared with SHAM; negative/blue means repressed in RYGB. p-value was 
calculated by unpaired student t test. 
 
B. Clustering heat map of differentially expressed microRNAs 
Heatmap and clustering of significantly changed plasma microRNAs in RYGB operated and SHAM operated group. The 
calculated value are log2 transformed microRNA fold change (RYGB/SHAM). Samples were clustered using 
Spearman’s correlation. Yellow colour means up regulated in RYGB group, while blue means down-regulated in RYGB. 
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3.3.2.7 MicroRNAs-metabolite correlation 
In addition to the microRNA target prediction based on the their nucleotide compositions, 
three data sets, i.e. metabolite profiles, microRNA expression profiles and the peptide gut 
hormones were statistically integrated in order to probe transgenomic-metabolic 
interactions following RYGB surgery. A correlation map was generated by Dr. Jia Li 
(Collaborator, Imperial College London) in order to aid understanding of post surgical 
metabolic alteration and the relationship with microRNAs (Fig 3.12).  
MicroRNAs are linked to cellular metabolism via two directions: (1) microRNAs can be 
regulated by the cellular metabolic status including oxidative stress, glucose levels and 
hypoxia; and (2) microRNAs can modulate transcriptional and posttranscriptional 
processes to directly or indirectly impact on metabolic pathways (Singh et al. 2012). 
MicroRNA-metabolite communication is beginning to be examined, but the complexity of 
these interactions is not fully understood. As an exploratory step, a heat map was used to 
visualize the global association between circulating microRNAs and metabolites in the 
plasma, urine and liver. A number of distinctive sets of microRNAs were found to be 
correlated with lipids, TCA cycle intermediates, host-gut microbial co-metabolites, and liver 
and plasma energy metabolites. Down-regulated miR-342-3p and up-regulated miR-34c* 
in RYGB-operated rats demonstrate broad correlation with metabolites, indicating their 
extensive involvement in many metabolic processes (Figure 3.12). MiR-206, miR-1188, 
miR-1971 and miR-34c* are reversely correlated with plasma lipid fractions observed in 
NMR profiles, whereas miR-320 and miR-342-3p, together with miR-7* to a lesser extent, 
exhibit a positive correlation (Figure 3.12). TCA cycle intermediates including citrate, 
succinate, 2-oxoglutarate and fumarate are positively correlated with miR-143, miR-126-
3p, miR-146a, miR-150 and miR-155, which are also inversely correlated with urinary host-
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microbial co-metabolites such as p-cresyl glucuronide, p-cresyl sulphate and 
phenylacetylglycine (PAG) (Figure 3.12). In addition, miR-872*, miR463*, miR-30e, miR-
2183, miR-1971, miR-150, miR-146a, miR-1188 and miR-93* all potentially relate to liver 
energy metabolism such as glycolysis and glycogenesis involving glucose, glycogen and 
lactate.  
Very few metabolic related mechanistic studies of the above-mentioned microRNAs have 
been reported. Interestingly, most of the above-mentioned microRNAs are reported to be 
dysregulated in either diabetes or obesity development processes. For example, in rodent 
models, miR-143 was up-regulated in the liver of obese mice (Jordan et al. 2011), whereas 
the newly discovered miR-1188 and miR-1971 were down-regulated in diabetic cats’ blood 
(Fleischhacker, Bauersachs, Wehner, Hartmann & Weber 2013a). In human studies, miR-
206 was significantly reduced in diabetes patient’s muscle (Gallagher et al. 2010). 
Circulating miR-126-3p, miR-155 miR-342-3p, miR-30e, miR-146a, miR-320 family and 
miR-150 have all been reported to be dysregulated in T2DM patients, but the direction of 
change was not consistent (Zampetaki et al. 2010). These previous profiling studies 
indicated that these microRNAs, which strongly correlated with certain metabolites, are 
highly likely to be involved in energy metabolism.  
          83  
          84 
 
3.3.2.8 Correlation of altered miR-122 expression and metabolites —  An energy 
requirement hypothesis 
Among the fourteen significantly changed microRNAs post RYGB surgery, miR-122 was 
affected most (Figure 3.9). Pearson correlation indicated that miR-122 expression is highly 
positively correlated with D-3-hydroxybutyrate (3HB) and acetoacetate (AcAc) (Figure 
3.12). Ketone bodies exist in plasma and the expression level is determined by glucose 
and insulin levels. A significant elevated ketone body level was observed in diabetes 
patients’ plasma (Laffel 1999). To understand the altered ketone levels, we need to 
consider the metabolism of ketone bodies from two process, ketogenesis and ketolysis. 
For ketogenesis, blood derived free fatty acid can be taken up by hepatocytes and enter 
mitochondria. Fatty acid is then metabolised to acetyl CoA which could either enter the 
TCA cycle or divert to form ketone bodies. Under normal conditions, glycolysis can 
generate adequate amounts of oxaloacetate, which is essential for leading acetyl CoA into 
the TCA cycle. However, under extreme metabolic conditions such as long time fasting 
and diabetes, the glycolysis rate falls to a very low level, oxaloacetate is therefore not 
available to condense with acetyl CoA so that acetyl CoA diverted from the TCA cycle gets 
into ketone body synthesis (Laffel 1999). For ketolysis, liver-produced ketone bodies can 
be transferred into other organs, such as heart, brain and kidney, and generate 
acetoacetyl CoA by the enzyme succinyl CoA-oxoacid transferase (SCOT). During 
Figure 3-10 Metabolites-microRNA correlation heat map 
Correlation between miRNome and metabolic profiles. The heat map is generated from the Pearson correlation 
coefficient values between circulating microRNA expression and metabolite levels using a two-way clustering method. 
The horizontal axis shows all detectable circulating microRNAs while the vertical axis exhibits altered plasma, urinary 
and hepatic metabolites following RYGB. The color bar next to the metabolites indicates metabolic functions (amino 
acid metabolism, lipid metabolism and ketone body metabolism, glycolysis and glycogenolysis, TCA cycles, microbial 
activity, nucleic acid metabolism, muscle metabolism, and vitamin metabolism) of the metabolites. MicroRNAs, which 
are significantly altered by RYGB surgery, are shown in yellow (up-regulated) and blue (down-regulated), respectively. 
SHAM n=4, RYGB n=4. Keys: PAG, phenylacetylglycine; TMAO, trimethyalmine-N-oxide; TCA, tricarboxylic acid. 
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starvation, the rate determining SCOT is down-regulated (Laffel 1999). Hence, circulating 
levels of ketone bodies are significantly increased by both favored ketogenesis and 
inhibited ketolysis. The balance between ketogenesis and ketolysis determines the final 
circulating ketone body concentration.  
In the current study, the RYGB-operated rats had significantly lower circulating levels of 
miR-122 and ketone bodies (3HB and AcAc) (Table 3.4, metabonomics data acquired by 
Dr Jia Li), suggest that the ketogenesis process had been significantly inhibited in the liver. 
In fact, inhibition of miR-122 has been shown to increase fatty acid oxidation, which should 
theoretically lead to an increased acetyl CoA production. Acetyl CoA could then either get 
into TCA cycle or divert to form ketones (Figure 3.13). The metabolic profiling data 
obtained here shows 1) an increased whole body TCA cycle metabolism, evidenced by 
decreased urinary citrate, succinate, 2-oxoglutarate and fumarate, 2) increased glycolysis 
in the liver, supported by elevated concentrations of pyruvate, alanine and lactate in the 
liver and plasma and 3) inhibited ketonegenesis or increased ketolysis, evidenced by 
reduced circulating ketone levels. Therefore, it appears that the β-oxidation product acetyl 
CoA could preferably enter into TCA cycle instead of diverting to synthesise ketone bodies 
(Figure 3.13). Furthermore, the tendency toward glycolysis in the liver also supports the 
hypothesis because adequate amounts of oxaloactete are needed with acetyl CoA for the 
TCA cycle. Interestingly, two key metabolic enzymes citrate synthase (CS) and aldolase A 
(ALDOA), regulating TCA cycle and glycolysis respectively, are validated miR-122 targets 
(Boutz et al. 2011). Since circulating miR-122 exhibited a significant 56 fold decrease, it is 
very likely that the post RYGB rat hepatic miR-122 expression also is inhibited. Hence, the 
hepatic miR-122 mediated CS and ALDOA inhibition could then be relieved, which would 
result in increased glycolysis and TCA cycle in liver. As a consequence, the fatty acid 
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metabolised acetyl CoA would be more likely to go into TCA cycle to generate energy 
instead of ketone body production to store energy and reduced expression of miR-122 and 
ketone levels in blood. This hypothesis will be experimentally examined in chapter 4.  
 
 
 
 
 
Figure 3-11 Role of miR-122 in RYGB operated rats 
CS (citrate synthase); ALDOA (aldolase A, fructose-bisphosphate); TCA( tricarboxylic acid cycle)  
Compared with SHAM rats, red arrow stands for a favored process/up-regulation in RYGB, whereas blue arrow means 
inhibited process/ decreased expression.  
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Table 3-4 Plasma, urinary and hepatic aqueous metabolites  
Plasma, urinary and hepatic aqueous metabolites found to be altered between RYGB- and SHAM-operated rats 
based on O-PLS-DA models. R2X represents the variation in 1H NMR spectral data explained by the O-PLS-DA 
model. Q2Y indicates the level of significance of the metabolic differences between two classes. The p and q 
values in the table represent the significance of the metabolite changes and false discovery rate-adjusted p 
values, respectively. The “+” or “-“ represents the increased or decreased trend of metabolites in RYGB-
operated rats compared with SHAM controls. Data provided by Dr Jia Li, Imperial College London. 
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3.3.2.9 TLDA method validation by qPCR 
A number of differentially expressed microRNAs in the TLDA data was further validated 
using RT-qPCR (quantitative real-time reverse transcriptase polymerase chain reaction). 
RT-qPCR is a two-step method, which employs the enzyme for reverse transcriptase to 
generate complementary DNA (cDNA) and followed by PCR amplification (process 
including denaturation, annealing and extension). The measurement is taken in the 
exponential phase as this phase exhibits the least variability without saturation of 
amplification. RT-qPCR is considered to be the “gold standard” for detecting gene 
expression. Here, to validate the circulation TLDA data, I selected three microRNAs, 
namely miR-122, miR-34c-3p and miR-1188, to examine their expression across tested 
SHAM and RYGB rats. As shown in figure 3.14, miR-122 and miR-1188 exhibited similar 
fold change with TLDA derived data. MiR-122 was shown to be down-regulated 56 fold in 
TLDA and 155.3 fold in qPCR. MiR-1188 exhibited 5.39 fold up-regulation in RYGB by 
TLDA and 7.7 fold increase by qPCR. In fact, by using RT-qPCR, miR-122 was only 
detected in one RYGB animal and miR-1188 was not detected in any SHAM operated 
animal  (a Ct value of 40 was assumed in order to calculate the relative expression using 
delta/delta Ct method). MiR-34c*, on the other hand, showed 11 fold up-regulation in 
TLDA data set, but 1.2 fold marginal up-regulation in by qPCR. This inconsistency may be 
due to the pre-amplification procedure required for TLDA. Pre-amplification step is 
introduced due to the very low concentrations of RNA in plasma. However, pre-
amplification itself has the potential to introduce bias due to the uneven RNA 
amplification/degradation rate. Therefore, the validation results supported the most 
significant changes detected by TLDA, for example, when no microRNA exist at all or 
relatively abundant microRNAs were expressed. However, microRNAs detected by TLDA 
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with relatively low expression need to be firstly validated before carrying out any 
downstream analysis.  
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Figure 3-12 Circulating microRNA expression validation by RT-qPCR and correlation analysis 
Determined by qRT-PCR of the same samples used for TLDA (4RYGB and 4SHAM animals). Data are expressed as 
mean with SEM error bars  
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3.4 Colon microRNA profiling after RYGB surgery  
3.4.1 Sequence method data process procedure 
Colon microRNAs were sequenced by Illumina microRNA deep sequencing platform after 
removing both side-attached adapters. The length of the sequenced RNAs varied between 
15 and 35 nucleotides. Original sequencing data were processed with Cutadapt 
(http://code.google.com/p/cutadapt/) to trim  both of the side adapters to filter the 
sequencing size (greater than 15-nucleotide long). CLC genomic workbench was then 
used to select the sequence between 15 and 35-nucleotide long and count the copy 
number and the length of these sequences. (This part of the work was done in 
collaboration with  Mariana Flores, Imperial College London.) 
All detectable colorectal microRNAs are mapped into the following read length distribution 
figure (Figure 3.15), which shows three peaks at 21,22 and 23. This result is consistent 
with other non-coding RNA sequencing system results (Schulte et al. 2010) and indicated 
successful microRNA deep sequencing. These three nucleotide peaks around 22 
nucleotides suggest that samples contain enriched mature microRNAs.  
Interestingly, besides the peaks around 22, nucleotide length 30 also exhibited a 
significant enrichment of reads. It perhaps represents the newly discovered RNA class, 
namely piwi interacting RNA (piRNA). In 2006, four groups independently isolated 30nt 
length small RNA from testis(Lau et al. 2006; Kim 2006; Aravin et al. 2006; Girard et al. 
2006). Small non-coding RNAs exhibit their function by combining with the evolutionarily 
conserved protein family piwi/argonaute (PAZ-PIWI or PPD), which can be divided into 
AGO and PIWI subfamilies. AGO proteins bind to siRNAs and microRNAs, whereas PIWI 
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proteins bind to PIWI-interacting RNAs (Siomi et al. 2011). The study of piwi protein was 
initially on germ cells with functions in meiosis, spermiogenesis, and transposon silencing 
(Thomson & H. Lin 2009). Despite the common belief that PIWI proteins only have 
germline-restricted functions, the role of PIWI/piRNA in somatic tissues has recently been 
explored (Malone et al. 2009). However, it is still not clear about the biological function of 
piRNAs and what role that PIWI proteins play in biogenesis of piRNAs. The expression 
and function of this 30nt piRNA is certainly worth exploring in future.  
 
 
As seen in Table 3.5, each sample mapped mature microRNA and the numbers varied 
from 256 to 340. The total detectable microRNA number is 372 (the detectable rat colon 
mature microRNA list is presented in Appendix 1). Among these microRNAs, the most 
highly expressed microRNAs are rno-miR-143-3p (on average account for 38.7% of total 
microRNAs) and rno-miR-192-5p (average 11.73%) followed by less expressed rno-miR-
10a-5p and rno-miR-22a-3p (Figure 3.16). Interestingly, our result is consistent with a 
previous study in human, which also reported that miR-10a-5p, miR-21-5p, miR-22a-3p, 
miR-143-3p and miR-192-5p are the top five most abundant microRNAs and represent 
Figure 3-13 Read length distribution of deep sequencing reads 
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54% of all microRNAs in colorectal cancer patients (Schee et al. 2013). The result 
demonstrated microRNA’s conservative feature across species and also suggested that 
our result in rats may be translatable to human. 
 
 RYGB1 RYGB2 RYGB3 RYGB4 SHAM1 SHAM2 SHAM3 SHAM4 
Mapped mature 
microRNA 
number 
340 268 256 256 288 302 256 317 
 
 
 
 
3.4.2 Overall colon data comparison 
PCA analysis was performed to generate an overall view of the microRNAome between 
RYGB- and SHAM-operated groups. As seen in Figure 3.17, the two groups were 
separated along the second principal component. The corresponding loading plot (Figure 
3.17) shows that the first component is mainly driven by the most abundant microRNAs 
Table 3-5 Mapped microRNA number in deep sequenced colorectal samples 
Figure 3-14 Read counts distribution of all microRNAs 
The x axis shows 8 deep sequencedsamples. Y axis is the expression percentage of certain microRNA within total 
microRNA. Read counts are normalized to all reads, includes both mapped and unmapped reads.  
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(miR-143-3p and miR-192-5p), whereas the second component is contributed by the most 
of the differently expressed colonic microRNAs between two groups (such as miR-181a-
5p, miR-150-5p and miR-142-5p etc). 
 
 
 
3.4.3 Altered mature known colonic microRNAs 
DESeq is a method developed by Anders et.al. to perform differential expression analysis 
on RNA sequence count data (Anders & Huber 2010). The package DESeq provides 
methods to test for differential expression by use of the negative binomial distribution 
Figure 3-15 PCA and loading plot of colorectal microRNA expression in 8 deep sequenced samples 
Each symbol represents a biological sample, with its colour indicating the group to which it belongs to (Blue=SHAM, 
Red=RYGB) 
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which allow less restrictive variance assumptions than Possion distribution (Anders & 
Huber 2010). As seen in Figure 3.18 below, 13 colonic microRNAs are significantly 
different between RYGB- and SHAM-operated groups. Among them, three microRNA 
families (miR-216 family, miR-19 family, and miR-142 family) exist and hierarchical 
clustering grouped microRNAs from the same family together. It is expected that 
microRNAs belonging to the same family would be correlated across all samples. Indeed, 
as Figure 3.19 shows, we observed a high correlation within each microRNA family 
(R2>0.99). This suggested that 1) microRNAs from same family are likely to be regulated 
by the same promoter and 2) the deep sequencing method is robust and generated a 
good quality data.  
Among these 13 microRNAs, most of them showed 2 to 10 fold change, except for rno-
miR-216 family (Figure 3.18), which was calculated as infinite because all four SHAM 
operated rats do not contain any miR-216 members and three out of four RYGB operated 
rats expressed of miR-216 family members. Colon expressed miR-216 family has not yet 
been well studied. Two studies have suggested that the liver miR-216 and miR-217 may 
be associated with lipid metabolism (Hoekstra et al. 2012) (Yin et al. 2012). Hepatic miR-
216 was markedly decreased in mice fed a western-type high fat diet, but up-regulated in 
response to fasting (Hoekstra et al. 2012). Another paper showed that chronic ethanol 
exposure up-regulated miR-217 and its increase promotes ethanol-induced fat 
accumulation by down regulating hepatic sirtuin 1 (SIRT1) (Yin et al. 2012). These results 
indicate that miR-216 family expression may be regulated by the cell’s energy state and its 
alteration may in turn control the cellular metabolic state. However, it is still not clear 
whether colonic miR-216 family shares a similar function as hepatic miR-216. It would be 
interesting to explore the consequences of post RYGB miR-216 family alteration. It will 
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also be important to mimic some of the RYGB-induced benefits by manipulating this 
“RYGB specific” microRNA in the colon.  
In addition to miR-216 family, other microRNAs have also previously been reported to be 
involved in metabolism. For example, miR-142 family (miR-142-5p and miR-142-3p) in 
adipose tissue showed up-regulation in mice fed on high-fat diet for 5 months 
(Chartoumpekis et al. 2012). More interestingly, Francisco et al. revealed a close positive 
correlation between circulating miR-142-3p level and the extent of obesity (BMI) (Ortega et 
al. 2013). The significance of their result is further demonstrated by a decreased miR-142-
3p upon weight loss (Ortega et al. 2013). It would be important to investigate the function 
of colonic miR-142-3p and miR-142-5p in response to RYGB surgery in future. A 
microRNA-target based functional analysis will be discussed in the next section in order to 
generate an overall picture of which communal targets these microRNA may regulate and 
what the potentially involved biological pathways are.  
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Figure 3-16 Differentially expressed colorectal microRNAs 
Fold change is the microRNA expression ratio between the two experimental conditions (RYGB:SHAM). Positive 
means that microRNA is up- regulated at RYGB compared with SHAM; negative means repressed in RYGB. P-value 
was calculated by unpaired student t test with Bonferroni adjustment. Three microRNA families are labelled with red 
(miR-216 family), blue (miR-19 family) and green (miR-142 family), respectively. 
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Figure 3-17 microRNA family members correlation between samples;  
Pearson correlation. The p value of all correlation tests <0.0001. 
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3.4.4 Unknown novel colonic microRNA examination 
Using a machine learning-based technique, miRanalyzer generated a putative microRNA 
list based on the mature and precursor sequences, and their folding/binding kinetics 
(Hackenberg et al. 2009). In general, around 50 novel microRNAs were detected in each 
biological sample. However, most of them were mapped into chromosome unknown 
(ChrUN), which contains clone contigs that cannot be confidently placed on a specific 
chromosome. These candidates, which mapped to ChrUN, were filtered out and the rest of 
thirteen novel microRNA candidates were listed in Table 3.7. A final step for examination 
of a putative novel microRNA is to determine if it is conserved across species (Martin et al. 
2007). By applying UCSC genome browser (https://genome.ucsc.edu), conservation 
across rat, mouse, human, dog and cow could be accessed. Among these thirteen novel 
microRNA candidates, two of them are conservative across species (Figure 3.20) and are 
highlighted with red in Table 3.7.  
Candidate 1 locates on chromosome X (88,278,172 - 88,378,290). This microRNA has a 
mature sequence similar to mmu-miR-676-3p (mmu-miR-676) and hsa-miR-676-3p (hsa-
miR-676). Hence, here we name it as rno-miR-676-3p (rno-miR-676). There are currently 
very few studies focusing on the biological function of miR-676-3p in other species. One 
study showed that mmu-miR-676 was up-regulated in the liver of leptin deficient db/db 
mice (Kaur et al. 2011). Additionally, rno-miR-676-3p locates within ectodysplasin-A (EDA) 
gene. EDA protein belongs to the tumour necrosis factor family, acts as a homotrimer and 
may be involved in cell-cell signalling during the development of ectodermal organs (Kere 
et al. 1996). However, there is currently no literature to suggest EDA has any colorectal or 
metabolic function. Interestingly, rno-miR-676-3p is an intronic microRNA located on 
chormosome X, which has highly enriched microRNAs compared to autosomes, whereas 
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surprisingly, Y chromosome has no detectable microRNAs at all (X. Guo et al. 2009). The 
contribution of X chromosome microRNAs to the gender difference for cancer, immune 
and metabolic diseases has not yet been explored. Previous reports have shown that the 
cancer protective effects of bariatric surgery is strongest for female obesity-related 
tumours (Ashrafian et al. 2011). Hence, it would be interesting to explore that whether this 
chromosome X microRNA contributed to these sex specific post-operative benefits in the 
future.  
Candidate 2 locates on chromosome 10 (34,069,743-34,069,860). By mapping the 
sequence with other species, candidate 2 was found to be similar to the mouse non-
coding RNA snoRNA U95 (snord95). Small nucleolar RNAs (snoRNAs) are a class of 
small RNAs which may guide chemical modification (such as methylation and 
pseudoridylation) of other RNAs, mainly ribosome RNAs, transfer RNAs and small nuclear 
RNAs (Kiss 2001). It has been commonly used as a microRNA expression normalizer 
(Mestdagh et al. 2009). My data suggested that, not only mice, but also rats express this 
small non-coding RNA. The function and expression of rat snord95 needs to be further 
explored in the future.  
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chromo-
some 
chrom- 
Start 
chrom- 
End 
strand sequence log2 fold 
change 
p value conserved microRNA in 
other species 
Chromosome 
location 
chrX 88,378,172 88,378,290 + CCGTCCTGAGCTTGTCGAGCTA -2.7 0.0661 yes mmu-/hsa-
miR-676 
EDA intron 2 
chr7 10,394,873 10,395,011 - TCTGACCCTATGTCCCCCACAG -2.3 0.0955 no   
chr2 191,051,916 191,052,042 + AGTTTCCTGGTTGTGACCG -1.1 0.1207 no   
chr2 191,045,392 191,045,518 - AGTTTCCTGGTTGTGACCG -1.1 0.1207 no   
chr10 34,069,743 34,069,860 + CAGAGGCTGTTTCTGAGC -1.3 0.1235 yes mus  snord95 GNB2L1 
chr1 131,079,820 131,079,950 + CATAAGTGTAGAGAGTCTGTAGT -1.3 0.1335 no   
chr17 62,933,441 62,933,523 - GGGCCCTTCCCGTGGATCGCCC 2.1 0.1397 no   
chr20 6,853,008 6,853,148 - CTACTGAGCCACATTCCCAGCCC -1.7 0.1487 no   
chr5 24,497,507 24,497,593 + GGGGCGGGGTCCGCCGGCCT 1.1 0.1665 no   
chr4 152,578,763 152,578,853 - CAACCCGGTCAGCCCCCTCCCG 2.5 0.2093 no   
chr10 43,941,461 43,941,557 - GTCAGGATGGCCGAGTGGTCTAAGGC -0.8 0.7585 no   
 
 
 
Candidate1, Chromosome X, 88,378,172 to 88,378,290 
 
 
 
Candidate2, Chromosome 10, 34,069,743 to 34,069,860 
 
 
 
Table 3-6 Predicted novel colorectal non-coding RNAs 
Figure 3-18 The highly conserved colorectal novel non-coding RNAs 
The horizontal axis are the RNA sequence of rat, mouse, human dog and cow. The vertical block suggests the 
conservation of the particular nucleotide. 
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3.5 Chapter Discussion 
3.5.1 Bioinformatics based functional analysis of altered circulating 
microRNAs 
The discovery of microRNAs adds another layer of complexity to epigenetic regulation. 
Subtle change of a single microRNA has the potential to fine tune multiple biological 
processes. Although microRNAs remain a young research theme, it has become 
increasingly clear that a set of microRNAs could influence the metabolic behavior of 
biological systems by regulating multiple targets in a pathway. To investigate this, we first 
predict the mRNA targets of each significantly changed microRNA using ten available 
databases, namely, miRWALK, DIANA-mt, miRanda, miRDB, RNAhybrid, PICTAR4, 
PICTAR5, PITA, RNA22 and Targetscan (miRWALK database can summarise all targets 
from different databases . http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/micrornapredictedtarget.html). With the focus on 
microRNA target prediction, databases can be classified into two categories: established 
on the basis of the use or non-use of conservation comparison, a feature that significantly 
influences an outcome list of targets by narrowing the results (Yue et al. 2009). The 
algorithms based on conservation criteria include: miRanda, PicTar, TargetScan, DIANA-
mt; in contrast PITA and RNA22 employ algorithms using other parameters, such as free 
energy of binding or secondary structures of mRNA 3’UTRs that can promote or prevent 
microRNA binding. More detailed information can be found in a comprehensive review, 
which compares various publicly available microRNA target prediction databases (Witkos 
et al. 2011). Here I first used all of these algorithms to predict microRNA targets, but only 
included targets that are predicted by more than two databases, to increase the accuracy 
and confidence of the prediction results.  
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By summarizing the predicted mRNA targets, a pathway map was produced using 
PANTHER compare gene list tool. This expression overrepresentation tool is based 
conceptually on statistic binomial test described previously (Mi et al. 2013). An input list is 
divided into groups based on PANTHER classification (either molecular function, biological 
process, or pathway; here we used pathway, due to its specificity). A maximum of four lists 
can be uploaded for each analysis at the same time. A reference list, which usually 
contains all the genes/ proteins, is divided into groups in the same way. The output of the 
tool is a list of p values for under- or over- representation of each functional category in 
each of the input lists. A typical output webpage is presented below in Figure 3.10.  
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The predicted pathways, that are likely to be affected by RYGB surgery, were then ranked 
according to the number of microRNAs involved in each pathway (Figure 3.11), with four 
major related aspects including G protein signaling, neurodegenerative disease, 
inflammation, and growth/apoptosis. I shall discuss each of these pathways here.  
A) G protein signalling 
Increasing evidence indicates that the gut microbiota could influence the intestinal 
expression of short chain fatty acid (SCFA) receptors (Samuel et al. 2008) and the 
secretion of gut peptides such as PYY and GLP-1 via G-protein-coupled receptors 
including GPR41 and GPR43 (Bindels, Dewulf & Delzenne 2013a). A substantial shift in 
microbial phyla towards Gammaproteobacteria has been reported in RYGB-operated rats 
and human (J. V. Li et al. 2011a; H. Zhang et al. 2009a), together with elevated levels of 
faecal SCFAs (e.g. acetate, propionate, formate) and decreased levels of oligosaccharides 
(J. V. Li et al. 2011a). These results suggest that following RYGB surgery, GPR43 could 
be activated by higher levels of SCFAs and stimulate enteroendocrine L cells to release 
PYY and GLP-1 (Bindels, Dewulf & Delzenne 2013b) with a regulatory effect of the 
involved microRNAs. Multiple G-protein coupled pathways may be strongly influenced by 
differentially expressed microRNA, for example, miR-150 is indeed predicted to target 
GPR43 by miRANDA algorithm.  
B) Neurological related 
Figure 3-19 Gene expression data from Compared gene lists tool viewed on PANTHER web site.  
The results from Compare gene lists tool. One sample lists (miR-122) were uploaded to the tool. The NCBI rat gene list 
was used as the reference list. 
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As seen in Figure 3.11, these 14 altered microRNAs, particularly miR-342-3p, miR-320, 
miR-139-5p and miR-146a, are predicted to be involved in multiple neurological transmitter 
and receptor-related pathways, as well as two major neurodegenerative diseases (e.g. 
Parkinson’s and Huntington disease), suggesting that RYGB surgery may modulate 
neurological activity through a microRNA-mediated gut-brain axis. MicroRNAs are 
abundant in the brain and they act as effectors of neurological development and 
phenotype. Saba et al. have previously reported that miR-342-3p, miR-320, miR-139-5p 
and miR-146a, which are all down-regulated in the plasma of RYGB-group in our study, 
exhibited >2.5-fold up-regulation in  mouse brain tissue infected with mouse-adapted 
scrapie (prion induced nerodegeneration) (Saba et al. 2008). Interestingly, nine out of 
these 14 RYGB-related microRNAs are associated with Parkinson’s disease (PD) patients, 
who commonly experience unintended weight loss (H. Chen et al. 2003). The overlap in 
microRNA profiles between bariatric surgery and PD suggest that surgery-induced weight 
loss may share partial mechanism pathways with unintended weight loss in PD. The 
reason for weight loss in PD remains unclear, but factors including reduced food intake 
due to dysphagia, increased resting energy expenditure and potential peptide hormones 
such as ghrelin could account for the underlying mechanisms (Pfeiffer 2003). Furthermore, 
glutamate receptor group III pathway is also likely to be regulated by eight gastric bypass-
altered microRNAs (Figure 3.11). In fact, previous studies showed that mice with knock-
down glutamate receptor group III member, mGluR8, exhibited increased levels of anxiety 
and body weight compared to their wild type (Duvoisin et al. 2005). These multiple 
connections between metabolic abnormality and the pathogenesis of neurodegenerative 
diseases pose fascinating possibilities for research on the microRNA mediated post RYGB 
neurological alteration. 
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C) Wnt signalling pathway  
Most of these microRNA expression changes, such as miR-122, miR-150, miR342-3p and 
miR139-5p, are strongly predicted to target Wnt signaling pathway and inflammation-
related pathways mediated by chemokine and cytokine signaling.  Wnt signaling pathway 
has long been linked to metabolic syndrome due to its function in regulating adipose tissue 
differentiation and pancreatic cell mass and function (Ross et al. 2000; Rulifson et al. 
2007). The canonical WNT signaling cascade converges on the transcriptional regulator β-
catenin. In the absence of WNTs, cytoplasmic β-catenin is recruited to a degradation 
complex formed by axin and adenomatous polyposis coli (APC), protein phosphatase 2A 
(PP2A), glycogen synthase kinase 3 (GSK3) and casein kinase 1α (CK1α) (MacDonald, 
Tamai & He 2009a). The complex could initiate β-catenin ubiquitination and proteasomal 
degradation(X. He et al. 2004). Inactivation of the degradation complex results in 
hypophosphorylation of β-catenin and its translocation to the nucleus to activate WNT 
target genes (MacDonald, Tamai & He 2009b). The activation of Wnt signalling pathway 
can increase cells sensitivity to insulin, in particular Wnt10b, which  increases this 
sensitivity in skeletal muscle cells (Christodoulides et al. 2009). Furthermore, to support 
this, mutation of wnt10b leads to obesity by inactivation of canonical WNT signaling and 
block of adipogenesis (Christodoulides et al. 2006). Interestingly, in the present study, 
among the differentially expressed microRNAs between RYGB and SHAM animals, miR-
122, miR-139-5p, miR-146a, miR-150, miR-320, miR-343-3p are all predicted to target 
Wnt10b, which potentially indicates their crucial link to the activation of Wnt signalling 
pathway and the post RYGB anti-diabetic effects.  
With network features and relatively high expression in cells, microRNAs are believed to 
confer biological system robustness under condition of disturbance (Ebert & Sharp 2012). 
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Multiple sets of microRNAs and their targeted pathways appeared to be affected by RYGB 
surgery in the current study, suggesting that following a major anatomic alteration in the 
gastrointestinal track, the biological system is re-building a new metabolic balance by 
altering these microRNAs. Further studies need to be carried out to identify the commonly 
regulated crucial molecules and their relationship with the altered microRNAs.  
 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Parkinson disease
5HT2 type receptor mediated signaling pathway
Huntington disease
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Angiogenesis
PDGF signaling pathway
Synaptic_vesicle_trafficking
FGF signaling pathway
Inflammation mediated by chemokine and cytokine signaling pathway
Wnt signaling pathway
EGF receptor signaling pathway
T cell activation
VEGF signaling pathway
5HT1 type receptor mediated signaling pathway
Histamine H1 receptor mediated signaling pathway
Metabotropic glutamate receptor group II pathway
Oxytocin receptor mediated signaling pathway
B cell activation
TGF-beta signaling pathway
Thyrotropin-releasing hormone receptor signaling pathway
PI3 kinase pathway
Apoptosis signaling pathway
Circadian clock system
Enkephalin release
Metabotropic glutamate receptor group III pathway
Interleukin signaling pathway
Neurodegenerative disease and neurological related
G protein signalling related
Inflammation related
Growth and apoptosis related
p<0.001
0.001<p<0.01
0.01<p<0.05
p>0.05
 
 
3.5.2 Bioinformatics-based functional analysis of altered colonic microRNAs 
Similar to the functional analysis of the liver microRNA targets, we first predict the mRNA 
targets of each significantly changed microRNA using miRWalk. Again, only the targets 
Figure 3-20The predicted most likely altered pathways after RYGB (plasma analysis) 
The pathways are ranked according to the number of potentially involved microRNAs. The significant ranges are 
presented by the different red colours; those more likely to be regulated have a deeper colour. All pathways are 
classified into four biological process, with colour code on the left side of the table.  
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that are predicted by more than two databases were included to increase the accuracy 
and confidence of the prediction results. After summarising all of the predicted mRNA 
targets, a pathway map was then produced using Panther compare gene list tool (Mi and 
Thomas, 2009). These predicted pathways, which are likely to be affected by RYGB 
surgery, are ranked according to the number of microRNAs involved in each pathway and 
listed in Table 3.6. Interestingly, three classes of neurotransmitter-related pathways 
(glutamate receptor, 5HT receptor and opioid related pathway) were again (like the plasma 
analysis) among the most likely regulated biological pathway list. Previously, these 
neurotransmitter-related pathways were mainly studied in central neural system (CNS). 
However, recent findings showed that all three neurotransmitter systems (glutamate, 5HT 
and opioid) exist in the gastrointestinal tract (GI tract) (SANGER 2008) (Glass et al. 1999). 
Two possible mechanisms could be deduced from the altered microRNAs and potentially 
changed neurological pathways. 1) MicroRNAs could be involved in altered colorectal 
motility after RYGB. All three neurotransmitter- related pathways have been reported to be 
able to regulate the motility of gut (Talley 1992) (Toyomasu et al. 2010) (Porreca et al. 
1986). Furthermore, previous studies also showed that bariatric surgery could influence 
the intestinal motility (Suzuki et al. 2005). 2) These altered microRNA may relate to RYGB-
induced loss of appetite via glutamate receptor pathways. Studies suggest that altered gut 
hormones, such as ghrelin, PYY and GLP-1, and changed vagal nerve activity could be 
responsible for inhibited appetite after surgery (Tadross & Le Roux 2009). However, the 
specific neurotransmitter, which would be involved in mediating this interesting effect and 
detailed underlying molecular mechanisms, has not yet been explained. It is clear that 
signals from the gut are crucial for controlling appetite, regulating energy balance and 
glucose homeostasis. The peripheral and central vagus system could sense both 
mechanical distention and chemical stimulation by different nutrients (Näslund & Hellström 
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2007). By response to these vagus stimuli, intestinal L-cells could secrete higher levels of 
GLP-1 and PYY (Rocca & Brubaker 1999). Evidence suggests that glutamate is the 
primary afferent neurotransmitter of the vagus nerve conveying information from the gut to 
the brain (Hornby 2001). Here, three glutamate receptor pathways, both inotropic and 
metabotropic, were among the top ranking microRNA regulated pathway list. Therefore, it 
is possible that changed glutamate level/ glutamate receptor activity is responsible for 
altered vagus activity and subsequently leads to the increased secretion of gut hormones, 
which contribute to the post-operative effects on the brain, such as reduced appetite and 
shifted food preference.  
 
Pathway Number of microRNA involved 
Ionotropic glutamate receptor pathway 7 
5HT1 type receptor mediated signaling pathway 7 
EGF receptor signaling pathway 7 
Metabotropic glutamate receptor group III pathway 6 
Opioid proopiomelanocortin pathway 6 
Opioid proenkephalin pathway 6 
Metabotropic glutamate receptor group II pathway 6 
Dopamine receptor mediated signaling pathway 6 
Gonadotropin releasing hormone receptor pathway 6 
5HT3 type receptor mediated signaling pathway 6 
Angiogenesis 5 
TGF-beta signaling pathway 5 
Adrenaline and noradrenaline biosynthesis 5 
 
 
Table 3-7 The predicted most likely altered pathways after RYGB (colon) 
The pathways are ranked according to the number of potentially involved microRNAs. The significance of the 
pathway is determined as p<0.05. 
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3.5.3 General Discussion 
World-wide obesity epidemics have led to severe economic and health burdens. Bariatric 
surgery has previously been reported to be the only long-term effective treatment for 
morbid obesity and resolves type 2 diabetes mellitus within days after surgery. From 2010, 
numerous studies have been undertaken to investigate the mechanism of post bariatric 
surgery benefits, mainly focused on changed gut hormones and leptin, shifted gut 
microbiota and altered metabolic profiles. However, the molecular mechanisms, which 
underline all of these effects, have not been clarified. Here, the function of microRNAs as 
links mediating metabolic alteration after RYGB surgery has been addressed.  
Three principal methods are used to measure microRNA expression: real-time quantitative 
PCR, microarray hybridization and next generation deep sequencing. Generally, 
microarray is considered as the most cost-effective standardised high-throughput assay. 
The merit of deep sequencing is its ability to accurately assess expression and to identify 
novel microRNAs. However, both microarray and deep sequencing require pre-processing 
manipulation, such as annealing, RNA ligation, PCR amplification and recovery. These 
steps may induce inherent bias to the assay. Therefore, real time qPCR is often 
considered as a gold standard for microRNA detection. Microarray and deep sequencing 
approaches require at least 100ng of total RNA with good quality. Hence, I profiled the 
RYGB and SHAM operated rat plasma microRNAs using the most sensitive method 
available, Taqman TLDA cards, which is essentially real time qPCR. Sample size was less 
of a problem for colonic tissue so colonic microRNAome was examined using Illumina next 
generation deep sequencing platform.  
The first interesting finding of this study was that RYGB surgery altered both plasma and 
colonic microRNA profiles at 8 weeks post surgery. A previous study has reported 
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perturbation in circulating microRNA profiles of morbid obesity patients and after RYGB 
surgery (Ortega et al. 2013). However, using the animal model in this study allows a) 
examination of the non-obesity related and pure RYGB surgical effects on normal SD rats, 
b) exploration of the potential metabolic mechanisms behind this altered circulating 
microRNA profile.  
The second key finding was the 56-fold reduction of circulating miR-122 determined using 
TLDA cards. The result has been separately validated by qPCR. MiR-122 was first 
discovered in mouse liver in 2003. It was then widely studied across different species, 
including Homo sapiens, Bos Taurus , Sus scrofa , Mus musculus , and Rattusnor-
vegicus, and was found to be highly conserved (Bartel & C.-Z. Chen 2004). MiR-122 was 
reported to be highly and specifically expressed in liver and accounts for 70% total 
hepatic-expressed microRNAs (Chang et al. 2004). The function of miR-122 was found to 
contribute to hepatocarcinogenesis and hepatitis C virus RNA replication (Jopling et al. 
2005). Most interestingly, Christine Esau et al. elegantly proved that miR-122 plays very 
important roles in regulating lipid and cholesterol metabolism. By inhibiting the liver-
expressed miR-122 using 2’-O-methoxyethyl phosphorothioate antisense oligonucleotide, 
plasma cholesterol level was reduced, hepatic fatty-acid oxidation was increased and the 
hepatic fatty-acid and cholesterol synthesis rates were inhibited (Esau et al. 2006). 
Although hepatic miR-122 was well studied in the past, it was only recently that blood-
circulating miR-122 was detected (Starkey Lewis et al. 2011). By correlating my 
microRNAome profile with metabonomics data generated by Dr. Jia Li, it is hypothesised 
that the surgically induced miR-122 changes may be responsible for reduced ketone body 
generation after RYGB via increasing citrate synthase and aldoase expression in liver. In 
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chapter 4, I will further explore the metabolic function of hepatic miR-122 in the RYGB 
surgery model. 
The third interesting find is the potential brain related functional alterations predicted by 
changed microRNAs. A total of 14 circulating microRNA and 12 colonic microRNAs were 
statistically differently expressed between RYGB and SHAM operated groups. It is 
noteworthy that by predicting biological function of these altered microRNAs with their 
computational putative targets, both circulating and colonic microRNAs may have the 
ability to regulate neurodegenerative or neurotransmitter related pathways. My data 
highlight the potential connection between dramatic metabolic alterations and brain 
functional changes, which has been referenced as the “gut-brain axis” (Heijboer et al. 
2006). The gut-brain axis comprises both hormonal pathways (including hormones such 
as PYY and GLP-1, cytokines and neuropeptides) and neurological pathways (such as the 
enteric nervous system, sympathetic and spinal nerves and vagus). I shall refer to one 
example to demonstrate the potential multi-dimensional cooperative regulation mechanism 
among microRNAs, hormones and neurological systems.  
GLP-1, which is the most well studied “gut-brain” hormone, is secreted by intestinal L-cell 
and beneficial for glucose homeostasis and food intake control . As shown in Figure 3.21, 
gut microbiota produced (Gutzwiller et al. 1999) SCFAs can stimulate GLP-1 secretion via 
G-protein coupled receptor 2 (FFAR2/GPR43) (Maslowski et al. 2009). Additionally, 
serotonin (5-HT), which is an appetite and hedonic control neurotransmitter, also mediates 
physiological effects of SCFAs by activating GPR43 (Karaki et al. 2006). It has been 
shown by both by my current study and previous studies that RYGB surgery could 
influence gut microbiota, SCFA levels and gut hormones (J. V. Li et al. 2011a). Panther 
pathway analysis suggested that both 5-HT1 and 5-HT3 receptor types of pathways might 
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be influenced by altered colonic microRNAs. It could be possible that microbiota, GPR43, 
5HT and GLP-1 are working together as a link between the gut and brain after RYGB 
surgery, which contributed to reduced appetite. As a facilitator, the inhibition of miR-150 
(both in plasma and colon) could lead to up-regulation of colonic GPR-43 since it is a 
predicted target of miR-150 (predicted by miRANDA algorithm). A few questions should be 
further explored in future. For instance, is it possible that decreased miR-150 is able to 
stimulate GPR-43, which leads to an active secretion of GLP-1 and 5HT? Does the gut 
microbiota or changed SCFAs influence colon miR-150 expression either directly or 
through transcriptional factors? Do any other colonic microRNAs behave similarly as 
messengers between the gut and the brain?  
  
 
Figure 3-21 Potential mechanism of microRNA mediated crosstalk between gut-brain axis 
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In conclusion, the current study has shown that circulating and colonic microRNAome is 
fundamentally different between RYGB and SHAM operated rats. These findings here may 
shed some light on the mechanisms of microRNAs as metabolic regulators mediating post 
RYGB surgery benefits. Clearly, more work needs to be carried out to examine the 
underlying molecular functions of these altered microRNAs. Some of these points will be 
further investigated in Chapter 4, with a focus on the role of miR-122 in the rat RYGB 
model. 
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4.  Functionality of Hepatic MiR-122 in Rat RYGB Model 
4.1 Introduction 
A group of circulating and colonic microRNAs, which are dysregulated post RYGB surgery, 
are described in Chapter 3. In this chapter, the focus will be placed on miR-122, which 
exhibits the greatest change among all altered circulating microRNAs, regarding its hepatic 
expression and metabolic function in RYGB surgery using both in vivo and in vitro 
experiments.  
The liver is a vital organ, which plays critical roles in regulating energy homeostasis via 
controlling carbohydrate, lipid and protein metabolism. Liver receives blood from the 
intestinal tract, which contains the products of digestion and absorption. Depending on 
feeding or fasting conditions, the liver either stores carbohydrate as glycogen or mobilises 
it to contribute to blood glucose. Furthermore, glucose in liver can also be produced from 
other substrates, a process named gluconeogenesis. The liver can also oxidise fatty acids 
and produces smaller and water-soluble ketone bodies, which can be exported to other 
tissues. By investigating whether the liver function is influenced by altered microRNAs 
after bariatric surgery, we can understand the rationale behind the post-surgery benefits.  
In 2003, systematic cloning and sequencing of small non-coding RNAs led to the 
discovery of miR-122 in mouse liver (Lagos-Quintana et al. 2003). It locates on 
chromosome 18 intergenic region, from 61,512,747 to 61,512,831 (chromosome location). 
The structure detail and seed region of miR-122 is shown in Figure 4.1. MiR-122 was also 
identified as the most abundant microRNA in the liver, which reaches around 70% of total 
hepatic microRNAs (Lagos-Quintana et al. 2002). In 2004, Chang et al. detected, in 
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embryonic and new born mouse, that miR-122 increased from day 12, reaching a plateau 
level just before birth and continued to increase, but with a much slower rate after birth 
(Chang et al. 2004). This study built the primary link between the liver developmental 
process and the accumulation of miR-122. Subsequently, functional research considered 
the contribution of miR-122 to a) hepatocarcinogenesis (Kutay et al. 2006), b) hepatitis C 
virus amplification (Jopling et al. 2005) and c) energy metabolism (Elmen et al. 2008). 
Here in this chapter, we focused on the metabolic function of miR-122 after RYGB surgery.  
 
 
Interestingly, most of the liver metabolic pathways are under circadian control. By inducing 
mutation of the circadian Clock gene, mice developed metabolic syndrome with 
hyperleptinemia, hyperlipidemia, hepatic steatosis, hyperglycemia, and hypoinsulinemia 
(Turek 2005). Interestingly, both pri-miR-122 and pre-miR-122 are transcribed in a cyclic 
circadian fashion via a circadian nuclear receptor REV-ERBα (Gatfield et al. 2009). The 
expression level of miR-122 has been linked to the energy expenditure rate in previous 
studies (Elmén et al. 2008). It is possible that the oscillation of miR-122 across the day 
could damp the fluctuation of energy intake and expenditure between daytime and 
nighttime. Moreover, as shown in Table 4.1, a handful of metabolically related targets of 
miR-122 have been either experimentally validated or computationally predicted. These 
targets (Shown in Table 4.1) belong to multiple metabolic pathways, such as glycolysis 
Figure 4-1 The stem-loop structure and mature sequence of miR-122 (seed region highlighted) 
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(Aldoa), gluconeogenesis (G6pc, G6pc3), glycogenesis (Gys1), pentose phosphate 
pathway (G6pd), fatty acid synthesis (Fasn) and TCA cycle (Cs). Some of the targets 
behave as important metabolic regulators, for instance, two (α and β/δ) peroxisome 
proliferation-activated receptors (Ppar) and PPARγ co-activator a (Pgc1α) are among 
either validated or putative miR-122 target lists. PPARs are a group of nuclear receptors 
that function as transcription factors regulating various metabolic processes via 
heterodimers with retinoid X receptor (RXR) and binding to the promoter region’s 
peroxisome proliferator hormone response elements (PPRE). PPARs play important roles 
in obesity-related metabolic diseases such as hyperlipidemia, insulin resistance, and 
coronary artery disease (Evans et al. 2004). Besides PPARs, cellular energy sensor AMP-
activated protein kinase (AMPK, coded by Prkab1 and Prkab2) are also predicted as 
targets of miR-122. AMPK acts as a sensitive cellular energy switch. Under energy 
deficient status (high AMP:ATP ratio), AMPK can switch off ATP-consuming biosynthesis 
pathways, such as fatty acid synthesis, cholesterol synthesis and gluconeogenesis, and 
switch on ATP-producing catabolic pathways, for example, fatty acid oxidation  and 
glycolysis in multiple tissues (Hardie 2008).  
 
Validated and putative miR-122 metabolic enzyme/ receptor targets 
Validated 
targets 
SLC7A1 ALDOA GYS1 PKM2 GK 
IDH1 G6PD G6PC G6PC3 FASN 
LDHA PGC1α ACLY CS  
Putative 
targets 
HK2 UCP2 AMPKβ1 AMPKβ2 PPARβδ 
PPARα     
 
Table 4-1 MiR-122 predicted and validated metabolic related targets 
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The large number of crucial metabolic targets and circadian expression of miR-122 
supports its metabolic importance. Additionally, as described in the Introduction Chapter, 
the inhibition of miR-122 leads to decreased circulating cholesterol level and increased 
hepatic fatty acid oxidation rate. Furthermore, miR-122 is the most dramatic altered 
circulation microRNA (decreased 56 fold) after RYGB surgery (see chapter 3.3.2.6). 
Therefore, in this chapter, the expression of hepatic miR-122 and its metabolic targets are 
examined both in in vivo RYGB surgical model and in an in vitro mechanistic model.    
4.2 Methods and experiment outline 
1. Tissue total RNA extraction is described in 2.3.2 
2. Taqman single microRNA assay is described in 2.4.2 
3. Taqman mRNA qPCR assay is described in 2.4.2 
4. Tissue protein extraction and quantification is described in 2.6.1 and 2.6.2 
5. Immunoblot is described in 2.7 
6. FAO and B13H cell line culture condition is described in 2.2.5 and 2.2.6 
7. MicroRNA mimic/ inhibitor transfection is described in 2.2.11 
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4.3 Results with discussion 
4.3.1 Hepatic miR-122 expression in RYGB- and SHAM- operated rat 
Similar to circulating miR-122, hepatic miR-122 expression is significantly inhibited (41%) 
in RYGB operated rats (n=8) compared with SHAM operated rats (n=5) (student’s t-test, 
p=0.0295), but to a much lesser extent (Figure 4.2). Stably expressed endogenous non-
coding RNA U6 was applied as a normalisation control and the result is presented as fold 
change (RYGB/SHAM) using 2-[delta][delta]Ct method (Livak & Schmittgen 2001). The 
result suggests that the liver, where miR-122 is believed to be synthesised, appears to 
produce less miR-122 with presumably less being released into the blood stream. 
Alternatively, in RYGB animals, the liver-secreted miR-122 is transported more to/ taken 
up into other organs as a hormone, which leads to a moderated suppression in liver but a 
dramatically decrease in blood. Interestingly, unlike liver, they found brain miR-122 was 
up-regulated after RYGB surgery. The drastic alteration of miR-122 in circulation 
compared to liver and its increased level of expression in brain highlights the exciting 
potential of circulating microRNAs to behave as paracrine hormones.  
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Figure 4-2 Hepatic miR-122 mRNA by qPCR in RYGB 
and SHAM rats 
Aliquots of RNA (2ng/µL) was used for qPCR. Y-axis is 
displayed with averaged expression fold change 
(RYGB:SHAM). SHAM n=5, RYGB n=8. Error bars are 
the mean with SEM and * signifies statistically significant 
as determined by student t test p<0.05. 
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4.3.2 Examination of miR-122 targets in SHAM- and RYGB- operated rats 
To examine the targets of hepatic altered miR-122 in RYGB rats, 12 metabolic related 
enzymes and transcriptional factors, which belong to 10 metabolic processes, were 
chosen to be measured ex vivo. As seen in Table 4.2, both computer predicted putative 
targets (blue) and experimental validated (red) targets were selected. The metabolic 
pathways, which are regulated by the selected targets, belong to several aspects of the 
liver glucose metabolic processes (Figure 4.3). Generally, glucose is absorbed from the 
intestine into the hepatoportal vein. The hepatocytes are therefore exposed to absorbed 
glucose, transported through glucose transporters (predominantly GLUT2, but also 
GLUT1 (G W Gould 1993)). Within the hepatocyte, glucose is phosphorylated to glucose 
6-phosphate and enters the pathways of glycogen synthesis or glycolysis. In the 
carbohydrate excess situation, glucose 6-phosphate can also enter the pentose 
phosphate pathway to generate pentoses, which are required for synthesis of nucleic 
acids. Glycolysis product, pyruvate, can be oxidised to acetyl-CoA or oxaloacetate and 
directly metabolised in the tricarboxylic acid cycle (TCA). Alternatively, acetyl-CoA could 
be transported out of mitochondria and enter fatty acid synthesis pathway. Besides the 
aforementioned metabolic pathway enzymes, three energy regulating systems, energy 
sensor AMP-activated protein kinase (AMPK), oxidative phosphorylation related 
uncoupling protein (UCP) and nuclear receptor proteins peroxisome proliferator-
activated receptors (PPARs), were all included in the following study. 
          120 
 
 
No. Metabolic pathway/ function Target name 
1 Glucose transportation Glut1  
2 Glycolysis ALDOA  
3 Gluconeogenesis G6PC  
4 Glycogenesis IDH1  
5 Pentose phosphate pathway G6PD  
6 Fatty acid metabolism FASN  
7 Oxidative phosphorylation UCP2  
8 TCA cycle CS  
9 AMPKs AMPKβ1 AMPKβ2 
10 PPARs PPARa PPARb 
 
 
Figure 4-3  metabolic pathways which are targeted by the selected molecules (see also table 4.2) 
Table 4-2 miR-122 metabolic targets  
Red=experimentally validated by previous study (Boutz et al. 2011), blue=computational predicted targets.  
The No. in the table  corresponds with the pathway number in Figure 4.3 
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4.3.2.1 Glucose transportation 
Glucose plays a central role in cellular homeostasis and metabolism. It is well established 
that nearly all cell types possess a glucose transportation system, which allows the 
movement of glucose down its chemical gradient into cells (Olson & Pessin 1996). The 
class I glucose transporter, GLUT or SLC2A family, is the most common and well-studied 
glucose transporter protein family in mammalian cells. GLUT1 is widely distributed in fetal 
tissues and expressed at the highest level in erythrocytes (G W Gould 1993). Albeit highly 
expressed in fetal tissues, it  exists in all cell types and is responsible for the low-level 
basal glucose uptake required to sustain respiration (Pessin & Bell 1992). Here, Glut1 is a 
validated miR-122 target, whose 3’ UTR has an exact match to positions 2-8 of the mature 
miR-122 sequence. Taqman quantitative PCR was used to examine whether reduced 
miR-122 expression in RYGB could affect Glut1 mRNA expression in the liver. Ribosome 
18S RNA was used to normalize data and results are presented as RYGB to SHAM group 
fold change (all the following hepatic target experiments used an identical protocol and 
same normalisation method). As seen in Figure 4.4, although Glut1 mRNA alteration is not 
significant (student’s t-test, P=0.1477), there is a suggestion that hepatic Glut1 was up-
regulated.  
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Figure 4-4 Hepatic SLC2A1/GLUT1 mRNA by 
qPCR in RYGB and SHAM rats 
RNA (200 ng/µL) was used for qPCR. Y-axis is 
displayed with averaged expression fold change 
(RYGB:SHAM). SHAM n=5, RYGB n=8. Error bars 
are the mean with SEM. 
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4.3.2.2 Glycolysis 
Glycolysis, occurs in the cytosol of the cell and  is a metabolic pathway which converts 
glucose into pyruvate. Fructose-biphosphate aldolase (aldolase), is an enzyme catalysing 
a reversible reaction that splits hexose 1,6-biphosphate into two triose sugars, 
dihydroxyacetone phosphate (a ketone) and glyceraldehyde 2-phosphate, an aldehyde 
(Figure 4.5). There are three aldolase isozymes (A, B and C), which are encoded by three 
different genes. Here, I focused on ALDOA since it is an experimentally validated miR-122 
target (Elmén et al. 2008). Systematically administrating unconjugated locked nucleic acid 
(LNA) anti-miR-122 led to up-regulation of aldolase A both at the mRNA and protein levels 
(Elmén et al. 2008). As expected and shown in Figure 4.6, RYGB-operated rats exhibited 
a significant 79.9% up-regulation of Aldoa compared to SHAM operated rats (student’s t-
test, p=0.0051). The result confirmed the hypothesis made in Chapter 3, that the inhibited 
miR-122 could favour glycolysis by increasing its target aldoa expression. 
 
 
              
Figure 4-5 Reaction catalysed by aldolase 
Figure 4-6 Hepatic ALDOA mRNA by qPCR in RYGB 
and SHAM rats 
RNA (200ng/µL) was used for qPCR. Y-axis is 
displayed with averaged expression fold change 
(RYGB:SHAM). SHAM n=5, RYGB n=8. Error bars are 
the mean with SEM and ** signifies statistically 
significant as determined by student t test p<0.01. 
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4.3.2.3 Gluconeogenesis 
Liver generates glucose by de novo synthesis from non-carbohydrate precursors, such as 
lactate, pyruvate, glycerol and alanine, so called gluconeogenesis process. Compared to 
glucogenesis, another glucose generating pathway, gluconeogenesis occurs more rapidly 
and is suggested to be more important with prolonged fasting (GF, 1970). The rate of 
gluconegenesis is controlled by key metabolic enzymes (phospoenolpyruvate 
carboxykinase <PEPCK>, fructose-1,6-bisphosphatase and glucose-6-phosphatase 
<G6PC>) and nuclear transcription factor peroxisome proliferator-activated receptor 
gamma coactivator 1 alpha (PGC1α). MiR-122 is a predicted regulator of G6PC. 
Surprisingly, as shown in Figure 4.7, instead of being up-regulated by decreased miR-122 
level, G6pc mRNA expression was significantly reduced by 82% in the RYGB group 
(student’s t-test, p=0.0039). By decreasing levels of the key enzyme of gluconeogenesis, 
the conversion rate from non-carbohydrates to glucose in the RYGB-operated rats would 
be expected to be reduced and indeed it was significantly inhibited in the liver, the result of 
which was confirmed by NMR based metabonomics study.  
Figure 4-7 Hepatic G6PC mRNA by qPCR in RYGB and SHAM 
rats 
RNA (200ng/µL) was used for qPCR. Y-axis is displayed with 
averaged expression fold change (RYGB:SHAM). SHAM n=5, 
RYGB n=8. Error bars are the mean with SEM and * signifies 
statistically significant as determined by student t test p<0.05. 
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4.3.2.4 Glycogenesis 
The metabolic synthesis of glycogen, in which glucose molecules are added to the chains 
of glycogen for storage is termed glycogenesis. In liver, this process can be activated by 
insulin in response to high glucose levels at the post-prandial stage(Miller & Larner 1973). 
Glycogen synthase (GYS) converts glucose residues one by one into a polymer chain. As 
the key enzyme of glycogenesis, over-expressing the GYS gene in transgenic mice 
yielded excess glycogen storage levels (Manchester et al. 1996). Hence, the level of GYS 
expression directly indicates the glycogen synthesis rate. Two isoforms of glycogen 
synthase exist in mammals. One encoded by Gys2 appears only to be expressed in the 
liver, whereas the other one coded by Gys1, is expressed in multiple tissues, including 
skeletal and cardiac muscle, brain and liver with relatively lower amounts (Kaslow & 
Lesikar 1984; Kaslow et al. 1985). Based on computational prediction and previous 
studies, only Gys1 is a bone fide target of miR-122 (Esau et al. 2006). Injection of anti-
sense miR-122 systematically leads to a dose-dependently increase in the hepatic Gys1 
expression (Esau et al. 2006). As figure 4.8 shows, unexpectedly, there is no significant 
alteration in Gys1 mRNA expression between the two biological groups. However, 
changes in mRNA levels do not necessarily relate directly to activity levels of a particular 
enzyme as post transcriptional control and cofactor availability will govern protein activity. 
It is therefore important to confirm activity using enzyme kinetics or metabolite 
measurement.  
 
                 
Figure 4-8 Hepatic GYS1 mRNA by qPCR in RYGB 
and SHAM rats 
RNA (200ng/µL) was used for qPCR. Y-axis is displayed 
with averaged expression fold change (RYGB:SHAM). 
SHAM n=5, RYGB n=8. Error bars are the mean with 
SEM. 
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4.3.2.5 Pentose phosphate pathway 
The Pentose phosphate pathway generates NADPH, which is subsequently used in fatty 
acid biosynthesis, and pentose for nucleic acid synthesis. Glucose-6-phosphate 
dehydrogenase (G6PD) is the first and rate-limiting enzyme in pentose phosphate 
pathway. The role of G6PD in diabetes and obesity development process is still 
controversial. Conflicting results have shown that G6PD and NADPH levels can be 
inhibited in the liver of ¡diabetes patients (Cedola & Cabarrou 1975) or up-regulated in the 
liver of of Zucker diabetic fa/fa rat (Gupte et al. 2009). Genetically, the consensus is that 
G6PD deficiency is associated with increased risk of diabetes mellitus (Wan et al. 2002). 
G6PD is an experimentally validated target of miR-122 (Boutz et al. 2011). Here, in the 
RYGB-operated rats, the G6pd mRNA expression is significantly up-regulated by 91% in 
the liver of RYGB-operated rats compared to SHAM-operated  (Figure 4.9; p=0.0009). 
G6PD is not only essential for the pentose phosphate pathway, but also plays an 
important role in defending against oxidative stress by generating NADPH (Pandolfi et al. 
1995). The up-regulated G6pd could indicate a favoured pentose phosphate pathway and 
an enhanced protection against the accumulated reductive oxygen species generated by 
intensive oxidative phosphorylation after RYGB surgery.  
          
Figure 4-9 Hepatic G6PD mRNA by qPCR in RYGB and 
SHAM rats 
RNA (200ng/µL) was used for qPCR. Y-axis is displayed with 
averaged expression fold change (RYGB:SHAM). SHAM n=5, 
RYGB n=8. Error bars are the mean with SEM and *** signifies 
statistically significant as determined by student t test p<0.0001. 
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4.3.2.6 Fatty acid metabolism 
Fatty acid synthase (FASN), synthesises long-chain fatty acids by using acetyl coenzyme 
A as a primer, malonyl-CoA as a 2-carbon donor, and NADPH as a cofactor reducing 
equivalent. It catalyses the last step in the fatty acid biosynthesis pathway and is 
frequently used as a marker of de novo hepatic lipogenesis (Yanxin Wang et al. 2004). 
Numerous studies have focused on the function of FASN in obesity, diabetes and non-
alcoholic fatty liver disease (NAFLD) (Menendez et al. 2009). Hepatic Fasn knock-out mice 
have previously been used to specifically study FASN function. The mutant mice possess 
a similar phenotype to the control mice when fed with normal chow diet. However, 
surprisingly, under a low-fat/high-carbohydrate diet, mice lacking hepatic FASN exhibited 
accelerated de novo lipogenesis with a reduced β-oxidation rate (Chirala et al. 2003) 
(Chakravarthy et al. 2005). This mouse model has led to an interesting concept that the 
fatty acids, in particular palmitate, are synthesised when FASN acts as an agonist to 
activate a pool of nuclear receptors, such as peroxisome proliferator receptor α (PPARα). 
These nuclear receptors are in turn responsible for enhancing fatty acid β-oxidation rate 
(Chakravarthy et al. 2005). In the current study, as a validated target of miR-122, Fasn 
was significantly up-regulated by 74% in RYGB rats (p=0.0475). This suggests up-
regulation of de novo lipogenesis in the liver after RYGB. Whether the increased Fasn 
expression post-RYGB surgery is beneficial for fatty acid oxidation will need to be carefully 
examined in the future.  
 
               
Figure 4-10 Hepatic Fasn mRNA by qPCR in RYGB and 
SHAM rats 
RNA (200ng/µL) was used for qPCR. Y-axis is displayed with 
averaged expression fold change (RYGB:SHAM). SHAM n=5, 
RYGB n=8. Error bars are the mean with SEM and * signifies 
statistically significant as determined by student t test p<0.05. 
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4.3.2.7 Oxidative phosphorylation 
Oxidative phosphorylation is the ATP-generating process in mitochondria, where ATP 
synthase makes ATP via chemiosmosis of protons. Uncoupling protein (UCP) creates an 
alternative way for protons to return to the mitochondrial matrix, by uncoupling the electron 
transport chain required for ATP synthesis (Brand & Esteves 2005). There are three sub-
groups of UCP, namely UCP1, UCP2 and UCP3. Uncoupling protein 2 (UCP2) has been 
shown to have a crucial role in multiple physiological and pathological processes 
(Arsenijevic et al. 2000; Fleury et al. 1997; C.-Y. Zhang et al. 2001). Prolonged fasting and 
exposure to high levels of fatty acids can induce UCP2 expression, which then promotes a 
metabolic shift from carbohydrate metabolism towards lipid metabolism (Andrews et al. 
2008). Furthermore, the up-regulation of UCP2 can protect mitochondria from reactive 
oxygen species generated via intensive fatty acid β-oxidation (Patterson, Shah, 
Matsubara, Krausz & Gonzalez 2012a). In the present study, a significant increase in 
UCP2 expression was observed in the liver of RYGB-operated rats at both mRNA (71.4%, 
student’s t-test p=0.0039) (Figure 4.11) and protein level (150.7%, student’s t-test 
p=0.0081) (Figure 4.12). The up-regulated UCP2 suggests an accelerated fatty acid 
oxidation rate and a metabolic shift towards lipid metabolism after RYGB surgery.  
         
Figure 4-11 Hepatic Ucp2 mRNA by qPCR in RYGB and SHAM 
rats 
RNA (200ng/µL) was used for qPCR. Y-axis is displayed with 
averaged expression fold change (RYGB:SHAM). SHAM n=5, 
RYGB n=8. Error bars are the mean with SEM and ** signifies 
statistically significant as determined by student t test p<0.01. 
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4.3.2.8 TCA cycle 
Citrate synthase (CS) is an essential enzyme for nearly all living cells and it plays a key 
role in regulating the tricarboxylic acid (TCA) cycle. It is coded by nuclear genomic DNA, 
translated in cytoplasm and almost exclusively located in the inner membrane of 
mitochondria (Wiegand & Remington 1986). CS catalyses the condensation of 
oxaloacetate and acetyl coenzyme A to form citrate in the TCA cycle. It is the first and 
rate-limiting step of the TCA cycle and plays a crucial role in regulating energy generation 
and mitochondrial respiration (Wiegand & Remington 1986). In the present study, post 
RYGB surgical rats exhibited a 1.8-fold increase in Cs expression transcriptionally 
(student’s t-test p=0.0195) (Figure 4.13) and a 2-fold significant increase of CS protein 
expression in comparison to the SHAM-operated group (student’s t-test p=0.0435) (Figure 
Figure 4-12 Hepatic UCP2 protein expression by immunoblot in RYGB and SHAM rats 
Y-axis is displayed with averaged expression fold change (RYGB:SHAM). SHAM n=5, RYGB n=8. Error bars are the 
mean with SEM and ** signifies statistically significant as determined by student t test p<0.01. 20µg of protein was 
loaded for immunoblot. Protein expression was quantitated using Kodak Imaging Station 4000MM. A total of 20 ng of 
protein was loaded into each well and β-actin was used as a loading control and normaliser. 
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4.14). This result supports the hypothesis proposed in Chapter 3 that RYGB surgery 
affects the TCA cycle by regulating its rate-limiting enzyme CS. The favoured TCA cycle 
would be predicted to sequester acetyl-CoA into TCA instead of generating ketones.  
 
 
 
 
Figure 4-13 Hepatic CS mRNA by qPCR in RYGB and SHAM rats 
RNA (200ng/µL) was used for qPCR. Y-axis is displayed with 
averaged expression fold change (RYGB:SHAM). SHAM n=5, 
RYGB n=8. Error bars are the mean with SEM and * signifies 
statistically significant as determined by student ttest p<0.05. 
Figure 4-14 Hepatic CS protein expression by immunoblot in RYGB and SHAM rats 
Y-axis is displayed with averaged expression fold change (RYGB:SHAM). SHAM n=5, RYGB n=8. Error bars are the 
mean with SEM and * signifies statistically significant as determined by student t test p<0.05. 20µg of protein was 
loaded for immunoblot. Protein expression was quantitated using Kodak Imaging Station 4000MM using beta-actin as 
a loading control. 
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4.3.2.9 AMPK 
AMP-activated protein kinase (AMPK) is a key regulator of energy balance. It is expressed 
in the central nervous system (brain) and in peripheral tissues, including liver, pancreas, 
skeletal muscle, heart and adipose cells (B. B. Kahn et al. 2005). Generally, AMPK can 
sense and be modulated by environmental energy status reflected by the AMP:ATP ratio 
(Hardie et al. 2012). Under energy deficient status (high AMP:ATP ratio), for instance 
glucose deprivation during exercise, AMPK can be activated to switch off ATP-consuming 
biosynthesis pathways such as fatty acid synthesis, cholesterol synthesis and 
gluconeogenesis, and switch on ATP-producing catabolic pathways, for example fatty acid 
oxidation and glycolysis (Hardie et al. 2012). AMPK exists as a heterotrimer containing a 
catalytic α subunit and non-catalytic regulatory β and ɣ subunits (function as scaffold and 
contain glycogen binding domain) (Hardie et al. 2012). Both AMPKβ1 and AMPKβ2 are 
predicted as miR-122 targets (Mirtarget: www.microRNA.org). The inhibition of AMPKβ1 
mRNA (Prkab1), but not AMPKβ2 (Prkab2), was significantly relieved by decreased miR-
122 leads in RYGB- compared to SHAM- operated rats (student’s t-test p=0.0067) (Figure 
4.15). To confirm the effect of this on Prkab1 expression, immuno blot was then carried 
out. Surprisingly, instead of increased expression in line with the mRNA changes, protein 
expression of AMPKβ1 was significantly down regulated by 61% in the RYGB group 
(Figure 4.16). The result was consistent in three independent immunoblot experiments. 
This inconsistency between mRNA and protein expression levels could be explained by 
the fact that AMPKβ1 unit requires activation via phosphorylation. Hence, the decreased 
non-phosphorylated AMPKβ1 may result from an increased level of active phosphorylated 
AMPKβ1. Indeed, immunoblot showed that the active phosphorylated-AMPKβ1 protein 
was significantly up-regulated by 2 fold (Figure 4.16). 
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Figure 4-15 Hepatic Prkab1 and Prkab2 mRNA by qPCR in RYGB and SHAM rats 
RNA (200ng/µL) was used for qPCR. Y-axis is displayed with averaged expression fold change (RYGB:SHAM). 
SHAM n=5, RYGB n=8. Error bars are the mean with SEM and ** signifies statistically significant as determined 
by student t test p<0.01. 
Figure 4-16 Hepatic AMPKβ1 and ser-AMPKβ1 protein expression by immunoblot in RYGB and SHAM rats 
Y-axis is displayed with averaged expression fold change (RYGB:SHAM). SHAM n=5, RYGB n=8. Error bars are the 
mean with SEM and *** signifies statistically significant as determined by student t test p<0.0001. 20µg of protein was 
loaded for immunoblot. Protein expression was quantitated using Kodak Imaging Station 4000MM. 
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4.3.2.10 PPARs 
Lipid and glucose metabolism are inherently related. The findings of three “lipid-sensing” 
nuclear receptors, peroxisome proliferator-activated receptors (PPARα, PPARβ/δ and 
PPARγ) improved our understanding of the links between glucose and lipid metabolism 
(C.H. Lee et al. 2003). These nuclear receptors can be activated by both dietary fatty acids 
and their metabolic derivatives, and thus serve as lipid sensors which can markedly 
redirect metabolism (Willson et al. 2000). Activating PPARα and PPARβ/δ results in fatty 
acid oxidation, whereas PPARγ can regulate the whole body insulin sensitivity and 
maintain a balance between lipogenesis and lipid storage (Evans et al. 2004). Both 
PPARα and PPARβ/δ are predicted to be miR-122 targets (Mirtarget: www.microRNA.org). 
Hence, their mRNA expression was tested in the RYGB- and SHAM- operated rats. 
However, no significant alterations of Pparα and Pparβ/δ expression levels were observed 
between the two groups of animals (Pparα p=0.4146, Pparβ/δ p=0.7242) (Figure 4.17). It 
is worth noting that the unchanged Ppar expression does not necessarily indicate 
unaltered activation of PPARs. Post-operative PPARs activity should be determined by 
their downstream gene expression and this is certainly worth exploring in the future. 
        
Figure 4-17 Hepatic Pparα and Pparβ mRNA by 
qPCR in RYGB and SHAM rats 
RNA (200ng/µL) was used for qPCR. Y-axis is 
displayed with averaged expression fold change 
(RYGB:SHAM). SHAM n=5, RYGB n=8. Error bars are 
the mean with SEM. 
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4.3.3 Correlation between hepatic miR-122 and its metabolic targets  
As expected, non-parametric Pearson correlation exhibited strong negative correlation 
trends between the expression level of miR-122 and its targeted mRNAs (Figure 4.18). It 
suggests that miR-122 may play an essential role in regulating its hepatic metabolic 
targets post RYGB surgery. However, the ultimate determination regarding whether miR-
122 possesses the ability to regulate these targets should be examined by a miR-122 
manipulating experiment.  
Figure 4-18 Pearson correlation between hepatic 
miR-122 expression and its altered metabolic targets 
Red dots represent for RYGB animals (n=8), whereas 
blue stands for SHAM (n=5). The horizontal axis is the 
fold change of miR-122 and vertical axis is the fold 
change of the tested miR-122 metabolic targets 
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4.3.4 Observed miR-122 metabolic function in RYGB model could be 
mimicked by in vitro manipulation 
To further confirm that the alterations of the above-mentioned miR-122 targets are induced 
by a change in the microRNA, expression levels were manipulated in a set of in vitro 
experiments. Firstly, transfection reagent efficiency and dose/ratio optimisation were 
carried out in rat hepatocarcinoma cell line FAO. Secondly, a miR-122 mimic transfection 
study was performed in both FAO cells and in a rat pancreatic-derived hepatocyte-like cell 
line B13H (see section 2.2.6 and 4.3.4.3 for details of this cell line). Finally, the miR-122 
targets that were observed to be altered in vivo were examined using Taqman qPCR in 
the successfully transfected B13H cells in vitro.  
4.3.4.1 Lipofectamine 2000 is the optimal transfection reagent  
HiPerFect transfection reagent (Qiagen) and SiPort NeoFX transfection facilitator   
(Applied Biosystems) were evaluated for transfection efficiency in the rat liver carcinoma 
cell line FAO using 6-carboxyfluorescein (FAM)-labelled oligonucleotides (25 nucleotide 
long, random sequence oligo). The ratio of oligonucleotide to transfection reagent was 
optimised and shown in Figure 4.19. Based on the manufacturer’s recommendation, a 
fixed amount of FAM-labelled oligo (3µL, 1µM) was co-incubated with various volumes of 
the transfection reagent with the ratios of oligo:transfection reagent (volume:volume) from 
2:1 , 3:2, 6:5, 1:1, 6:7 and 3:4, respectively. The background fluorescence reading was 
measured using a none FAM oligo treated population of cells (negative control). 
Transfection efficiency was calculated as described below:  
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Unfortunately, none of the following tested samples exhibited a successful transfection 
outcome (all samples transfection efficiency <8%). Negative transfection efficiency results 
from fluctuating fluorescence background noise.  
 
 Negative control sample1 sample2 sample3 sample4 sample5 sample6 
Positive 
Control 
Transfection reagent 0 1.5 2 2.5 3 3.5 4 0 
FAM labelled oligos 0 3 3 3 3 3 3 3 
ratio (oligo/trasfection reagent) / 2:1 3:2 6:5 1:1 6:7 3:4 / 
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HiPerFect and SiPort reagents are specifically designed for transfecting small RNAs, such 
as siRNA and microRNA. However, due to their failure to generate satisfactory transfection 
efficiency, Lipofectamine 2000 (Invitrogen), a more general transfection reagent for both 
transfecting of small RNAs and plasmids, was then tested (details about all three 
transfection regents and transfection procedure can be found in chapter 2). Similarly, six 
Table 4-3 HiPerfect and SiPORT transfection condition with FAM labeled oligos 
Figure 4-19 Evaluating the transfection efficiency of FAO cells using siPORT and Hiperfect  
FAO cells were transfected for 24h with FAM-labelled oligo using either siPORTor or Hiperfect with various 
oligo:transfection reagent ratios. Y-axis is displayed with calculated transfection efficiency. Data represent mean ± 
SEM of three independent wells using 24 well plate. Triplicates were used for all tested ratios, NC is negative and PC 
positive controls. 
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different dose ratios were evaluated here with 24h transfection incubation time. As figure 
4.20 shows, 4µL Lipofectamine 2000 (ratio v:v= 3:4) appeared to be the most efficient 
transfection ratio (transfection efficiency=28.3%). Therefore, Lipofectamine 2000 was 
selected as the preferred transfection facilitator and a transfection ratio of 3:4 (V:V) was 
used for all the following functional studies of miR-122 inhibitor/mimic metabolic targets. 
 
 Negative control sample1 sample2 sample3 sample4 sample5 sample6 Positive Control 
Transfection reagent 0 3 4 5 6 7 8 0 
FAM labelled oligos 0 3 3 3 3 3 3 3 
ratio (oligo/trasfection reagent) / 1:1 3:4 3:5 1:2 3:7 3:8 / 
 
 
 
Table 4-4 Lipofectamine 2000 transfection condition with FAM labeled oligos 
Figure 4-20 Evaluating the transfection efficiency of FAO cells using lipofectamine 2000  
FAO cells were transfected for 24h with FAM-labelled oligo using lipofectamine 2000 with various oligo:transfection 
reagent ratios. Y-axis is displayed with calculated transfection efficiency. Data represent mean ± SEM of three 
independent wells using 24 well plate. Triplicates were used for all tested ratios, NC is negative controls and PC 
positive controls. 
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4.3.4.2 FAO cell is not a good model of rat liver  
Following the optimisation of the transfection condition, miR-122 mimic (Thermo Scientific 
Dharmacon miRIDIAN microRNA Mimics) was transfected into FAO cells in 24 well plates. 
Cells were incubated with miR-122 mimics (20nM) or the microRNA mimic scramble 
control (20nM) for 96 hours according to ThermoScientific guidelines 
(http://www.thermoscientificbio.com/uploadedFiles/Resources/miridian-brochure.pdf). 
Treated cells were viable and no significant cell death was observed during the 96 hour 
treatment time. All cell culture media (Opti-MEM) was removed at the end of the treatment 
and cells were washed with cold PBS to avoid any microRNA mimic residue 
contamination. Treatment with miR-122 mimic appeared to result in a significant increase 
(student’s t-test p<0.0001, 68 fold up-regulation) in cellular miR-122 level compared to 
control mimic-transfected cells, which indicated a successful transfection. However, 
despite the elevated levels of, the treatment failed to reduce the bona fide miR-122 target 
CS expression (Figure 4.21).  
 
 
Figure 4-21  MiR-122 transfection in hepatocarcinoma cell line FAO 
Quadruplicates were used for both control and miR-122 mimic treated test group. Error bars are the mean with SEM. 
A. The cellular expression of miR-122 after 96h transfection. *** signifies statistically significant as determined by 
student t test p<0.001 
B. The cellular expression of CS (citrate synthase) after 96h transfection. ns signifies as non significant determined by 
student t test. 
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A major hurdle to mimic liver function in vitro is the difficulties of generating dividable 
primary hepatocytes and their inability to retain differentiated phenotypes. Therefore, 
hepatoma cancer cell lines, which are readily available and easily expanded, are widely 
used instead. However, these cell lines exhibit limited hepatic phenotype and lack 
expression of major liver enzymes and crucial nuclear receptors (e.g. CYP450s and 
C/EBPb) (Rodríguez-Antona et al. 2002). Furthermore, the expression of the major 
hepatocyte-specific microRNA, miR-122, is significantly decreased during 
hepatocarcinogenesis, hence cancer-derived cell lines exhibit poor miR-122 expression 
(Kutay et al. 2006). Based on these considerations, an alternative in vitro rat liver cell 
model was examined and a rat pancreatic progenitor cell “B13-AR42J” was trans-
differentiated to a hepatocyte-like cell line, B13H (Marek et al. 2003; Shen et al. 2000), 
and then used in the following study.  
4.3.4.3 B13H cell is a hepatocyte-like cell line 
B13H cell line, a sub clone derived from a pancreatic AR42J-B13 cell line, was 
differentiated with glucocorticoid (dexamethasone, 10nM) for two weeks (Marek et al. 
2003). This allows the transdifferentiation of the pancreatic cell phenotypically into an 
hepatocyte-like cell line, similar to primary liver cells possessing the liver specific and 
enriched functional enzymes (Marek et al. 2003; Shen et al. 2000). Interestingly, as Figure 
4.22 shows, miR-122, the most abundant hepatic microRNA, was gradually up-regulated 
more than 12 fold during the transdifferentiation process. This significant induction 
indicated 1) pancreatic progenitor cell line, B13H, was gradually transdifferentiated into a 
hepatocyte-like cell line during the dexamethasone treatment process; 2) consistent with 
previous study, miR-122 could be behaving as a molecular switch to control the liver 
differentiation processes (Laudadio et al. 2012).  
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4.3.4.4 Post RYGB hepatic metabolic alteration could be mimicked by altering miR-
122 expression in vitro 
I next investigated whether miR-122 directly modulates mRNA targets by manipulating its 
expression in the B13H cell line.  
Treatment with 10nM dexamethasone was removed at day 14 and cells were left to 
recover in normal media for 24 hours. MiR-122 mimic (20nM) and microRNA scrambled 
control (20nM) were transfected into differentiated B13H cells under optimised reduced 
serum medium (Opti-MEM, Invitrogen) in 6-well plates. Similar to FAO cells, B13H cells 
were also collected at 96 hours and cells were washed in cold PBS before harvesting. A 
72.3 fold clear increase inthe intracellular miR-122 level was confirmed by Taqman qPCR 
(Figure 4.23 A). Next, by using Taqman mRNA RT-qPCR, I quantified all miR-122 targeted 
Figure 4-22  MiR-122 expression in B13 cell undergoing transdifferentiation 
B13 cells were treated with 10nM dexmethasone for 14 days. Triplicate samples were plated in T25 flask and 3 flasks 
of cell were harvested at each day during 14 days transdifferentiation. Error bars represents the mean with SEM. Data 
presented as the miR-122 expression fold change compared to Day 0, the un-treated B13 cells baseline miR-122 
expression. 
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metabolic enzymes/ regulators, which are significantly altered in the RYGB animal model. 
As Figure 4.23B shows, Cs, Slc2a1, Fasn and Aldoa expression exhibited significant 
inhibition in the B13H cells in contrast to control cells (transfected with scrambled oligo). 
The inhibition effects on G6pd, Prkab1 and Ucp2 were apparent but not statistically 
significant. Consistent with the aforementioned in vivo findings, the G6pc expression level 
was not affected by miR-122.  
These results are consistent with the effects of miR-122 noted in the post-RYGB liver.   
 
 
Figure 4-23  MiR-122 transfection in hepatocyte-like cell line B13H 
Quadruplicates were used for both control and miR-122 mimic treated test group. Error bars are the mean with SEM. 
A. The cellular expression of miR-122 after 96h transfection. *** signifies statistically significant as determined by 
student t test p<0.001 
B. The cellular expression of all miR-122 targets after 96h transfection. * and ** signifies statistically significant as 
determined by student t test p<0.05 and o<0.01, respectively. 
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4.3.4.5 In vivo treatment with locked-nucleic-acid anti-miR-122  supports the miR-
122 induced post-RYGB metabolic target alteration 
Based on the publicly available data from Array Express 
(http://www.ebi.ac.uk/arrayexpress/), transcriptomics data from diet-induced obese mice 
treated with LNA (locked-nucleic-acid-modified oligonucleotide) - anti-miR122 was 
analysed here (Elmen et al. 2008). Consistently, a systematic inhibition of miR-122 by anti-
miR-122 LNA  elicited similar effects on the hepatic protein targets studied in the present 
thesis (Figure 4.24). All miR-122 targets tested in vivo were up-regulated, except for 
Prkab1, which did not show any alteration (Figure 4.24). It is important to note that the  
changes in these targets are approximately around 1.1 fold, which is much less than 
expected. This may due to the different mRNA profiling platforms applied. LNA-miR-122 
targets presented below were detected using microRNA microarray. Figure 4.24 shows 
that Aldoa, a widely used bone fide miR-122 target, only exhibited 1.13 fold up-regulation 
by microarray. However, qPCR test result generated from the same mouse suggested that 
the hepatic Aldoa expression was up-regulated more than 3 fold in LNA treated animals 
(data presented in the paper (Elmen et al. 2008)). Therefore, the overall relatively smaller 
induction may result from the difference between profiling platforms.  
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Based on the above results, it is concluded that miR-122 directly and significantly 
modulated Cs, Glut1, Fasn, Aldoa, G6pd and Ucp2, and to a lesser extent, Prkab1. The 
association between G6pc and miR-122 is still peculiar and needs to be further 
investigated. 
 
Figure 4-24  Hepatic target expression in LNA miR-122 treated mice 
Control n=5, miR-122 LNA treated n=5 
* , ** and *** signifies as  student t test p<0.05, p<0.01, and p<0.001, respectively. 
Data was extracted from ArrayExpress Experiment No.E-MEXP-1406 (give published ref) 
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4.4 Chapter discussion 
Metabolic reactions can be either catabolic (dissimilation of food with the release of 
energy) or anabolic (absorption and incorporation of food into energy storage). The 
catabolic and anabolic state are determined mainly by two factors, food intake and energy 
expenditure. Natural weight loss is associated with compensatory changes in energy 
expenditure that oppose the maintenance of a body weight, which is different from the 
usual weight (Leibel et al. 1995). The compensatory decreased total energy expenditure 
may account for the poor long-term efficacy of weight loss treatments for obesity. RYGB 
surgery, on the other hand, provides sustained long-term weight loss with an increased 
body energy expenditure rate (Stylopoulos et al. 2009). It is possible that under this drastic 
anatomic alteration, molecules from different levels co-operate to establish a novel 
metabolic balancing point which is different from the auto-established body homeostasis 
point. Although many clinical studies and basic research on gut hormones, metabolites 
and the gut microbiota after bariatric surgery have been reported, there is no clear 
understanding of the underlying molecular mechanisms for the postoperative increased 
energy expenditure. Understanding the mechanism of this could not only explain the 
sustainable weight loss and multiple metabolic benefits post-RYGB surgery, but also 
provide an opportunity to mimic this effect to control body weight and diabetes using non-
invasive methods in the future. 
In this chapter, I investigated hepatic miR-122 expression. Although hepatic miR-122 
expression in RYGB rats was also decreased, the drop is much less in the liver compared 
to the plasma. It is possible that the liver produces less miR-122 and releases less into the 
blood stream. Alternatively, in the RYGB- operated rats, the liver-secreted miR-122 is 
transported more into other organs as a hormone. In fact, microRNA hormonal effects 
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have been proposed before. For instance, Vickers et al. observed that HDL participates in 
a mechanism of intercellular communication involving the transport and delivery of 
microRNAs (Vickers et al. 2011). More information about the concept of microRNAs 
functioning as hormones can be found in a recently published comprehensive review 
(Cortez et al. 2011).  
An important point to consider is that even a relatively subtle change in microRNAs can 
sometime induce a large physiological effect, such as when a positive feedback loop 
amplifies the change of microRNA and one microRNA simultaneously targets a set of 
genes that are in a shared pathway or similar function. As shown in Figure 4.25, the anti-
fatty acid oxidation function of miR-122 is one example. Activation of AMPK increases fatty 
acid oxidation either via activating PGC1α and PPARα or phosphorylates (inactivate) actyl-
CoA carboxylase (ACC) (Cantó & Auwerx 2009; W. J. Lee et al. 2006). The ensuing 
activation of PPARα increased UCP2 which could further inactivate ACC (Kelly et al. 
2013). PPARα, AMPK, UCP2, PGC1α and phosphorylated ACC typically form a complex 
network in order to control fatty acid oxidation. The presence of miR-122 may 
simultaneously shut down all three crucial pathways, which are important for fatty acid 
oxidation (PGC1α and AMPK are validated miR-122 targets (Burchard et al. 2010; Esau et 
al. 2006), UCP2 is a putative target of miR-122 which was also tested in the present 
study). This effect could be even stronger with other positive feedback loops which 
reinforce miR-122 expression (An example of the positive feedback loop between miR-122 
and PPARs will be further discussed in chapter 5). Hence, even with relatively small 
alterations of miR-122 in the liver, it is still appropriate to assess all crucial miR-122 
metabolic targets in order to generate an overview of RYGB surgery effects. 
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Here it was found that, as expected, multiple miR-122 metabolic targets were up-regulated 
in the liver obtained from the of RYGB-operated rats. As shown in Figure 4.26, these 
alterations indicated a switch to the anabolism pathways, for instance, glucose 
transportation, glycolysis, TCA and fatty acid oxidation and a switch from catabolism 
pathways, such as gluconeogenesis. The extent of the up-regulation of these targets are 
similar, ranging from 1.53 fold (Slc2a1) to 1.91 (G6pd) fold. It is worth noting that not all 
targets were up-regulated as expected, for example, bone fide miR-122 target G6pc was 
reduced by 80% while one experimentally validated target Gys1 and three putative targets 
Pparα, Pparβ/δ and Prkab2 did not show any changes at all. One possibility that may 
account for the decreased G6pc is that transcriptional inhibitors of G6pc are negatively 
regulated by miR-122 and therefore are up-regulated following miR-122 inhibition. 
Alternatively, other more potent translation/post-translation regulation mechanisms co-
regulate G6pc expression and masked the effect of miR-122 up-regulation. The RYGB 
surgery model we are investigating is a complex multi-input-output system, and not a 
simple single input - output model. Therefore, any direct causal-consequence link or 
explanation needs to be carefully evaluated. 
Figure 4-25 An example of one microRNA simultaneously targeting multiple pathways which amplifies small 
changes and fundamentally influence the homeostasis 
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In mechanistic studies I examined miR-122 and its target relationships in vitro using 
pancreatic progenitor cell derived hepatocyte B13H. Here it was found that expression of 
all miR-122 targets were reduced to different extents except for G6pc (not affected), which 
is consistent with the in vivo finding. Additionally, in vivo data from public available data of 
LNA miR-122 treatment experiments further confirmed this conclusion. Whether miR-122 
is the only (crucial) molecule that causes the post RYGB benefits needs to be carefully 
explored. To unequivocally conclude that inhibition of miR-122 contributes to post-RYGB 
benefits, operated rats should be administrated miR-122 mimics after surgery to examine 
whether post surgery metabolic benefits are diminished. Alternatively, the surgery could be 
carried out in miR-122 knockout animals with the prediction that less surgical benefits are 
to be expected. 
The current findings are consistent with previous studies related to post surgery effects. 
Mencarelli et al. have recently investigated the effects of ileal interposition (IT), where the 
Figure 4-26 Summary of the potential metabolic shift towards catabolism mediated via miR-122 regulated 
metabolic targets 
Red= up-regulated/activated/favoured        Green= down-regulated/ inactivated/ inhibited 
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distal ileum is relocated into the proximal jejunum, which mimics a partial procedure of 
RYGB surgery (Mencarelli et al. 2013). Consistent with my RYGB results, the hepatic 
expression of G6pc was also suppressed in this IT model (Mencarelli et al. 2013). 
Furthermore, Peng et al. observed that RYGB increases hepatic levels of SIRT1, AMPK, 
and p-AMPK (Peng et al. 2010). In the RYGB model, I also observed Prkab1 up-regulation 
in mRNA level and ser-AMPKβ1 in protein. In terms of accelerated TCA cycle, Li et al. 
have shown that urinary TCA cycle intermediates, including succinate, 2-oxoglutarate, 
citrate and fumarate, are all decreased in RYGB-operated rats (2, 4, 6 and 8 weeks post 
surgery) (J. V. Li et al. 2011a). Consistent with the up-regulation of CS, the TCA cycle key 
enzyme I observed, these decreased urinary metabolites indicate an increased utilisation 
of TCA cycle intermediates and an accelerated TCA cycle.   
In conclusion, it is likely that the individual metabolic effects I and other researchers 
observed are tightly linked by the alterations of this small non-coding hepatic microRNA, 
miR-122. The potential reasons, which caused miR-122 changes, will be discussed in 
Chapter 5. 
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5.  Causes of Hepatic miR-122 Alteration after RYGB surgery 
5.1 Introduction  
In chapter 3, a set of microRNAs which were significantly altered by RYGB surgery was 
described. In chapter 4, a paradigm microRNA, namely miR-122, was focused upon to 
reveal its crucial role in mediating post-RYGB metabolic related alterations. The study thus 
far examined the microRNA profiles following bariatric surgery and what the metabolic 
consequences were. Another important question is what are the fundamental causes of 
these observed microRNA changes? Therefore, in this chapter, I will investigate the 
potential causes of the altered hepatic miR-122 with focus on 1) changed metabolic 
environment and 2) activated transcriptional factors.  
5.1.1 Metabolic environment and microRNA expression are tightly linked 
Physiologically and pathologically altered metabolic environments are frequently 
associated with dysregulated microRNA expression. Here, I will introduce this microRNA-
metabolism link with three aspects, glucose, fatty acids and hormones.  
5.1.1.1 Impaired glucose metabolism is associated with alteration of 
microRNA expression.  
A well-studied example is microRNA-375. In 2004, the pancreatic islet specific miR-375 
was found to maintain glucose homeostasis and regulate insulin secretion via targeting 
exocytosis protein mytorphin (Mtpn) (Poy et al. 2004). By over-expressing miR-375, 
glucose-induced insulin secretion could be suppressed, and conversely, inhibition of 
endogenous miR-375 improved insulin secretion function. Ouaamari et al. reported that 
          149 
diabetic Goto-Kakizaki rats exhibited an elevated pancreatic miR-375 expression level 
(Ouaamari et al. 2008). Interestingly, increasing environmental glucose concentration to 
11 mM and 22 mM could decrease miR-375 expression both in INS-1E pancreatic cell line 
and in freshly isolated rat pancreatic islets, respectively (Ouaamari et al. 2008). These 
findings highlighted the possibility that microRNAs can operate as mediators to sense 
environmental glucose concentration and adjust its own expression to maintain the normal 
glucose level. Besides miR-375, miR-296 and miR-9 were also found to be up-regulated 
by increased glucose concentration (Ouaamari et al. 2008).  
5.1.1.2 Elevated fatty acid concentration is a predisposing factor for 
diabetes and non-alcoholic fatty liver disease (NAFLD), the mechanism of 
which is believed to involve microRNAs.  
For instance, prolonged exposure of the pancreatic beta-cell line MIN6B1 and primary 
pancreatic islets to palmitate caused a time- and dose-dependent increase of miR-34a and 
miR-146 (Lovis, Roggli, et al. 2008b). Elevated levels of miR-34a and miR-146 were also 
observed in islets of diabetic db/db mice (Lovis, Roggli, et al. 2008b). It is believed that at 
least part of the detrimental effect of palmitate on beta-cells (such as reduced insulin 
production, defective insulin secretion, and apoptosis) is caused by alterations of specific 
microRNAs. Additionally, microRNAs (including miR-122, miR-34a, miR-132 and miR-150) 
were all dysregulated in the visceral adipose tissue and plasma of NAFLD patients (Estep 
et al. 2010). Like glucose-responsive microRNAs (e.g. miR-375), it is possible that miR-
122, miR-34a, miR-132 and miR-150 are responsive to the altered environmental fatty 
acids level. Indeed, by feeding mice with high-fat diet, multiple microRNAs (including miR-
122, miR-192, miR-30c* etc.) were down-regulated (J. Zhang et al. 2009b). It has been 
suggested that these microRNAs together with PPAR and cpt-1α were working together to 
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adapt to the increased FFA by increasing fatty acid oxidation rate (Gatfield et al. 2009).  
Previous studies also showed that  
5.1.1.3 Exposure to hormones, such as insulin and glucocorticoids, 
significantly affected microRNA profiles.  
For example, insulin treatment down-regulates the expression of 39 microRNAs in human 
skeletal muscle including miR-1, miR-133a and miR-30a/miR-30e family (Granjon et al. 
2009). Additionally, two independent studies showed that treatment  with glucocorticoid 
(dexamethasone) represses expression of miR-17-92 family in rat (Molitoris et al. 2011) 
(Smith et al. 2010). In summary, these previous studies highlight both the capability of 
metabolites and hormones to behave as microRNA regulators, and microRNAs’ ability to 
adapt to these environmental metabolic changes which in turn help the biological system 
to maintain metabolism homeostasis.  
5.1.2 Bariatric surgery influences metabolic processes, which could trigger 
decreased hepatic miR-122 expression 
Not surprisingly, dramatic anatomical alteration such as bariatric surgery fundamentally 
influences metabolic processes, such as glucose, fatty acid and glucocorticoid 
metabolism. 1) Bariatric surgery is reported to be the most effective treatment for type 2 
diabetes and significantly influences glucose homeostasis, since I) diabetes often resolves 
within days after surgery, long before weight-loss has occurred (Rubino & Marescaux 
2004); and II) homeostatic model assessment of insulin resistance (HOMA-IR) and basal 
glucose production is reduced within 1 week (Bojsen-Møller et al. 2013). To investigate 
bariatric surgery related glucose controlling mechanisms, the majority of previous studies 
focused on the fasting stage. However, it was shown that the metabolic changes are more 
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pronounced in the postprandial stage rather than in the fasted period after RYGB surgery 
(Camastra et al. 2013) (Jacobsen et al. 2013). Peripheral postprandial glucose, for 
example, exhibits a biphasic profile with a rapid increase followed by a sharp drop, a 
pattern that was mirrored by glucagon and insulin secretion (Camastra et al. 2013). 
Circulating glucose concentration represents the net effect of multiple metabolic 
processes, including dietary intake and absorption, endogenous glucose production (via 
gluconeogenesis and glycogenolysis), and glucose utilisation. Jacobson et al. proposed 
that the driving force for the altered postprandial circulating glucose levels after RYGB is 
the rapid entry of glucose into the systemic circulation brought about by modified 
gastrointestinal anatomy, causing hypersecretion of insulin and other hormones, which in 
turn influence glucose disappearance and endogenous glucose production (Jacobsen et 
al. 2013). In fact, in our study, metabonomics data also showed that hepatic glucose and 
glycogen levels were significantly higher in RYGB operated rats compared to SHAM 
animals, which suggested altered glucose metabolism after RYGB surgery. Hence, 
glucose concentration is potentially important to the regulation of hepatic miR-122 
expression. 2) Fatty acid metabolism is significantly influenced after RYGB. The most 
symbolic effect of bariatric surgery is sustainable drastic weight loss. Multiple obesity 
related lipid dysfunction effects could be normalised after RYGB surgery. Specifically, 
post-RYGB surgery patients consistently showed a reduction in circulating cholesterol, 
triglycerides and an increase in high density lipoprotein levels (Williams et al. 2007). 
However, very few studies suggest mechanisms related to the observed altered lipid 
metabolism after RYGB. Thus, in this study, fatty acids will also be tested to examine 
whether they promote reduction of miR-122, in turn accelerating fatty acid metabolism. 3) 
Glucocorticoid levels could be altered by the reduced body weight associated with bariatric 
surgery. It is well-known that increased local glucocorticoid (such as cortisol) levels in 
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adipose tissue and liver is an important factor in the insulin resistance syndrome (RIZZA et 
al. 1982). Previous studies have suggested that in obese subjects, cortisol secretion is 
elevated but circulatory concentrations of cortisol are normal or low, suggesting that 
peripheral disappearance rate is elevated (Andrew et al. 1998). Surprisingly, weight loss 
could further stimulate tissue cortisol rate by activating key cortisone-contisol metabolic 
enzyme, 11β-Hydroxysteroid Dehydrogenase Type 1 (Tomlinson et al. 2004). Notably, 6 
month after laparoscopic adjustable gastric banding (LAGB), patients showed a significant 
inhibition of plasma cortisol levels (Ram et al. 2005). These observations lead me to 
propose that glucocorticoids could also play a role in miR-122 regulation. 
 
 
As mentioned above, bariatric surgery dramatically changed multiple metabolic processes 
(such as glucose, fatty acid and glucocorticoid metabolism, Figure 5.1 blue arrow), and 
could also drastically influence microRNA expression profile (Figure 5.1, red arrow). 
Moreover, it has been shown that these metabolic processes, which were greatly 
influenced by surgery, are tightly linked with microRNA function  (Figure 5.1 purple arrow).  
Figure 5-1 The relationship between bariatric surgery, metabolism and microRNA proposed in this thesis 
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5.1.3 MicroRNA maintaining system homeostasis via transcriptional factors 
The activity of microRNAs is believed to offer robustness to biological processes by aiding 
transcriptional regulation and attenuating aberrant transcripts (Ebert & Sharp 2012). 
Networks and feedback mechanisms are likely to help suppress random fluctuation in 
transcript copy number (Hobert 2004). MicroRNAs are of course not the only class of 
cellular transcriptional regulatory factors that contribute to system robustness. 
Interestingly, transcriptional factors (TFs), share a lot of similarities with microRNAs. 
Recently, it was found that microRNAs and TFs are often linked in gene regulatory 
pathways, specifically, microRNA expression is determined by complex transcriptional 
regulatory inputs and microRNAs themselves show a propensity to regulate TFs (Shalgi et 
al. 2007). Additionally, microRNAs and TFs could also co-ordinate to regulate common 
targets (Shalgi et al. 2007). Furthermore, microRNA and their targets are often involved in 
feedback loops with switch-like behavior to amplify changes (such as carcinogenesis and 
development process). Negative feedback loops function to “fine tune” in order to maintain 
system homeostasis (such as metabolism control). In view of the common crosstalk 
between TFs and microRNAs and the mechanistic studies reported in chapter 4, we 
focused on one class of transcriptional factor, peroxsiome proliferation associated 
receptors (PPAR) in this chapter, to investigate whether the activation of PPAR could be 
responsible for decreased hepatic miR-122.  
Thus, in this chapter, I will examine potential mechanisms involved in the control of hepatic 
miR-122, with focus on metabolites (glucose, and fatty acids), hormones (glucocorticoid) 
and TFs (PPARs).  
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5.2 Methods and experiment outline 
1. FAO and B13/B13H cell line culture condition is described in 2.2.5 and 2.2.6, 
respectively. 
2. Design and detail of glucose treatment is described in 2.2.7 
3. Design and detail of dexamethasone treatment is described in 2.2.8 
4. Design and detail of PPARα/γ (fenofibrate/rosiglitazone) treatment is described in 
2.2.9 
5. Design and detail of fatty acid (arachidonic acid) treatment is described in 2.2.10 
6. Cell total RNA extraction is described in 2.3.2 
7. Taqman single microRNA assay is described in 2.4.2 
8. Semi-quantitative PCR and primer sequences is described in 2.4.3 
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5.3 Results with discussion 
5.3.1 The acute post-prandial high hepatic glucose concentration may not be 
the reason of inhibited miR-122 after RYGB 
Most published gastric bypass related glucose/insulin resistance research has utilized 
methods based on fasting measurements, such as Homeostatic Model Assessment 
(HOMAs) and giving glucose challenge, such as Oral Glucose Tolerance Test (OGTT). 
However, these approaches lack the capacity to investigate the impact of digestion and 
absorption processes. The most prominent effect of RYGB surgery is on the subject’s 
physiology, due to its drastic anatomical change of digestive organ organization. Clearly, 
investigating the impact of RYGB on the disposition of a mixed meal is a more 
physiological relevant approach to understand the consequence of surgery. Additionally, 
besides fasting, the postprandial period could also be a crucial stage, alteration of which 
may tightly relate to post-surgical benefits. In 2013, several studies reported the effect of 
gastric bypass on altered postprandial metabolism (such as glucose and branch chain 
amino acid metabolism) by using Mixed Meal Test (MTT) (Camastra et al. 2013). 
Consistently, these studies have reported that although the overall glucose response 
(measured as area under the curve during meal challenge) is unchanged after RYGB 
surgery, the postprandial plasma glucose peak shifts to the left, which indicates a more 
rapid absorption and clearance of glucose (Camastra et al. 2013) (Figure 5.2). 
 
Figure 5-2 Postprandial plasma glucose 
concentration shift before and after RYGB 
surgery 
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Here in our study, we observed an increased hepatic glucose and glycogen concentration 
in RYGB compared to SHAM operated rats (by Dr. Jia Li, shown in Table 3.4). I therefore 
investigated whether the increased glucose concentration alone could inhibit endogenous 
miR-122 expression using a cell culture model with rat FAO cells. Short treatment time 
points (2h and 8h) were used because the relatively high-glucose exposure post-RYGB is 
limited within the postprandial stage, normally only lasting around 2 hours (Camastra et al. 
2013). In my FAO cell culture experiments, glucose concentrations of 5mM, 15mM and 
25mM were chosen since 1) normal rat plasma glucose concentration is similar to human 
(around 5.5mM ≡ 100mg/dL) 2) the plasma and portal vein glucose concentration (which 
indicate liver glucose concentration) could be increased to as high as 13.75mM (≡ 
250mg/dL) after a meal (the postprandial glucose concentration varies and depends on 
the meal size)(Strubbesteffens AB, 1977). As Figure 5.3 shows, treating hepatic cell line 
FAO with different doses (5mM and 15mM) of α-D-glucose did not result in any inhibition 
of miR-122 compared to non-glucose treated FAO.  
Surprisingly, treating FAO cells with the highest dose of glucose (25mM) resulted in a 
significant (p=0.0216) increase in miR-122, up to 1.84 fold compared to control at 2 hours 
and a significant 1.6 fold up-regulation at 8 hours (p=0.0364) (Figure 5.3). This result 
suggested that FAO cells were under stress with high concentration glucose treatment. In 
support of this, using another human hepatocarcinoma cell line HepG2, two independent 
studies reported that 25mM and 50mM glucose were enough to induce glucotoxicity 
(Gautier-Stein et al. 2012). It has been reported before that cellular responses to high 
glucose are numerous and varied, but the ultimate result is functional change often leading 
to cell death (Baumgartnerparzer et al. 1995). The mechanism of glucose induced 
apoptosis has been reported to include induced expression of oxidative and nitrosative 
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stress caused by generation of species such as superoxide, nitric oxide and peroxynitrite 
(Allen et al. 2005). Furthermore, high glucose concentration can also cause activation of 
apoptotic related proteins, such as Bcl-2 families (H. K. Li et al. 2005). Interestingly, the 
anti-apoptotic Bcl-2 is an experimentally verified miR-122 targets (C. J.-F. Lin et al. 2008). 
Therefore, it is possible that in my experiment the increased expression of miR-122 
decreases the anti-apoptotic Bcl-2 which subsequently led to the reduction of cell viability 
under high concentration of glucose treatment. 
In all, these data suggest that increased postprandial hepatic glucose concentration is 
unlikely to lead to inhibition of miR-122 expression post-RYGB. 
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Figure 5-3 MiR-122 expression in rat liver FaO cells with glucose treatment  
RNA (2ng/µL) was used for qPCR. Y-axis indicates averaged expression fold change (treatment:control<0mM>). U6 was 
used for qPCR normalization. N=3 across all groups. Values are the mean with SEM and ** signifies statistically 
significant (p<0.01) as determined by one-way ANOVA with Dunnett’s multiple comparisons test. 
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5.3.2 Glucocorticoid involvement in altered miR-122 expression 
Previous studies link obesity and metabolic syndrome with increased plasma 
glucocorticoid level (such as cortisol). Human obesity shares similar clinical features with 
hypercortisolism, for example, increased insulin resistance, impaired glucose tolerance, 
elevated blood pressure, and dyslipidemia (Bjorntorp & Rosmond 2000). Several animal 
models of obesity have also characterised an increased secretion of glucocorticoids 
(Bjorntorp & Rosmond 2000). Additionally, clinically administrating glucocorticoids to treat 
inflammatory disease has also been associated with metabolic adverse effects such as 
hypertension, obesity, hyperlipidemia and insulin resistance as seen in metabolic 
syndrome (Minghan Wang 2005).  
Cortisol is the natural glucocorticoid (GC) hormone which can be converted to/from 
cortisone via 11β-hydroxysteroid dehydrogenase (11β-HSD). Two forms of 11β-HSD exist, 
11β-HSD1 converts inactive cortisone to cortisol in human or inactive 11-
dehydrocorticosterone (11-DHC) to corticosterone in rodents, while 11β-HSD2 catalyses 
the opposite reaction (van Uum & Hermus 1998). GC’s action is mediated by 
glucocorticoid receptors (GR), a nuclear receptor that regulates physiological events 
through activation or repression of target genes involved in inflammation, gluconeogenesis 
and adipocyte differentiation (Bamberger et al. 1996). In the active state, a GR dimer binds 
to GC response elements (GRE), which interact with components of the transcription 
machinery to activate/repress the transcription of downstream genes (Schoneveld et al. 
2004). Over-expression of 11β-HSD1 in liver could subsequently elevate GC levels, which 
is sufficient to trigger insulin resistance and increased hepatic lipid synthesis and flux 
(Paterson et al. 2004). On the contrary, 11β-HSD1 knockout mice are protected from high-
fat diet-induced pre-adipocyte differentiation and obesity (Kotelevtsev et al. 1997). Obesity 
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is highly correlated with increased 11β-HSD1, which could favour cortisone-cortisol 
transition and activate GRs (Figure 5.4). GR activation mediated hyperglycaemia and 
dyslipidemia could be explained by increased hepato-gluconeogenesis (via 
phosphoenolpyruvate carboxykinase, PEPCK; and glucose-6-phosphatase, G6Pase), 
reduced fatty acid oxidation (via acetyl-Coenzyme A carboxylase 2, ACACB; acetyl-
Coenzyme A acyltransferase 2, ACAA2; and carnitine palmitoyl transferase 1, CPT1) and 
decreased triacylglycerol hydrolysis (via pancreatic lipase, PNL; and PNL-related protein 
2, PNLRP2)1 (Jen-Chywan Wang et al. 2012).  
 
 
As described in chapter 4, RYGB in the rat favored fatty acid oxidation and inhibited 
gluconeogenesis compared to SHAM operated rats. This mirrors reduced GC-GR 
activation. In fact, previous studies in humans have shown a significant decrease in 11b-
HSD1 expression in subcutaneous adipose tissue and a decreased cortisol/cortisone ratio 
after gastric bypass surgery (Simonyte et al. 2010). Hence, I hypothesized that reduced 
expression of endogenous glucocorticoid after RYGB surgery may contribute to the 
inhibited hepatic miR-122 expression, and thus the activation of glucocorticoid receptor 
could potentially increase hepatic miR-122 expression. To test this hypothesis, I have 
used an in vitro cell culture model and glucocorticoid treatment. 
Figure 5-4 The relationship between obesity, cortisol and altered metabolic process 
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5.3.2.1 Treatment with glucocorticoid significantly induced miR-122 expression 
Treating with glucocorticoid allows the transdifferentiation of the pancreatic cell B13 into a 
hepatocyte-like cell line B13H, similar to primary liver cells possessing the liver specific 
and enriched functional enzymes, such as albumin and Cyps (Shen et al. 2000; Marek et 
al. 2003). By treating the pancreatic progenitor cell derived B13 cell with 10nM 
dexamethasone (synthesized glucocorticoid), cells exhibited a more than 300 fold up-
regulation of miR-122 at week 2, 3 and 4 compared to un-treated cells (Figure 5.5). This 
finding is compatible with my hypothesis, which suggests that activating glucocorticoid 
receptor might up-regulate miR-122 expression in the hepatocyte. However, it is important 
to note that 1) B13 is not originally a liver cell line. 2) In view of its dramatic up-regulation, 
miR-122 might be behaving as a molecular “switch”, mediating the differentiation process, 
instead of a cellular “fine tuner”, which maintains metabolic homeostasis. Therefore, 
additional dexamethasone treatment experiments were performed in the rat liver cell line, 
FaO.  
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Figure 5-5 MiR-122 mRNA expression during pancreatic to 
hepatic transdifferentiation process in B13/B13H cells 
Transdifferentiation was induced by continuous dexamethasone 
treatment (10nM). RNA (2ng/µL) was used for qPCR. Y-axis 
shows averaged expression fold change compared to untreated 
cells. U6 was used for qPCR normalization. N=3 across all 
groups. Values are the mean with SEM and *** signifies 
statistically significant (p<0.001) as determined by one-way 
ANOVA with Dunnett’s multiple comparisons test. 
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5.3.2.2 Treatment of rat liver cell line FaO with glucocorticoid 
FaO cell line is a well differentiated rat hepatoma cell line which possesses an active 
gluconeogenic pathway . Dexamethasone treatment (10nM) was used since 1) B13 cell 
line responded successfully to treatment with dexamethasone (10nM) and 2) physiological 
cortisol expression level various during the day and night time average around 300 nM 
(Selmaoui & Touitou 2003) and the glucocorticoid effect of dexamethasone is  25 times 
more potent than cortisol, hence 10nM treatment should fall in the meaningful 
physiological range of endogenous glucocorticoid level. Dexamethasone was dissolved in 
ethanol, so ethanol was used as a vehicle control. As Figure 5.6 shows, treating FAO cells 
with 10nM dexamethasone for 24 and 96 hours did not cause any up-regulation of 
intracellular miR-122 expression. This suggested that short-term activation of GC-GR may 
not influence the expression of miR-122. However, expanded time and dose dependent 
experiments need to be carried out in future before drawing any final conclusion. 
  
Figure 5-6 MiR-122 expression in FAO cells after 
glucocorticoid dexamethasone (10nM) treatment in 
24 and 96 hours 
RNA (2ng/µL) was used for qPCR. Y-axis shows 
averaged expression fold change compared to 
untreated control cells. U6 was used for qPCR 
normalization. N=3 in 24 hours treatment groups and 
n=6 in 96 hours treatment groups. Error bars are the 
mean with SEM. One-way ANOVA was used for 
statistical analysis. 
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5.3.3 Do fatty acids influence miR-122 expression? 
Nuclear receptors are a class of ligand-activated transcription factors, which can regulate 
gene expression in response to small lipophilic compounds. For example, the oxidised 
derivatives of cholesterol, oxysterols, can regulate liver X factor (LXR), bile acids are able 
to activate farnesoid X receptor (FXR) and retinoid acid can bind to retinoid acid receptor 
(RXR) (Repa & Mangelsdorf 1999). The finding of peroxisome proliferation-activated 
receptors (PPARs) greatly aided our understanding of lipid metabolism. Followed the 
discovery of the first PPAR (PPARα) in the early 1990’s, a galaxy of studies examined 
PPAR’s powerful regulation in metabolic related gene transcription. There are three PPAR 
subtypes (namely α, β/δ and γ), which can be activated by both dietary fatty acids and 
their metabolic derivatives in the body, and serve as lipid sensors possessing the capacity 
to markedly redirect metabolism (Evans et al. 2004). These three PPARs exhibit distinct 
tissue expression patterns; PPARα is highly expressed in liver, brown adipose tissue, 
kidney, heart and skeletal muscle; PPARγ is most highly expressed in adipose tissue, but 
is also in muscle, colon and liver; PPARβ/δ shows pan-expression pattern with relatively 
low levels in liver (Evans et al. 2004). The activation of PPARs require heterodimerization 
with the retinoid X receptor (RXR) and binding to specific sequences (namely, PPAR-
response elements <PPRE>, DNA sequence <aggtca>) in the promoter regions of target 
genes (Figure 5.7) resulting in either activation or inhibition of target genes. 
         
Figure 5-7 The heterodimer PPAR and RXR system and 
their binding with the PPRE region 
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All three PPARs are involved in regulation of glucose and fatty acid metabolism with 
different targets and pathways.  
PPARα directly regulates genes related to fatty acid β oxidation (acyl-CoA oxidase) and 
fatty acid uptake associated fatty acid binding protein (FATP). PPARα knock out mice do 
not show any obvious phenotype alteration under normal diet. However, when fasted or 
fed with a high-fat diet, these mice accumulate massive amounts of lipid in their livers and 
also exhibit hypoglycaemia and increased circulating non-esterified fatty acids which 
indicate a deficiency in fatty acid uptake and oxidation (Guerre-Millo et al. 2001).  
PPAR β/δ has been less investigated due to its pan-expression pattern and the lack of 
specific agonists. PPAR β/δ has been shown to regulate fatty acid oxidation and energy 
metabolism as well (Y X Wang et al. 2003). The transgenetic expression of activated 
PPAR β/δ produces lean animals, which are resistant to obesity and hyperlipidemia 
induced by high fat diets(Y X Wang et al. 2003). On the contrary, by knocking down PPAR 
β/δ, mice exhibited a reduction in energy expenditure via uncoupling proteins (UCP) and 
are prone to obesity (Y X Wang et al. 2003).  
Both PPARa and β/δ have been linked with fatty acid oxidation, whereas the most 
extensively studied family member PPARγ has been linked with 1) regulating glucose 
homeostasis via reducing insulin resistance, increasing glucose uptake (glucose 
transporter 4, GLUT4), inhibiting liver gluconeogenesis (pyruvate dehydrogenase 4, PDK4 
and phosphoenolpyruvate carboxykinase, PEPCK); 2) controlling adipogenesis; 3) 
maintaining lipogenesis and lipid storage (FATP, and acyl-CoA synthetase) and 4) 
increasing energy expenditure (UCP2, UCP3 and glycerol kinase, GyK) (Rogue et al. 
2010).  
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As Figure 5.8 shows, the PPAR system and miR-122 share metabolic functions, such as 
fatty acid oxidation, energy expenditure and glucose uptake/metabolism. More 
interestingly, PPARα, PPARβ, PPARα co-activator (SMARCD1/BAF60a) and PPARγ co-
activator (PGC1α) are all bone fide miR-122 targets (Gatfield et al. 2009), thus miR-122 is 
capable of regulating PPAR member expression through direct targeting (as Figure 5.8 
blue line shows). Since miR-122 and PPARs share so many function similarities, I 
hypothesised that PPARs may also posses the ability to control miR-122 expression (as 
Figure 5.8 red dash line indicates).  
Figure 5-8 The crosstalk between PPAR system and miR-122 
Blue line shows miR-122 is able to regulate PPAR system. Red dotted line indicates relationship postulated in this 
study. Coloured line with arrow shows known mechanisms of PPARs and miR-122 in regulating metabolism. Black 
dotted line shows the bone fide target of miR-122  
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5.3.3.1 PPAR binding site (PPRE) in the promoter region of miR-122 
To test whether PPARs could potentially directly regulate miR-122 expression, I attempted 
to identify if there are any PPAR responsive elements (PPRE) in the promoter region of 
miR-122. PPRE (also called peroxisome proliferator hormone response element) is the 
DNA region where PPAR and RXR heterodimer binds. PPRE consists of direct repeats of 
AGGTCA (or TGACCT) motifs with a variable number of intervening or spacer nucleotides 
and a tolerance of mismatches. First, by using UCSC genome browser (http://genome-
euro.ucsc.edu/index.html), I identified that miR-122 genome expression region is located 
in chromosome18,59,956,811-59,956,895 (Rattus norvegicus) and conservatively exists 
across human, rhesus, mouse, rat and dog. By screening 5 kilobase upstream of miR-122, 
potential PPREs were found by Dragon PPAR Response Element (PPRE) Spotter v.2.0 
(http://www.cbrc.kaust.edu.sa/ppre/index.php) and shown below (Figure 5.9). Thus PPARs 
are indeed possibly involved in the regulation of miR-122 expression.  
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5.3.3.2 PPAR agonists are able to regulate hepatic miR-122 expression in vivo 
To prove that PPAR agonists could regulate miR-122 expression, I examined the liver of 
rats treated with PPAR agonists. Diethylhexylphthalate (DEHP) is a compound widely 
used as a plasticizer, which possess the ability to activate PPARα  and induce the 
expression of PPARγ (Hao et al. 2013). Cinnamyl Anthranilate (CA) is a synthetic food 
Figure 5-9 Potential PPREs exist in the promoter region of miR-122 
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flavouring and fragrance agent which is also a PPARα agonist (Klaunig et al. 2003). 
Dehydroepiandrosterone (DEHA), is a pan-PPAR agonist which can activate all three 
PPARs (Mastrocola et al. 2003). Rat (Sprague Dawley) were treated with DEHP 
(12000ppm), DEHA (25000 ppm) and CA(1250 ppm) in the diet for 7 consecutive days 
and killed on day 8. Livers were harvested and used for transcriptomics analysis. In the 
first instance, to prove that all three compounds did activate PPARs during the 7 days in 
vivo treatment, transcriptomic data of PPAR downstream genes Cyp4a1, Pex11a and 
PDK4 was analysed in GeneSpring® software. As Figure 5.10 shows, all compounds 
significantly induced PPAR downstream gene expression compared to the control. The 
results indicated that PPARs were indeed activated in these chemical treated rat livers. All 
transcriptomics data mentioned-above was acquired by Syngenta.  
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In vivo hepatic miR-122 expression was then examined in the liver of the rats treated with 
the three PPAR agonists (sacrificed after 7 days of treatment). To examine the hepatic 
miR-122 expression, Taqman single microRNA test was used with snoRNA as a 
normalization control. As Figure 5.11 shows, the livers of rats treated with all three 
Figure 5-10 Rat hepatic PPAR downstream gene mRNA expression with DEHP, CA and DEHA treatment 
examined by Agilent microarray 
Data was acquired by Syngenta. Y-axis shows average expression fold change compared to control group. N=5 
across all control groups and n=3 in all treatment groups. Error bars are the mean with SEM. *, ** and **** signifies 
statistically significant as determined by one-way ANOVA with Dunnett’s multiple comparisons test p<0.05, p<0.01 
and p<0.0001, respectively. 
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chemicals exhibit significant reduction of hepatic miR-122 expression, 26% by DEHP, 41% 
by CA and 63% by DEHA. These results suggested that PPARs could be involved in miR-
122 regulation. However, it is important to note that 1) all three compounds were used at a 
toxic dose which is likely to have affected many other biological activities besides of PPAR 
activity and 2) none of these compounds are PPAR subtype specific. Therefore, it is 
necessary to carefully examine whether pure natural/synthetic PPAR subtype specific 
agonists could elicit similar regulating effects on miR-122.  
 
Figure 5-11 Rat hepatic miR-122 expression after DEHP, CA and DEHA treatment, examined by qPCR 
Y-axis shows averaged expression fold change compared to control group. U6 was used for normalization. N=5 
across all control groups and n=3 in all treatment groups. Values are mean with SEM. *, ** and *** signifies 
statistically significant as determined by one-way ANOVA with Dunnett’s multiple comparisons test p<0.05, p<0.01 
and p<0.001, respectively. 
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5.3.3.3 B13H cell line possess functional PPAR system 
One of the biggest challenges in toxicology is to model liver function in vitro. Primary 
hepatocytes are able to express drug metabolism enzymes and various types of nuclear 
receptors. However, such activity rapidly declines within 2 hours of isolation (Boess et al. 
2003). The viability and differentiated functions, such as the presence of liver-specific 
markers like albumin and the maintenance of a response to peroxisome proliferators, are 
maintained for only 2-3 days (UI et al. 1969). Hence, most published studies of in vitro 
PPAR activation use recombinant adenovirus vector to induce PPAR expression. I 
therefore choose to verify whether the pancreatic cell derived hepatocyte-like B13H cells 
(See section 5.3.2.1) possess functional PPAR systems. In the first instance, I treated 
B13H cells with the PPARα agonist fenofibrate with 3 different concentrations, 10µM, 
30µM and 50µM. Treated cells were collected at 24 hours and total RNA extracted 
following standard TRIZOL protocol. By using semi-quantitative qPCR, I examined three 
PPAR down stream genes Cyp4a1, fatty acid binding protein (FABP) and acyl-CoA oxidise 
(ACO) expression using beta-actin as loading control and for normalization. As a positive 
control, the same amount of normal rat liver homogenate was used with identical 
extraction and measurement protocol. Details about semi-qPCR primer sequence, 
denature temperature, protein quantification method and standard curve were presented in 
section 2.4.3. By quantifying the bands using Kodak Imaging Station 4000MM, we found 
that the PPARα agonist fenofibrate indeed induced a clear up-regulation of all three 
PPARα down-stream genes, whereas the control beta-actin expression remained stable 
across all treatments (Figure 5.12). This result indicated that B13H cell possess a 
functional PPAR system.  
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B 
Figure 5-12 PPAR downstream gene 
expression following fenofibrate treatment 
A. PPAR downstream gene expression in B13 
cells with fenofibrate treatment examined by 
semi-qPCR 
 
B. The quantitation of PPAR downstream gene 
expression in B13 cells with fenofibrate treatment 
Y-axis shows average expression fold change 
compared to control group. β-actin was used for 
normalization. N=3 across all groups. Error bars 
are the mean with SEM. **, *** and **** signifies 
statistically significant as determined by ANOVA 
with Dunnett’s multiple comparisons test p<0.01, 
p<0.001 and p<0.0001, respectively. 
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5.3.3.4 Activation of PPARα does not alter the expression of miR-122 
PPARα can bind to various ligands, such as arachidonic acid metabolites (prostaglandins 
and leukotrienes), plasticizers (DEHP) and synthetic fibrate drugs, including clofibrate, 
bezafibrate and fenofibrate (Staels et al. 1998). The fibrate class of drugs have been used 
since 1960s’ to treat a wide range of metabolic disorders, particularly 
hypercholesterolemia. To examine whether PPAR subtype α could regulate endogenous 
miR-122 expression, we first treated B13H cell for 24 hours with the selective PPARα 
agonist fenofibrate (Abcam, ab120832) with concentrations of 10µM, 30µM and 50µM. 
Fenofibrate was dissolved in DMSO and the same amount of DMSO was used as a 
negative vehicle control. Using Taqman single microRNA qPCR, we found that cellular 
miR-122 levels were only marginally reduced at all three concentrations. However, none of 
these treatments significantly different from control, based on one-way ANOVA test 
(Figure 5.13). Since fenofibrate is a potent and selective PPARα agonist, I conclude that 
PPARα is probably not responsible for regulating miR-122 expression.  
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Figure 5-13 MiR-122 expression with 24h fenofibrate treatments in B13H cells 
Y-axis shows average expression fold change compared to control group. U6 was used for normalization. N=3 across 
all groups. Values are the mean with SEM. 
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5.3.5 Activation of PPARγ can inhibit miR-122 expression  
To investigate the potential of PPAR subtype γ to regulate miR-122 expression, the in vitro 
PPARγ agonist rosiglitazone was used to treat B13H cells. Rosiglitazone was a 
commercialised anti-diabetic drug that belongs to the thiazolidinedione class of drug. By 
selectively activating PPARγ, rosiglitazone is capable of inducing regression of fasting and 
postprandial glycemia in human (Raskin et al. 2000). The mechanism is believed to 
involve regulating adipocyte differentiation, stimulating muscle glucose disposal and 
inhibiting hepatic glucose output (C. R. Kahn et al. 2000). Using the B13H cell culture 
model and 3 concentrations of rosiglitazone (10µM, 20µM and 30µM) for 24 hours, I 
observed a dose-dependent reduction of endogenously expressed miR-122, with 6% 
reduction in 10µM, 47% in 20µM and a significant 63% decrease with 30µM treatment 
(Figure 5.14). This result suggested that PPARγ may possess the capability to regulate 
hepatic miR-122 expression.  
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Figure 5-14 MiR-122 expression with 24h rosiglitazone treatment in B13H cells 
Y-axis shows average expression fold change compared to control group. U6 was used for normalization. N=3 
across all groups. Values are the mean with SEM.* signifies statistically significant as determined by ANOVA with 
Dunnett’s multiple comparisons p<0.05. 
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5.3 Can miR-122 expression be altered by unsaturated fatty acid?    
It has been shown that PPAR is an important fatty acid sensor and all three types of 
PPARs can be activated by fatty acids, with preference for unsaturated fatty acids, such as 
docosahexaenoic acid, linolenic acid, linoleum acid and arachidonic acid (Keller, et al. 
1993). Hence, the existence of fatty acid can control its own intracellular concentration via 
nuclear receptor PPARs (Figure 5.15). Thus, a simple negative feedback loop exists 
between PPARs (B in Figure 5.15) and environmental fatty acids (A in Figure 5.15).  
 
 
Previous study showed that by feeding animals a high fat diet, PPAR activation and miR-
122 reduction could be induced simultaneously (J. Zhang et al. 2009b). Additionally, the 
activation of PPAR and reduced expression  of miR-122 could both lead to increased 
energy expenditure, in favor of fatty acid oxidation and reduced circulating cholesterol 
levels (Esau et al. 2006; Evans et al. 2004). Therefore, I hypothesized that, fatty acids, as 
a class of natural PPAR ligand, could active PPARs which then directly targets and 
decreases cellular miR-122 expression (Figure 5.16). The decreased miR-122 could in 
turn release the inhibition effect on PPARα, PPARβ, PPARα coactivators and PPARγ 
Figure 5-15 The two component negative feedback system of environmental fatty acids and PPAR 
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coactivators. Thus, the activity of miR-122 adds another layer to PPAR mediated fatty acid 
metabolism regulation. A positive feedback loop may be formed between PPARs (B in 
Figure 5.16) and miR-122 (C in Figure 5.16), which could amplify the response of the input 
signal (increased environmental FFAs, A in Figure 5.16). Furthermore, both PPAR 
activation (B) and decreased miR-122 expression (C) could generate double negative 
feedback loops, which simultaneously decrease FA generation and increase FA oxidation 
resulting in the maintenance of overall fatty acid homeostasis.  
 
 
To test this hypothesis, a polyunsaturated omega-6 fatty acid, arachidonic acid, was used. 
Arachidonic acid was selected since 1) it is capable of activating PPARs (α, β and γ) 
(Gottlicher et al. 1992; Krey et al. 1997) and 2) bariatric surgery patients exhibited 
increased circulating arachidonic acid concentrations (Jia Li, metabonomics data). The 
majority of previous studies with arachidonic acid used short exposure times, such as 5 
minutes to 1h (Keller et al. 1993; Forman et al. 1997). Therefore, in the first instance, three 
concentrations (30µM, 100µM and 300µM) and 1 hour treatment with arachidonic acid was 
employed to investigate whether natural fatty acids could directly regulate miR-122 
Figure 5-16 The potential of miR-122 to regulate fatty acid homeostasis 
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expression (Keller et al. 1993; Forman et al. 1997). Figure 5.17 shows that at the 
concentrations of arachidonic acid used, there was a marginal reduction of miR-122, with 
the maximum effect at 100µM, however, none of these effects was statistically significant 
by one-way ANOVA.  
         
To further examine this result, a more comprehensive experiment was then employed with 
an increased time of exposure and concentrations around 100µM. Three concentrations 
(50µM, 100µM and 150µM) and 4 time points (10 min, 1hour, 4hour and 10hours) were 
subsequently used. Unfortunately, none of the tested concentrations successfully induced 
a statistically significant decrease  of mature miR-122 expression at any time point (Figure 
5.18). There are several possible explanations for this negative result, 1) compared to 
rosiglitazone, arachidonic acid is a much less potent PPARγ agonist; 2) mature 
microRNA’s half life is surprisingly long; previous studies have suggested it could be 5-12 
days (Gantier et al. 2011). Perhaps the relatively small inhibition effects were difficult to 
detect in the large pool of endogenous mature miR-122. Since the metabolic homeostasis 
regulation function of microRNA is thought to “fine tune” gene expression, relatively small 
fold changes are likely to be important in preserving homeostasis. Therefore, to 
understand this delicate “fine tune” mechanism, it may be more appropriate to evaluate 
Figure 5-17 MiR-122 expression with 1h arachidonic 
treatments in B13H cells 
Y-axis shows averaged expression fold change compared 
to control group. U6 was used for normalization. N=3 
across all groups. Values are the mean with SEM. 
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endogenous pri- or pre-microRNA to study in greater depth the relationship between miR-
122 and fatty acids. It should also be borne in mind that arachidonic acid is only one of a 
large number of fatty acids and its use in experiments such as those described here may 
not be optimal. 
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Figure 5-18 MiR-122 expression with arachidonic treatments in B13H cells 
Y-axis shows average expression fold change compared to control group. U6 was used for normalization. N=3 
across all groups. Values are the mean with SEM 
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5.4 Chapter discussion 
In this chapter, I have attempted to investigate the mechanism of reduction of hepatic miR-
122 expression post-bariatric surgery with focus on three aspects, glucose, glucocorticoid 
and fatty acids. Given the fact that RYGB surgery is a complex anatomical alteration, it is 
highly likely that not one, but a combination of factors would contribute to the post surgery 
decrease in hepatic miR-122. Moreover, the overall complexity of in vivo digestion, 
absorption process and changed metabolism is difficult to mimic in an in vitro model.  
• What factors could influence microRNA expression? 
To understand the causes of the decreased hepatic miR-122, we should try to understand 
the possible factors that contribute to microRNA expression regulation. Although a huge 
amount of research has been completed with microRNA expression profiling under various 
conditions and what  targets microRNAs may regulate, surprisingly there are very few 
studies that identify what the crucial factors are and the fundamental mechanisms 
controlling microRNA expression. To address this question, one must consider microRNA 
expression as a dynamic process, where the microRNA expression level balances 
biosynthesis and degradation.  
For microRNA biosynthesis, transcriptional factors and epigenetic regulation  (e.g. 
methylation) directly regulate microRNA generation. For instance, the oncogenic 
transcription factor c-Myc directly binds to the DNA sequence (CATGTG) located 1.5kb 
upstream of miR-17 family, which was shown to promote tumourgenesis (Thomas et al. 
2013). Furthermore, a liver enriched transcriptional factor, namely hepatocyte nuclear 
factor 4α (HNF-4α), was demonstrated to directly bind to the miR-122 promoter region to 
activate miR-122 expression (Z.-Y. Li et al. 2011b). Interestingly, this activation could be 
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further augmented by addition of PGC1α (Z.-Y. Li et al. 2011b). Furthermore, it has been 
suggested that microRNAs are epigenetically regulated (Baer et al. 2013). For example, 
the transcription of microRNAs such as miR-148a, miR-9 and miR-34 family has been 
shown to be dependent on their methylation status and the activity of DNA 
methyltransferases (DNMT1 and DNMT3b) (Toyota et al. 2008; Lehmann et al. 2008).  
For the microRNA degradation process, multiple modifications could significantly affect 
microRNA stability. For instance, uridylation of the 3’ end by TUT4/Zcch11 and PUP2 
destabilises microRNA (Kai & Pasquinelli 2010), whereas 3′-terminal adenylation by GLD-
2 is required for the selective stabilization of microRNA in the liver (Katoh et al. 2009). 
Perhaps both the biosynthesis and degradation control exist to regulate a single 
microRNA’s expression. In this study, I only focused on the final outcome, the amount of 
mature microRNA expressed. Clearly, it is also interesting to explore if the decreased 
expression of mature hepatic miR-122 in RYGB rats resulted from inhibited synthesis or 
increased destabilisation. This could be examined by cutting-edge nascent RNA 
sequencing with RNA polymerase II pull down in future work. 
• Are the altered metabolite/ hormone levels noted after RYGB the reason for or 
caused by changes in the expression of microRNAs? 
RYGB surgery fundamentally influences systematic metabolism homeostasis. Data in 
chapter 4 have already showed that post RYGB animals liver exhibited a shifted metabolic 
preference towards catabolism instead of anabolism. It is reasonable to speculate that the 
body would be exposed to altered amounts of both consumed and endogenous generated 
nutrients and metabolites. Hence, I hypothesized that these altered levels of 
environmental metabolites and hormones significantly influenced the microRNAome, 
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which is believed to be crucial to maintain metabolic homeostasis. The obvious 
assumption of this hypothesis is that metabolites and hormones were altered first by the 
surgery, and the microRNA changes subsequently. I hypothesis that in reality, RYGB 
induced drastic alteration of metabolite levels may also happen before any underlining 
metabolic beneficial mechanism begins. A similar example of this cause-effect conundrum 
is the relationship between reduced energy intake and reduced appetite after RYGB 
surgery. One may think that the reduced appetite happens immediately after surgery and 
is the direct cause of reduced energy intake. However in reality, a Yoyo effect was 
observed for the energy intake (Zheng et al. 2009). By giving the rats three-choices of diet 
10 days after surgery, the rats did not immediately reduce their food intake, instead, they 
consumed a large amount of food on the first day, but only eat very little the next day 
(Zheng et al. 2009). The later reported overall reduced appetite and shifted food choice 
towards low fat diets, suggests the consequence of longer-term adaption. Similar with the 
relationship between microRNAs and metabolites, I believe it is unlikely that microRNA, 
the most highly and stably expressed of the nucleotides, which are believed to buffer 
biological system noise and maintain robustness, would be changed immediately after 
surgery. Instead, it seems likely that these altered microRNAs are an adaptation process 
to accommodate the shifted metabolism. It is probable that after the initial response, 
microRNA alteration could in turn regulate metabolites and therefore form feedback/feed 
forward control loops to establish the new metabolic balancing point.  
•  Are glucose, glucocorticoids and fatty acid the causes of decreased miR-122 
expression? 
Three metabolites/hormones were tested in this chapter in order to probe the causes of 
reduced miR-122 expression. I found that 1) short time exposure to a large amount of 
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glucose is not a factor contributing to reduced miR-122 expression. The different glucose 
treatments (time and dose) were selected in order to mimic the postprandial shifted 
glucose peak after RYGB surgery. Surprisingly, instead of decreasing miR-122 
expression, the highest concentration of glucose (25mM) significantly induced miR-122 in 
the in vitro model. This unexpected result highlighted miR-122 as a potential mediator of 
glucotoxicity, the mechanism of which was not fully tested in my study, but is worth 
exploring in the future. 2) The altered glucocorticoid level noted after RYGB may not 
change miR-122 expression. As a crucial metabolically regulated hormone, glucocorticoid 
was examined to determine its ability to regulate hepatic miR-122. Again, the synthetic 
glucocorticoid, dexamethasone, failed to elicit miR-122 alteration in 24 and 96 hours. 3) 
Finally, exposing cells to unsaturated fatty acid (arachidonic acid) did not significantly alter 
mature miR-122 expression. As mentioned before, these three negative results were 
based on Taqman RT-qPCR testing of mature microRNA. However, to observe the subtle 
physiological changes induced in microRNA alteration, it might be reasonable to examine 
freshly synthesised pri- and pre- microRNA expression in future studies. It is a challenge to 
mimic the in vivo spatial and temporal microRNA expression in in vitro models. It is 
important to note that in our in vivo surgical rat model, the rats were exposed to 
significantly shifted metabolic environments for 4 weeks post surgery. Hence, there is a 
need to further assess the post-surgery time in order to better understand these effects.  
• Is the crosstalk between transcriptional factors and microRNAs universal?  
All cells carry a full set of genes, but only about 20% of them express at a particular time. 
Hence, gene expression must be tightly controlled in biological systems. As seen in Figure 
5.19, among the various gene regulatory steps from DNA to protein, transcriptional and 
post-transcriptional control via microRNAs are  very important steps.  
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Both gene regulators, transcriptional factors (TF) and microRNAs, share a significant 
amount of similarity (K. Chen & Rajewsky 2007; Hobert 2008). For example, both TF and 
microRNA regulation are combinatorial processes, meaning that each microRNA/TF is 
expected to regulate hundreds of targets, while a given target could be regulated by 
multiple microRNAs/TFs. Furthermore, with such combinatorial effects, both TF and 
microRNA have been suggested to work as key components of complex regulatory 
networks. It is reasonable to propose the existence of connectivity between these gene 
regulation factors. Indeed, a recent theoretical model has shown that multiple 
feedback/feedforward controls may exist between transcriptional factors and microRNAs 
(Re et al. 2009). Like man-made control systems, the microRNA mediated control 
mechanism can be classified as type I (incoherent) feedforward loop (FFL) and type2 
(coherent) FFL (Figure 5.20). Type I circuit allows a fine tuning of gene expression, 
whereas type II circuit leads to a reinforcement of transcriptional regulation at the post-
transcriptional level, which might behave as a switch to mediate development and disease 
progression.  
Figure 5-19 Gene expression regulation mechanisms 
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Although the theoretical model has indicated the connection between TFs and microRNAs, 
there is no bone fide universal biological link established between these two classes of 
regulators. An interesting finding in this chapter was the capacity of PPAR’s ability to 
decrease miR-122 expression both in vivo and in vitro and the potential type II 
feedback/feedforward loops between miR-122 and PPAR (Figure 5.21). It will be 
interesting to further explore whether this coordinated regulation between transcriptional 
factors and microRNA is universal and if so, which biological link mediates this crosstalk.  
 
 
Figure 5-20 Type I and type II microRNA mediated gene expression circuits 
 
 
Figure 5-21 MiR-122 mediated type II gene expression circuit 
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6. Chapter 6 General Discussion 
6.1 General conclusion of the project 
Bariatric surgery is the most effective treatment for morbid obesity. Surprisingly, 
improvements in glucose homeostasis after RYGB are observed well before the well-
described significant weight loss has happened. This intriguing effect has stimulated 
mechanistic studies to interpret the underlying metabolic alterations after bariatric surgery, 
in the hopes of finding direct non-invasive treatments, which will eventually replace 
invasive surgery. During the past five years, mechanistic studies offering several possible 
explanations for post-surgery metabolic benefits, such as the shifted gut microbiota, the 
altered levels of gastrointestinal hormones and the influences on central neuron system 
have been suggested (J. V. Li et al. 2011a; Miras & le Roux 2013). However, it is 
important to note that 1) it is not clear whether these observed effects are the cause or the 
result of bariatric surgery benefits and 2) all of these previous studies have focused on a 
specific part of the surgical induced effect, but there is still lack of information on how 
these multi-layer effects coordinate each other and which is/are the key molecule(s) 
mediating these effects.  
Given the fact that microRNA is an important class of gene expression regulator, we have 
addressed microRNA’s potential metabolic regulation effect in bariatric surgery model 
(Roux-en-Y, RYGB). Briefly, among the key findings were:  
A) RYGB surgery fundamentally changed circulating and colorectal miRNome.  
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B) There is a possible link between altered circulating and colorectal microRNAs and the 
neurodegenerative disease/ neurotransmitter related pathways- as indicated by microRNA 
pathway analysis. 
C) One novel rat microRNA (rno-miR-676) and another small nuclear RNA (rno-snord95) 
were identified. 
D) The alteration of miR-122 could contribute to post-RYGB benefits via regulating various 
key metabolic enzymes/ receptors in liver.  
E) PPARγ could be involved in regulating miR-122 expression with a positive feedforward 
mechanism. 
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6.2 Everything is linked: microRNA, metabolites and metabolic enzymes 
The mechanisms of RYGB surgery are complex. Here in this study, I profiled the whole 
circulating miRNOME, and focused on the most dramatically altered circulating microRNA 
(miR-122) to investigate its metabolic function in RYGB model. MiR-122 is a liver-
produced microRNA. The effect of RYGB was to induce a lowered level of expression of 
miR-122 in the liver and a very pronounced lowing of serum miR-122. This model lowing 
expression of miR-122 in the liver compared with plasma suggested a restrained miR-122 
release into the blood stream. By antagonizing miR-122 in diet-induced obese mice for six 
weeks, total cholesterol level decreased by 30% without lipid accumulation in the liver 
(Elmen et al. 2008). Esau et al. demonstrated that injecting miR-122 antisense 
oligonucleotide into mice for 5 weeks results in reduced plasma cholesterol levels, 
increased hepatic fatty acid oxidation, decreased hepatic fatty acid and cholesterol 
synthesis rate (Esau et al. 2006), effects that are also seen in primates (Elmen et al. 
2008). The first microRNA target drug (Miravirsen) which entered human clinical trials was 
designed to recognize and sequester miR-122 in order to treat hepatitis C. Interestingly, 
besides the intriguing anti-virus effect, Miravisen also decreased circulating cholesterol 
level in human, which is consistent with the animal studies (Janssen et al. 2013). These 
facts have led us to hypothesis that miR-122 could potentially behave as a key regulator 
mediating post RYGB metabolic benefits.  
As seen in figure 6.1, miR-122, metabolites and key metabolic enzymes are linked as a 
network, which coordinately alter the metabolic homeostasis point post RYGB. 
Following RYGB surgery, we observed increased glucose transportation, accelerated 
glycolysis and inhibited gluconeogenesis in the RYGB rats. Glut1, a glucose transporter, 
was up-regulated consistent with the decreased miR-122 expression in the liver and 
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increased levels of hepatic glucose and glycogen were observed, indicating that RYGB 
promoted glucose transportation and glycogen synthesis. The metabolic and miR-122 
target expression data showed that RYGB surgery suppressed gluconeogenesis and 
stimulated glycolysis, evidenced by the down-regulation of G6pc and up-regulation of 
Aldoa. Furthermore, the result was further proved by elevated concentrations of glycolysis 
end products including pyruvate, alanine and lactate in the liver and plasma. Mencarelli et 
al. have recently investigated the effects of ileal interposition (IT), where the distal ileum is 
relocated into the proximal jejunum, which mimics a partial procedure of RYGB surgery 
(Mencarelli et al. 2013). Consistent with our results, the hepatic expression of G6pc was 
also suppressed in this IT model. Furthermore, G6pd was found to be up-regulated and 
this is an indicator for the oxidative activity of the pentose phosphate pathway. G6pd is 
probably stimulated by the unbalanced ratio of NADPH/NADP+ (normally 100:1 in the 
hepatic cytosol) to produce NADPH. This unbalanced ratio could be due to the utilization 
of NADPH in the liver by reductive biosynthesis, such as lipid biosynthesis. G6PD 
expression and enzyme activity have been reported to be up-regulated in the Roux limb of 
RYGB-operated rats, as well as Glut1, and the authors concluded that the reprogramming 
of intestinal glucose, including enhanced basolateral glucose uptake, augmented 
glycolysis and stimulated pentose phosphate pathway, could contribute to the glycemic 
control after RYGB (Saeidi et al. 2013). 
Decreased miR-122 levels induced the up-regulation of Cs (CS) and Ucp2 (UCP2). CS is 
a well-studied rate-limiting enzyme in TCA cycle, whereas the metabolic function of UCP2 
is still controversial and varies between various types of tissues (Brand & Esteves 2005). 
Hepatic UCP2 expression, which uncouples oxidative phosphorylation with ATP 
production, is highly associated with oxidative phosphorylation and fatty acid oxidation. 
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The up-regulation of UCP2 and CS indicates that the RYGB-operated animals exhibit 
higher cellular metabolic activity such as in favoured fatty acid oxidation and increased 
TCA cycle metabolism, which is further supported by the decreased levels of urinary TCA 
cycle intermediates. Furthermore, UCP2 is a downstream effector of AMPK. In my study, I 
also observed increased Prkab1 expression followed by up-regulated UCP2. After RYGB, 
fat stored in adipose tissue could be mobilized and metabolized in the liver (Johansson et 
al. 2008), generating increased levels of free fatty acids, which could result in up-regulated 
UCP2 (Samec et al. 1998). It has been shown that increased UCP2 could not only 
promote the energy expenditure towards lipid utilization (Mattiasson & Sullivan 2006) and 
compensate reduction of reactive oxygen species (ROS) (Castro et al. 2011), but also 
reduce oxidative stress (Collins et al. 2005) and protect mitochondria during fatty acid β-
oxidation (Patterson, Shah, Matsubara, Krausz & Gonzalez 2012b). This is consistent with 
decreased ROS reported in patients after bariatric surgery (Ueda et al. 2011; Huang et al. 
2011). We noticed that fatty acid synthase (fasn) also increased following RYGB. The 
underlying reason is unclear, but one possibility is that RYGB extensively affects lipid 
metabolism and leads to a restoration of adipose redox balance. Therefore, further studies 
should address lipid metabolism during the re-adjustment period after bariatric surgery. 
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6.3 Future work 
Based on the main findings of this project, there are several further lines of research that 
can be pursued in future.  
6.3.1 Validation of the altered microRNAs in other models 
A first obvious experiment is to validate these altered circulating microRNAs 1) in a obese 
and diabetic rat model (such as ob/ob), to explore whether the microRNA profiles would be 
similar in a disease situation, 2) in a body weight matched experiment, in which weight-
loss dependent mechanisms could be eliminated and 3) in the human blood samples, to 
investigate the conservatism of these observed effects. 
6.3.2 Determine the bone fide microRNA targets 
In this study, in order to examine whether the miR-122 could directly regulate metabolic 
enzymes/ receptors, we used microRNA mimic assay. However, it should be noted that 
microRNA mimic assay is highly artificial and up-regulated cellular miR-122 expression 
more than 70 fold, the level of which does not correspond to the normal physiological 
microRNA fluctuation range. Hence, further experiments should be carefully carried out to 
examine the two novel miR-122 targets (Prkab1 and Ucp2).  
To date, there are three primary methods to determine microRNA targets (Hausser & 
Zavolan 2014): 1) microRNA manipulation experiments (such as microRNA mimic, anti-
miR, microRNA target protector and microRNA sponge) (Krutzfeldt et al. 2005; Ebert et al. 
2007); 2) Ago cross-linking immunoprecipitation (Ago-CLIP) experiments, such as high 
throughput – CLIP (HITS-CLIP), photo activatable ribonucleotide analogue – CLIP (PAR-
CLIP), the individual nucleotitide resolution CLIP (iCLIP) and the most recent CLASH 
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method (cross linking ligation and sequencing of hybrids) (Darnell 2010; Chi et al. 2009; 
Helwak & Tollervey 2014); 3) the gold standard 3’UTR assay, which validate microRNA 
targets by including 3’ untranslated region of a microRNA target coupled to a reporter 
gene (Lytle et al. 2007). However, these systems are highly artificial and there is no 
indication of the in vivo stoichiometry between the microRNA and targets. Recent study 
has used the newly developed CRISPR-Cas genome engineering technology to determine 
bone fide microRNA targets. The mechanism involves using CRISPR-mediated homology-
directed repair with short oligonucleotide donors to delete the endogenous MRE sequence 
and subsequently assess the MRE activity (Bassett et al. 2014). Clearly, these above 
mentioned cutting-edge methods should be considered in microRNA target validation 
experiments in future.  
6.3.3 Study the miR-122 and PPARγ coherent feedforward loop 
In chapter 5, I showed that the activation of PPARγ could dose-dependently inhibit cellular 
miR-122 expression. It has been shown before that both PPARγ and PGC-1α are bone 
fide miR-122 targets. This raised an interesting question of whether miR-122 and PPARγ 
could form a coherent feedforward loop, which accelerated the efficiency of fatty acid 
metabolism. In order to quantitively investigate this effect and determine whether fatty acid 
oxidation rate could indeed be accelerated or not, four hepatic cell models should be 
established (See Figure 6.2). 1) Wild type model can be applied to calculate the intrinsic 
miR-122 and PPARγ mediated fatty acid oxidation rate (FAOR); 2) MiR-122 knock out 
(KO) model used to determine PPARγ mediated FAOR; 3) the PPARγ KO model can be 
applied to test miR-122 mediated FAOR; 4) MiR-122 and PPARγ dual KO model to decide 
the background FAOR, the rate of which could be controlled via other cellular 
mechanisms. Recently, with the rapid development of genome engineering technology, 
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these cell knock out models are feasible and could be readily generated (Sander & Joung 
2014). Multiple in vitro fatty acid oxidation assays are also available and can be applied 
quantitively (Hirschey & Verdin 2010).  
 
	  
6.3.4 Examine the potential microRNA mediated gut-brain effect  
In chapter 3, I showed that both RYGB altered circulating microRNAs and colorectal 
microRNAs are predicted to regulate neurotransmitter and neurodegenerative disease 
related pathways. This sheds some light on the potential mechanism of 1) colorectal 
microRNA regulate neurological receptors in gut and 2) microRNAs are transported 
between gut cell and neurons and behave as neurotransmitters. The first point has been 
extensively discussed in chapter 3 discussion section. Here I will suggest two experiments 
to test the potential of microRNA as neurotransmitters.  
1) The first step is to determine whether microRNA can be enclosed in synapsis 
vesicles or not. Synapsis vesicle isolation has been developed and it has been 
shown that antibody specific for vesicular neurotransmitter transporters can be used 
to quantitatively immune isolate synaptic vesicles which are specific for the 
Figure 6-2 Models to investigate the coherent feedforward loop of miR-122 and PPARγ 
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transmitter (such as GABA), with no contamination by vesicles specific for other 
neurotransmitters (Takamori et al. 2000). Subsequently, microRNA profiling (such 
as deep sequencing) could be carried out to determine whether synapsis vesicle 
contains microRNA or not. Alternately, qPCR could be used to target neuron 
enriched microRNAs in synapsis vesicles.  
2) The second possibility to test microRNA as neurotransmitters is to investigate 
mRNA and microRNA localization in a spatial specific fashion by establishing a 
primary culture system for intestinal cells (such as L-cells) and neurons. MicroRNA 
expression and localization can then be visualised via single cell fluorescence in 
situ hybridization (FISH) (Figure 6.3). A similar co-culture cell model was 
established before in C elegans, in which neuron cell-specific GFP reporters are 
expressed in culture to enrich the primary neuron cells by fluorescence-activated 
cell sorting (Christensen et al. 2002). Furthermore, it is known that the mRNA and 
protein expression are highly variant in dendritic tree, cell body and axons 
(Quattrone et al. 2012). Generally, two types of protein exist in neuron cells, distal-
site synthesis (DSS) proteins and the transport after synthesis (TAS) proteins 
(Weatheritt et al. 2014). The DSS mRNA is transported into the distal site and then 
translated. DSS protein is enriched for post transcription regulating site (Weatheritt 
et al. 2014), the mechanism of which is possibly involved in microRNAs. It is 
possible that intestinal enriched microRNAs could be transported via synapsis and 
regulates the neuron DSS proteins in axon. Hence, the expression of these 
microRNAs and their target mRNA may be highly spatial specific in the axon and 
can be visualized via FISH in vitro.  
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Figure 6-3 Co-culture model of neurons and intestinal cells 
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8. Appendices 
Table 8-1 All detectable rat colon mature microRNA list 
ID  log2FoldChange  padj  ID  
log2FoldChan
ge 
 padj 
rno-miR-217-5p  Inf 4.35E-44  rno-miR-6315  -Inf 0.9679 
rno-miR-150-5p -2.95E+00 2.89E-29  rno-miR-29c-5p -5.92E-01 0.9679 
rno-miR-216a-5p  Inf 3.76E-24  rno-miR-199a-5p -2.39E-01 0.9679 
rno-miR-142-5p -2.17E+00 3.15E-12  rno-miR-411-5p 0.4534 0.9679 
rno-miR-6215 -2.77E+00 3.97E-10  rno-miR-664-3p 0.0026 0.9679 
rno-miR-19b-3p 1.24 2.19E-06  rno-miR-101b-3p 0.0149 0.9679 
rno-miR-216b-5p  Inf 1.09E-05  rno-miR-203a-3p 0.0293 0.9679 
rno-miR-19a-3p 1.44 3.25E-05  rno-mir-145* -2.43E+00 0.9679 
rno-miR-142-3p -1.90E+00 6.34E-05  rno-miR-137-3p  Inf 0.9679 
rno-miR-181a-5p -9.99E-01 0.0002  rno-miR-183-3p -2.97E-01 0.9679 
rno-miR-342-3p -2.11E+00 0.0002  rno-miR-542-5p  -Inf 0.9679 
rno-miR-196c-5p 1.16 0.0143  rno-miR-133b-3p  Inf 0.9679 
rno-miR-541-5p 1.42 0.0344  rno-miR-181d-5p -1.40E-01 0.9679 
rno-miR-345-5p 1.28 0.0537  rno-miR-331-5p  Inf 0.9679 
rno-miR-672-5p  Inf 0.0701  rno-miR-542-3p -1.37E+00 0.9679 
rno-miR-598-3p 1.63 0.0701  rno-let-7f-1-3p 0.2098 0.9679 
rno-miR-338-5p 2.05 0.0701  rno-miR-138-5p 0.0726 0.9679 
rno-miR-92b-3p -1.19E+00 0.0703  rno-miR-29a-3p -2.34E-01 0.9679 
rno-miR-802-5p  Inf 0.0703  rno-miR-322-3p -3.45E-01 0.9679 
rno-miR-145-5p 0.6567 0.0703  rno-miR-152-5p -2.30E-01 0.9679 
rno-miR-455-3p -1.31E+00 0.0703  rno-miR-6321 -2.74E+00 0.9679 
rno-miR-451-5p 1.47 0.0775  rno-miR-217-3p  Inf 0.9679 
rno-miR-374-5p 0.8452 0.0997  rno-miR-126a-5p 0.0257 0.9679 
rno-miR-22-5p 0.9223 0.1033  rno-miR-219-5p  Inf 0.9679 
rno-miR-98-5p 0.5495 0.1033  rno-miR-410-3p 0.1783 0.9679 
rno-miR-363-3p -2.58E+00 0.1033  rno-miR-143-3p 0.0768 0.9679 
rno-miR-181a-2-... -1.83E+00 0.1033  rno-miR-196b-3p -1.60E+00 0.9679 
rno-miR-204-5p 0.2648 0.1033  rno-miR-324-3p 0.3294 0.9679 
rno-miR-351-5p -8.29E-01 0.1033  rno-miR-30b-5p 0.1645 0.9679 
          223 
rno-miR-423-5p -6.75E-01 0.1426  rno-miR-504 -7.45E-01 0.9679 
rno-miR-200b-5p 0.8549 0.1802  rno-miR-330-3p -1.11E-01 0.9679 
rno-miR-92a-3p -5.70E-01 0.1802  rno-miR-17-5p 0.276 0.9679 
rno-miR-872-5p -7.21E-01 0.182  rno-miR-425-3p -1.91E+00 0.9679 
rno-miR-376b-5p 0.1531 0.2177  rno-miR-125b-1-... -1.73E-01 0.9679 
rno-miR-214-3p -6.67E-01 0.2712  rno-miR-505-3p -2.75E-01 0.9679 
rno-miR-154-5p 3.64 0.2818  rno-miR-185-5p -4.35E-01 0.9679 
rno-miR-194-3p 0.847 0.3165  rno-miR-376b-3p  Inf 0.9679 
rno-miR-125a-5p -5.36E-01 0.3165  rno-miR-30e-3p -2.01E-01 0.9679 
rno-miR-434-3p 0.676 0.3187  rno-miR-337-5p 0.3783 0.9679 
rno-miR-134-5p 1.73 0.3187  rno-miR-376c-3p  Inf 0.9679 
rno-miR-1843-3p 1.14 0.3187  rno-miR-98-3p 0.2465 0.9679 
rno-miR-378a-5p 0.7238 0.3187  rno-miR-324-5p 0.3242 0.9679 
rno-miR-3068-3p -8.69E-01 0.33  rno-miR-330-5p -1.86E-01 0.9679 
rno-miR-361-3p -1.55E+00 0.33  rno-miR-488-3p 0.1727 0.9679 
rno-miR-136-3p 0.8094 0.33  rno-mir-350* -2.98E+00 0.9679 
rno-miR-326-3p 0.8118 0.3426  rno-miR-140-5p 0.0688 0.9679 
rno-miR-22-3p -3.11E-01 0.3508  rno-miR-200a-5p 0.3778 0.9679 
rno-miR-21-5p 0.4411 0.3508  rno-miR-449a-5p  -Inf 0.9679 
rno-miR-15b-5p -4.96E-01 0.3508  rno-miR-802-3p  Inf 0.9679 
rno-miR-31a-5p -6.88E-01 0.3544  rno-miR-181b-1-...  -Inf 0.9679 
rno-miR-150-3p  -Inf 0.3544  rno-miR-30a-5p 0.1251 0.9679 
rno-miR-34b-5p -9.14E-01 0.4128  rno-miR-379-5p  Inf 0.9679 
rno-miR-212-5p 0.3596 0.4128  rno-miR-361-5p -2.52E-01 0.9679 
rno-miR-192-3p 0.6619 0.4564  rno-miR-500-3p 0.2112 0.9679 
rno-miR-345-3p 0.7995 0.4564  rno-miR-431 0.307 0.9679 
rno-mir-126* 0.4047 0.4564  rno-miR-196c-3p 0.3314 0.9679 
rno-miR-132-5p -9.95E-01 0.4564  rno-miR-10a-3p -2.16E-01 0.9679 
rno-miR-221-3p 0.6355 0.4564  rno-miR-29b-3p 0.1357 0.9679 
rno-miR-3585-5p -8.98E-01 0.4564  rno-miR-429 0.0178 0.9679 
rno-miR-151-5p -3.82E-01 0.4564  rno-miR-362-3p 0.0066 0.9679 
rno-miR-136-5p 0.8087 0.4564  rno-mir-421* -5.09E-01 0.9679 
rno-miR-133a-5p -9.86E-01 0.4852  rno-miR-409a-3p 0.4536 0.9679 
rno-miR-411-3p -1.16E+00 0.5046  rno-miR-212-3p 0.4038 0.9679 
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rno-miR-339-3p -8.76E-01 0.5046  rno-miR-1306-5p  -Inf 0.9679 
rno-miR-3577 -8.93E-01 0.5046  rno-miR-153-3p 0.1801 0.9679 
rno-miR-1-3p -5.85E-01 0.5046  rno-miR-702-3p  -Inf 0.9679 
rno-miR-181c-5p -5.76E-01 0.5046  rno-miR-26b-3p -3.42E-01 0.9679 
rno-miR-382-5p 2.19 0.5385  rno-miR-532-3p 0.1383 0.9679 
rno-miR-421-3p -9.02E-01 0.5466  rno-miR-125a-3p 0.5053 0.9679 
rno-miR-181b-5p -5.85E-01 0.5466  rno-miR-216a-3p  Inf 0.9679 
rno-miR-369-5p -1.12E+00 0.5466  rno-miR-484 0.2519 0.9679 
rno-miR-201-5p -2.06E+00 0.5466  rno-miR-16-3p -2.53E+00 0.9679 
rno-miR-375-3p -1.39E-01 0.5466  rno-miR-331-3p -8.40E-02 0.9679 
rno-let-7d-5p -4.16E-01 0.5611  rno-let-7i-3p 0.228 0.9679 
rno-mir-147* 2.55 0.5611  rno-miR-133a-3p -7.48E-02 0.9679 
rno-miR-16-5p -3.00E-01 0.562  rno-miR-7a-1-3p -3.21E-01 0.9679 
rno-miR-222-3p 0.7154 0.562  rno-miR-490-3p 0.2278 0.9694 
rno-miR-128-3p -7.78E-01 0.5718  rno-miR-382-3p  Inf 0.9694 
rno-miR-466b-2-... -1.66E+00 0.5718  rno-miR-378b 0.7266 0.9694 
rno-miR-423-3p -4.29E-01 0.5718  rno-miR-26a-3p -3.26E-02 0.9694 
rno-miR-497-5p -4.50E-01 0.583  rno-miR-30c-1-3... 0.2536 0.9694 
rno-miR-99b-5p -3.73E-01 0.5854  rno-miR-28-3p 0.0068 0.9796 
rno-miR-497-3p -1.35E+00 0.6445  rno-miR-182 -7.05E-03 0.9796 
rno-let-7a-5p -4.04E-01 0.6626  rno-miR-339-5p 0.112 0.9796 
rno-miR-490-5p 1.52 0.6651  rno-miR-494-3p  Inf 0.9796 
rno-miR-381-3p 0.5934 0.6651  rno-miR-132-3p 0.3688 0.9921 
rno-miR-31a-3p -8.44E-01 0.6651  rno-miR-187-3p  -Inf 1 
rno-miR-203a-5p 0.2593 0.6651  rno-miR-34a-5p -6.81E-02 1 
rno-miR-27a-5p 0.7509 0.6651  rno-miR-879-5p -9.05E-03 1 
rno-miR-425-5p -3.45E-01 0.6651  rno-miR-487b-3p 0.233 1 
rno-miR-195-5p -3.98E-01 0.6651  rno-miR-103-3p 0.0126 1 
rno-miR-1249 -1.69E+00 0.6651  rno-miR-29a-5p 0.1931 1 
rno-miR-384-5p -1.36E+00 0.6651  rno-miR-99b-3p 0.2599 1 
rno-miR-433-3p -1.65E+00 0.6651  rno-miR-203b-3p  Inf 1 
rno-miR-210-3p 0.5315 0.6651  rno-miR-223-5p  Inf 1 
rno-miR-380-3p -6.31E-01 0.6651  rno-miR-27b-3p -9.12E-02 1 
rno-miR-219-1-3... 1.13 0.6651  rno-miR-30d-5p -1.93E-02 1 
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rno-miR-129-2-3... 1.44 0.6651  rno-miR-152-3p 0.028 1 
rno-miR-195-3p -7.58E-01 0.6928  rno-mir-194-1*  Inf 1 
rno-miR-3559-3p 0.5625 0.6937  rno-miR-210-5p  -Inf 1 
rno-miR-200c-5p 2.21 0.6937  rno-miR-218a-5p 0.18 1 
rno-miR-125b-5p -3.40E-01 0.7092  rno-mir-185*  Inf 1 
rno-miR-205 -3.80E-01 0.7103  rno-miR-495  Inf 1 
rno-miR-194-5p 0.0193 0.7103  rno-miR-3068-5p -4.54E-01 1 
rno-miR-18a-5p 0.7822 0.7103  rno-miR-130b-5p 0.1211 1 
rno-miR-106b-5p 0.285 0.7103  rno-miR-335 -1.70E-01 1 
rno-miR-708-5p 0.121 0.7106  rno-miR-192-5p 0.1142 1 
rno-miR-196b-5p 0.1585 0.7106  rno-miR-320-3p 0.0106 1 
rno-miR-1839-5p 0.3048 0.7106  rno-miR-708-3p -3.11E-01 1 
rno-miR-101a-5p -1.17E+00 0.7106  rno-miR-130a-5p  Inf 1 
rno-miR-3559-5p 0.4251 0.7106  rno-miR-301a-3p 0.0586 1 
rno-miR-143-5p -3.04E-01 0.7106  rno-miR-30e-5p 0.0272 1 
rno-miR-24-2-5p -3.51E-01 0.7106  rno-miR-10a-5p -9.59E-02 1 
rno-miR-671 -1.68E+00 0.7106  rno-miR-221-5p -3.37E-01 1 
rno-miR-23a-3p -3.43E-01 0.7138  rno-miR-379-3p  Inf 1 
rno-let-7a-1-3p... 0.3386 0.7222  rno-miR-547-3p  -Inf 1 
rno-miR-181c-3p -3.65E-01 0.7276  rno-miR-145-3p 0.048 1 
rno-miR-215 0.1543 0.7335  rno-miR-1839-3p -6.54E-01 1 
rno-miR-3585-3p -1.46E+00 0.7335  rno-miR-340-3p 0.2585 1 
rno-miR-28-5p -2.22E-01 0.7365  rno-miR-204-3p  Inf 1 
rno-miR-21-3p 0.502 0.7365  rno-miR-450a-5p -2.41E-01 1 
rno-miR-100-5p -4.47E-01 0.7365  rno-miR-126a-3p -1.94E-02 1 
rno-miR-20a-5p 0.3529 0.7478  rno-let-7b-5p 0.0288 1 
rno-let-7f-5p -3.75E-01 0.7478  rno-miR-130a-3p 0.0696 1 
rno-miR-139-5p 0.4524 0.7491  rno-miR-664-2-5... 0.2505 1 
rno-miR-181a-1-... -5.11E-01 0.7491  rno-miR-122-5p 0.0998 1 
rno-miR-872-3p 0.3315 0.755  rno-miR-140-3p 0.0174 1 
rno-miR-191a-3p -1.53E+00 0.755  rno-miR-30b-3p 0.2858 1 
rno-miR-7a-5p -9.22E-01 0.771  rno-miR-141-3p -1.61E-01 1 
rno-miR-10b-5p -1.84E-01 0.771  rno-miR-342-5p  -Inf 1 
rno-miR-674-5p -3.04E+00 0.771  rno-miR-27b-5p -1.19E-01 1 
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rno-miR-300-3p 0.4729 0.771  rno-miR-24-3p -7.21E-02 1 
rno-miR-124-3p 1.61 0.771  rno-miR-30c-5p 0.0412 1 
rno-miR-350 0.2949 0.7719  rno-miR-30d-3p -1.77E-01 1 
rno-miR-101a-3p 0.0903 0.7719  rno-let-7d-3p 0.0413 1 
rno-miR-378a-3p 0.333 0.7754  rno-miR-184  -Inf 1 
rno-miR-6329 -9.49E-01 0.7819  rno-mir-425* -2.01E-01 1 
rno-miR-191a-5p -2.14E-01 0.7828  rno-miR-15b-3p 0.0329 1 
rno-let-7c-5p 0.2001 0.7828  rno-let-7b-3p 0.0821 1 
rno-miR-146a-5p 0.3075 0.7828  rno-miR-96-5p 0.0279 1 
rno-let-7e-3p -9.28E-01 0.7828  rno-miR-874-3p  -Inf 1 
rno-miR-341 0.5032 0.7828  rno-miR-188-5p 0.2322 1 
rno-miR-24-1-5p -2.58E+00 0.7828  rno-miR-186-5p -1.21E-01 1 
rno-miR-30a-3p 0.3053 0.7828  rno-miR-200b-3p 0.2165 1 
rno-miR-25-5p 0.3744 0.7828  rno-miR-106b-3p 0.0443 1 
rno-miR-30c-2-3... 0.3459 0.7828  rno-miR-128-1-5...  -Inf 1 
rno-miR-27a-3p -2.56E-01 0.7869  rno-miR-674-3p -4.38E-02 1 
rno-miR-141-5p 0.4316 0.7869  rno-miR-493-5p  Inf 1 
rno-miR-540-3p 1.1 0.7869  rno-miR-652-5p  Inf 1 
rno-miR-384-3p -1.49E+00 0.7869  rno-let-7i-5p -1.08E-01 1 
rno-miR-322-5p -3.73E-01 0.7869  rno-miR-23b-3p 0.0821 1 
rno-mir-28* -1.38E+00 0.7869  rno-miR-211-5p  -Inf 1 
rno-miR-323-3p 0.6995 0.7869  rno-miR-3473 -9.13E-01 1 
rno-miR-21* -5.95E-01 0.7974  rno-miR-144-5p -1.00E+00 1 
rno-miR-223-3p 0.1874 0.7974  rno-miR-455-5p -1.99E-01 1 
rno-mir-21* -5.95E-01 0.7974  rno-miR-200a-3p 0.0277 1 
rno-miR-125b-2-... -3.12E-01 0.7974  rno-miR-99a-3p -6.29E-01 1 
rno-miR-99a-5p 0.1955 0.7974  rno-miR-25-3p -1.35E-02 1 
rno-miR-582-5p 0.8088 0.8026  rno-miR-499-5p 0.5796 1 
rno-miR-190a-5p 0.2552 0.8068  rno-miR-107-3p 0.1198 1 
rno-miR-434-5p 0.6304 0.8068  rno-miR-17-1-3p -3.16E-01 1 
rno-miR-26a-5p -3.21E-01 0.8068  rno-miR-374-3p -1.42E-01 1 
rno-miR-148b-3p -1.88E-01 0.8068  rno-miR-144-3p 0.5315 1 
rno-miR-301b-3p 0.7517 0.817  rno-miR-33-5p -1.15E-02 1 
rno-miR-26b-5p -2.45E-01 0.8219  rno-miR-758-3p  Inf 1 
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rno-miR-200c-3p 0.3066 0.8328  rno-miR-127-3p 0.2209 1 
rno-miR-93-5p -2.19E-01 0.8404  rno-miR-193-3p 0.0573 1 
rno-miR-340-5p 0.1755 0.8404  rno-miR-365-3p -1.97E-01 1 
rno-miR-338-3p -3.51E-01 0.8404  rno-miR-376a-3p  Inf 1 
rno-let-7e-5p -3.01E-01 0.8404  rno-mir-455*  -Inf 1 
rno-miR-652-3p 0.3143 0.8513  rno-miR-653-5p  -Inf 1 
rno-miR-199a-3p -5.52E-03 0.861  rno-let-7f-2-3p -1.51E-01 1 
rno-miR-9a-5p 0.1991 0.8644  rno-miR-148b-5p -2.35E-01 1 
rno-miR-147 0.475 0.8644  rno-miR-34c-5p -2.54E-01 1 
rno-miR-582-3p 0.4772 0.8683  rno-miR-93-3p 0.2916 1 
rno-miR-130b-3p 0.5377 0.8712  rno-miR-151-3p 0.0061 1 
rno-miR-328a-3p 0.2867 0.8712  rno-miR-33-3p -1.60E-01 1 
rno-miR-127-5p 1.47 0.8712  rno-miR-32-5p -2.79E-01 1 
rno-miR-190b-5p 0.3775 0.8857  rno-miR-29c-3p -3.97E-02 1 
rno-miR-216b-3p  Inf 0.8873  rno-miR-496-3p  Inf 1 
rno-miR-129-5p 0.3019 0.9069  rno-miR-369-3p -3.44E-01 1 
rno-miR-92a-1-5... -3.55E-01 0.9389  rno-miR-190a-3p  Inf 1 
rno-miR-6324  -Inf 0.9495  rno-miR-146b-5p 0.0665 1 
rno-miR-1843-5p -4.17E-01 0.9495  rno-miR-183-5p 0.0556 1 
rno-miR-18a-3p  -Inf 0.9495  rno-miR-511-3p -5.61E-01 1 
rno-miR-224-5p -2.40E+00 0.9495  rno-miR-532-5p -2.13E-01 1 
 
 
 
